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La vie est un sourire errant,
Miracle d’aimer ce qui meurt.
Albert Camus
Aan de liefde
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1.1 General Introduction
The human immunodeficiency viruses HIV-1 and HIV-2 are the causative
agents of the acquired immunodeficiency syndrome (AIDS). HIV-1 and
HIV-2 are retroviruses and members of the family of lentiviruses. The
hallmark of HIV infection is a reduction of the number of CD4+ T
lymphocytes, resulting in a progressive loss of cellular immunity, the
development of AIDS, and ultimately death. The three major transmission
routes of HIV are by sexual contact, by blood or blood products, or
vertically through maternal-fetal transmission. As of now, in June 2000, it
is estimated that 34.3 million individuals worldwide are infected with
HIV (1). In 1999, 2.8 million people died from AIDS and the infection
rate was 5.4 million people per year (1). More than 70% of the people with
HIV and AIDS live in developing countries. 
1.2 Clinical Manifestations Of HIV Infection
The course of an HIV infection can be divided into three stages: the acute
stage, the clinical latency stage and the clinical manifest or AIDS stage.
Primary or acute HIV infection is defined as the period from initial
infection to complete seroconversion. The incubation period of primary
HIV infection is around 4 weeks. Primary HIV infection is symptomatic
in up to 70% of HIV infected individuals and is associated with fever,
arthralgia, adenopathy, myalgia, truncal (and facial) maculopapular rash
and neurologic symptoms, including neuritis, myelopathy and aseptic
meningo-encephalitis (2-5). Patients with symptomatic primary infection
have a more rapid progression to AIDS than asymptomatic seroconverters
(6,7).
Primary HIV infection is followed by an asymptomatic carrier state of
variable duration with a median of 10 years, after which most patients
develop AIDS (8-12). The asymptomatic phase of HIV infection is
frequently characterized by a persistent generalized lymphadenopathy
(PGL) (40,41,45). 
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The AIDS diagnosis is defined by the occurrence of one or more
opportunistic infections and/or development of opportunistic malignancies
(Table 1). In addition, several organs may be directly affected by the HIV
virus including the gastro-intestinal tract (13-15), bone marrow (16-18)
and the central and peripheral nervous system (19,20) resulting in e.g.
wasting, thrombocytopenia, AIDS dementia, and neuropathy. Without
potent antiretroviral treatment, the average survival time after AIDS
diagnosis was 2 years (21).
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CD4 count < 200 cells/mm3*
Candidiasis: esophageal, trachea, bronchi
Coccidioidomycosis, extrapulmonary
Cryptococcosis, extrapulmonary
Cervical cancer
Cryptosporidiosis, chronic intestinal (> 1 month)
CMV retinitis, or CMV in other than liver, spleen, lymph nodes
HIV encephalopathy
Herpes Simplex with mucocutaneous ulcer, bronchitis, pneumonia
Histoplasmosis: disseminated, extrapulmonary
Isosporiasis, chronic, > 1 month
Kaposi’s sarcoma
Lymphoma: Burkitt’s, immunoblastic, primary in brain
M. avium or M.Kansassii, extrapulmonary
M. tuberculosis, pulmonary or extrapulmonary
Pneumocystis carinii pneumonia
Pneumonia, bacterial, recurrent (2 or more episodes in 1 year)
Progressive multifocal leukoencephalopathy
Salmonella bacteremia, recurrent
Toxoplasmosis, cerebral
Wasting syndrome due to HIV
*Not an AIDS defining criterium in the Netherlands.
Table 1. AIDS defining illnesses (revised CDC classification 1993)
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1.3 Pathogenesis Of HIV Infection
Primary HIV infection is characterized by high plasma HIV RNA levels,
high titers of HIV infected PBMC’s and transient depletion of CD4+ T
lymphocytes from the blood (Figure 1). During this stage, HIV is
disseminated throughout the body and virus is trapped on the protrusions
of follicular dendritic cells in the lymphoid tissue (22-27). 
Following the acute stage of HIV infection, plasma HIV RNA levels
decrease and the CD4 count increases, although it remains lower than in
healthy individuals (Figure 1). During the asymptomatic phase, a gradual
decline of CD4+ T lymphocytes is paralleled by a gradual increase of
plasma HIV RNA levels (28-39). On histological examination, lymph
nodes of asymptomatic HIV carriers with PGL show follicular hyperplasia
with endothelial cell proliferation and HIV is found in large amounts on
the follicular dendritic cells (40-45).
Initially it was believed that during the asymptomatic or clinically latent
phase the amount of viral replication would be very low and the amount of
virus present in the body minimal. It has been shown over the last couple
of years that this concept was seriously flawed. By inhibiting HIV
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Figure 1. Pathogenesis of HIV infection
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replication with potent antiretroviral drugs and by measuring the decline
in the amount of HIV RNA in plasma, the magnitude of viral replication
before start of therapy was estimated (46,47). Using a mathematical
model, it was estimated that the average lifespan of free HIV virions in
plasma was 0.3 days. This corresponds to a half-life (t½) of ~ 6 hours. The
average lifespan of productively infected cells was calculated to be 2.2 days
(t½ ~ 1.6 days). It was estimated that approximately 1010 virions are
produced and destroyed each day (48). Thus, the asymptomatic phase is a
virologically extremely dynamic process.
Clinical progression towards AIDS is reflected by a rapid decrease of CD4+
lymphocytes, increasing plasma HIV RNA levels (Figure 1)(38,39) and
deterioration of the lymph node architecture, from follicular hyperplasia to
follicular involution and follicular depletion (43). 
1.4 Mechanisms Underlying CD4+ T-Lymphocyte Depletion
The exact mechanism causing CD4+ T-cell depletion in HIV infection has
not yet been unraveled. The decline of CD4+ T lymphocytes during HIV
infection is due to an imbalance between production and destruction, i.e.
due to increased destruction and/or a reduced regeneration capacity.
Several mechanisms of CD4+ T-cell destruction have been proposed
(reviewed in 49). First, HIV-infected CD4+ T-cells could be destroyed due
to the cythopathic effect of the virus, analogous to observations of HIV
killing of CD4+ T cells in vitro. Other proposed mechanisms include
dysregulation of cytokine production, auto-immunity, apoptosis due to
non specific activation and destruction of infected CD4+ T cells by
cytotoxic T-lymphocytes (CTL’s). It has been hypothesized that CTL’s may
also kill uninfected CD4+ T cells (innocent bystander theory) (49). 
Evidence has been provided that T-cell renewal may be compromised in
HIV infected individuals. First, it was shown that CD34+ hematopoietic
progenitor cells are susceptible to HIV infection (50), and have impaired
survival and clonogenic capacity during HIV infection (51,52). Second, it
was demonstrated that the thymic tissue is affected in individuals with
AIDS (53). In studies with SCID-hu mice it was shown that HIV infection
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results in depletion of CD4+/CD8+ thymocytes and reduction of the
number of CD4+ T-lymphocytes from the thymic implants (54-46).
Furthermore, measuring T-cell receptor excised circles (TREC’s) to identify
recent thymic emigrants showed that the number of TREC positive T cells
is decreased as compared to HIV negative individuals, which was taken as
evidence for a reduced export of new T cells from the thymus in HIV
infection. Finally, it has been proposed that infection of naive CD4+ T cells
by syncytium-inducing HIV variants, via the CXCR4 co-receptor, may
interfere with CD4+ T-cell production (166).
It has also been hypothesized, that infection with HIV causes an increased
daily production and destruction rate, resulting in the exhaustion of the
capacity to regenerate new CD4+ T cells. This hypothesis was based on
two studies investigating the repopulation of CD4+ T cells in blood
following initiation of potent antiretroviral therapy (46,47). Assuming
that the rapid increase of CD4+ T cells during therapy reflects the
pretreatment rate of CD4+ T-cell production, it was estimated that the
turnover CD4+ T cells is around 2 x 109 cells/day. However, it has been
suggested by others that the initial rise of CD4+ T lymphocytes in the
blood after start of antiretroviral therapy could also be due to
redistribution of CD4+ T cells from lymphoid tissue to peripheral blood,
rather than by de novo production of cells (57).
In addition, several findings argue against a substantial increase in the
turnover of T cells. First, by determining the fraction of dividing cells via
the expression of the nuclear antigen Ki67 (58), it was shown that T-cell
proliferation rate is increased maximally two- to three fold in the CD4+
population, and 6-7 fold in the CD8 population (59-62). This limited
increase in the division rate is consistent with studies measuring the
replicative history of T cells by the average telomere lengths (63,64).
Secondly, using deuterated glucose to label DNA in vivo, showed that the
turnover of CD4+ and CD8+ T cells in HIV infected patients is ~3 times
higher than that of healthy individuals (65). A 2 to 6 fold increased
turnover of CD4+ lymphocytes has also been observed in SIV infected
macaques using BrdU to label DNA in vivo (66). 
Thus, since T-cell turnover in HIV infection is only slightly increased (2 to
6 fold), it seems that a limitation in the capacity to produce CD4+ T cells
plays an important role in the CD4+ T cell depletion during HIV
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infections, rather than a high turnover of CD4+ T cells and exhaustion of
the immune system. 
1.5 T-Cell Abnormalities In HIV Infection
The most prominent feature of HIV infection is the depletion and
dysfunction of CD4+ T lymphocytes. In addition, HIV causes numerous
other disturbances of both the cellular and the humoral immune system.
This thesis focuses on the HIV induced changes of the T-cell population
and the restoration of the T-cell population during potent antiretroviral
therapy. 
1.5.1. The T-lymphocyte Population
Based on phenotypic and functional properties, the T-cell population can
be divided in two subsets, helper cells and cytotoxic/suppressor cells. The
helper T cells express CD4, recognize antigen together with major
histocompatibiltiy complex (MHC) II and play a crucial role in initiating
and orchestrating the specific immune response, such as activation of B
cells, helping CD8+ cytotoxic effector cells and activation of macrophages.
The cytotoxic/suppressor T cells express CD8, recognize antigen together
with MHC I, and play a role in host defense by cytokine release, lysing of
target cells or suppressing immune responses by eliminating antigen
presenting cells (APC’s).
The CD4+ and CD8+ T-cell populations can again be subdivided in naive
and memory cells. Naive cells have not yet encountered their specific
antigen. To distinguish naive T cells from memory T cells, the high (RA)
and low (R0) molecular weight isoform of the CD45 cell surface antigen
can be used. 
Naïve T cells express CD45RA, memory T cells express CD45R0.
However, because memory cells may revert from the CD45R0 to the
CD45RA phenotype during cell differentiation (67,68), additional
markers are used to identify naive and memory cells, such as CD62L and
CD27. T cells co-expressing CD45RA and CD27 can be considered truly
naive T cells (or T cells co-expressing CD45RA and CD62L). T cells with
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the CD45R0+ and the CD45RA+/CD27- phenotype (or
CD45RA+/CD62L-) are considered memory/effector cells (69-71).
1.5.2 Kinetics Of T-Cell Subsets In HIV Infection
Infection with HIV causes progressive depletion of both naive and memory
CD4+ T cells. The CD8 count of HIV infected patients is usually increased
until shortly before the onset of AIDS. This increase is due to expansion of
the memory CD8+ T-cell population. Naive CD8+ T-cell counts decrease
gradually from early in HIV infection (69,72). The loss of naive CD4+ and
CD8+ T cells implies a defect in the capacity to respond to new antigens,
which may include new HIV variants that are continuously generated due
to the high mutation rate of HIV. 
Besides changes in the absolute numbers of T cell subsets, HIV also
induces a perturbation of T-cell receptor repertoire of CD4+ and CD8+ T-
cell population. Drastic restrictions in CD8+ T-cell repertoire usage were
found at all stages of HIV infection (73). In contrast, significant CD4+ T-
cell repertoire perturbations are not found in early stages of infection but
are most prevalent in patients with the lowest CD4+ T-cell counts (73,74).
1.5.3 Dysfunctions Of T-lymphocytes In HIV Infection
HIV induces severe functional immunologic abnormalities in T cells, B
cells and APC’s early in infection before the number of CD4+ T cells starts
to decline (75-78). 
In vitro, the T lymphocytes of HIV infected individuals have a diminished
or absent proliferative response to aspecific stimuli such as pokeweed
mitogen (PWM), phytohemagglutinin (PHA), or by monoclonal
antibodies (mAb) to CD3, and combined CD3 plus CD28 mAb’s (75,77-
82). It was shown that low T-cell responses to PWM and to CD3 mAb
with or without CD28 mAb’s is predictive for progression to AIDS
(80,82). In addition, the in vitro response of T cells of HIV patients to
specific stimuli such as Candida antigens, CMV antigens, tuberculin and
tetanus toxoid is decreased (81, 83-86).
1.5.4 The Response Of T cells To HIV Infection
HIV infection results in a HIV specific response of CD4+ and CD8+ T
lymphocytes, which may play an important role in the control of HIV
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replication (87-98). However, in most patients, the T-cell responses cannot
prevent an increase of the viral load and deterioration of the immune
system. 
It was shown that in individuals who control viremia in the absence of
antiviral therapy, polyclonal, persistent, and vigorous HIV specific CD4+
T-cell proliferative responses were present. The HIV specific proliferative
responses of CD4+ T cells to p24 antigen were inversely related to viral
load (93). Lymphoproliferative responses of helper T cells to p24 gag, but
not p17 gag or gp160 env, can be detected in long term non progressors
(LTNPs), whereas they are totally absent in patients progressing to AIDS
(94). 
The frequency of HIV gag, pol and env specific CTL’s is higher in
asymptomatic individuals than in people progressing to AIDS, and the
HIV specific CTL precursor frequency correlates inversely with the plasma
HIV RNA levels (87-92,97,98). A positive correlation has been found
between the cytotoxic T-cell response and the T helper response,
suggesting that CD4+ T cell help is critical for an effective cytotoxic T-cell
response (95,96). 
Besides a role in suppressing replication of HIV, it has been proposed that
HIV specific CTL’s may derange the immune response to HIV by
eliminating CD4+ T cells, APC’s and by destroying the lymphoid tissue
architecture (49). 
1.5.5 T-Cell Hyperactivation In HIV Infection
HIV infections are characterized by a general activation of the immune
system (114), as is evidenced by elevated serum levels of TNF-alpha,
soluble IL-2, neopterin and Beta-2-microglobulin (99-101). The B cell
compartment is also activated, resulting in hypergamma globulinemia
(102). The CD4+ and CD8+ T lymphocytes of HIV infected individuals
have increased expression of the activation markers HLA-DR and CD38
and the proliferation marker Ki67 (103-113). 
Expression of CD38 on CD8+ T cells was shown to be a strong predictor of
progression to AIDS (115). The origin of the increased activation and
proliferation of T cells in HIV infection will be discussed in chapters 7 and
8. 
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1.6 Antiretroviral Therapy
Progress in the field of antiretroviral therapy in the past 5 years has been
dramatic. This is due to several reasons, including increased knowledge
about viral dynamics and the development of reliable techniques for
monitoring antiviral response, such as quantitative plasma HIV RNA
measurements. In addition, the number of approved antiretroviral agents
has increased greatly. In particular, the introduction of the class of protease
inhibitors was a crucial step towards a more effective suppression of HIV
replication. Presently, 3 classes of antiretroviral drugs are available for the
clinical practice: the nucleoside analogue reverse transcriptase inhibitors
(NRTI’s), the non-nucleoside reverse transcriptase inhibitors (NNRTI’s)
and the protease inhibitors. 
1.6.1 Highly Active Antiretroviral Therapy
A combination of 3 or more antiretroviral agents has proven the most
effective approach to treat HIV disease (116). Compared to mono or dual
therapy, the so-called triple therapy, consisting of two NRTI’s and one
protease inhibitor, showed a more durable suppression of plasma HIV
RNA levels and a more pronounced rise of the CD4 count. Moreover,
introduction of the highly active antiretroviral therapy (HAART),
consisting of 3 or more antiretroviral drugs, has resulted in a significant
reduction in mortality and morbidity among patients with advanced HIV
infection in Western Europe and the USA (117-121). 
The rationale for the use of combination therapy encompasses 4
arguments. First, to provide additive or synergistic antiviral effect. Second,
to prevent the emergence of drug resistant HIV variants. In previously
untreated patients, the probability is very small that HIV variants are
present with mutations simultaneously conferring resistance to 3 different
drugs. In addition, such multidrug resistant viruses may have severely
compromised replication capacity. Third, to minimize the toxicity per
drug. Fourth, to provide antiretroviral activity in different anatomic and
cellular compartments. 
The current recommended standard of initial antiretroviral treatment is a
combination of two NRTI’s and one protease inhibitor or two NRTI’s and
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one NNRTI (122). Regimens of three NRTI’s and regimens including
drugs from all three classes are also being evaluated. 
Despite the success of HAART, several practical limitations and concerns
should be recognized. In a significant number of patients, failure of
HAART occurs, as defined by an increase of the plasma HIV RNA levels
during treatment. Two studies investigating the virologic response to
HAART in clinical practice showed that after 1 year, plasma HIV RNA
levels remain below 500 copies/ml in 37% to 60% of the patients
(123,124). 
Therapeutic failure may be caused by drug resistance or by low active drug
levels due to non-adherence, interactions with other drugs or diminished
absorption as a result of concomitant intestinal infections. Due to cross-
resistance, regimens instituted after failure of the first regimen have been
less effective, with a lower percentage of patients achieving maximal
suppression for shorter periods of time. 
Besides the threat of therapy failure and multidrug-resistance, many other
problems have been identified that reduce the quality of life for patients on
HAART, such as a high pill burden, multiple daily dosing and dietary
constraints. In addition, antiretroviral drugs have numerous adverse
effects. NNRTI’s may cause skin rash (125-129). NRTI’s may cause
mitochondrial toxicity, resulting in anemia, myopathy, peripheral
neuropathy, pancreatitis or lactic acidosis (130,131). The toxicity
associated with the class of protease inhibitors includes diarrhea, nausea,
vomiting and fatigue and several laboratory abnormalities such as
increased levels of aminotransferases, hyperglycemia, hypertriglyceridemia
and hypercholesterolemia. A long-term serious side effect associated with
the use of protease inhibitors is lipodystrophy, a syndrome of peripheral
lipoatrophy with central adiposity (132-135). The exact role of protease
inhibitors in the pathogenesis of lipodystrophy has not been unraveled and
it has been hypothesized that NRTI’s may also contribute to lipodystrophy
(130,131).
1.6.2 The Effect Of HAART On HIV Replication
In a majority of patients, HAART results in a sustained suppression of
plasma HIV RNA levels to below 50 copies/ml for up to four years. In
addition, HAART significantly reduced the amount of HIV RNA in
CHAPTER 1 11
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lymphoid tissue (136-138), where most of the HIV replication and virus
shedding occurs. The HIV RNA load is also decreased by HAART in
other compartments such as the cerebrospinal fluid (139) and semen (140). 
The decline of HIV RNA levels in plasma is biphasic. It was hypothesized
that the two phases reflect the decline of two different pools of HIV
producing cells with different decay rates (141). The plasma HIV RNA
level drops by approximately 99% in the first two weeks of treatment
owing to the rapid elimination of free virus with a half-life (t½) of
approximately 6 hours and loss of productively infected cells with a t½ of
1.6 days. This initial decrease is followed by a slower second-phase decay
of plasma viremia with a t½ of 1-4 weeks, which may reflect the decline of
long-lived infected cells (141).
Based on these decay characteristics, the possibility of eradication of HIV
from all anatomical compartments was proposed. Assuming that the
suppression of viral replication was complete and that the t½ of chronically
infected cells was 10-14 days, it was estimated that eradication could be
possible within 2.3-3.1 years (141). 
Newer data however question the feasibility of HIV eradication. Evidence
has been provided suggesting that low level of ongoing replication may
occur despite a plasma HIV RNA levels < 50 copies/ml during HAART
(142-145). In addition, HIV can persist in a latent form, as proviral DNA
in resting memory CD4+ T cells. In patients on HAART with prolonged
suppression of plasma viremia for up to 30 months, infectious virus could
be recovered from latently infected cells (146-149). The average half-life of
these latently infected long-lived cells is calculated to be 43.9 months
(150). Assuming that the latent reservoir consists of 1x105 cells,
eradication would take as long as 60 years (150). Thus, with HAART
alone, eradication of HIV does not seem feasible at present.
1.6.3 Immune Reconstitution During HAART
In most patients, highly active antiretroviral therapy (HAART) leads to a
substantial rise of the CD4 count, primarily due to an increase of memory
CD4+ T cells (151-153). The effect of HAART on the CD8 count varies
per study from a slight increase (152,154,155) to a decrease
(151,156,157). Naive CD4+ and naive CD8+ T cells increase slowly
during HAART (151,152,158). 
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During HAART, proliferative lymphocyte responses to recall antigens and
mitogens are enhanced over time (151,155,158-160), while T-lymphocyte
activation is largely reduced (151,154,161-163) and T-cell receptor (TCR)
repertoires are partly restored (73,74). Proliferative lymphocyte responses
specific to HIV-1 antigens, in contrast, remain weak (86,160,164). In
addition, it was shown that treatment, initiated even at advanced stages of
HIV-1 disease, is capable of reversing the pathological changes in the FDC
network (165). A complete normalization of HIV-1 associated
immunological alterations has not been reported so far, but the observation
period of subjects on potent antiretroviral therapies is still relatively short.
Focus Of This Thesis
This thesis focuses on the effect of potent antiretroviral combination
therapy on HIV replication and on the immune system. The majority of
the work (Chapters 2,3,5,6,7 and 8) is based on the CHEESE study. This
was a randomized, open label, multicenter study in the Netherlands
comparing the efficacy and tolerability of saquinavir soft-gelatin-capsules
(SGC) versus indinavir, both given as part of a triple therapy containing
zidovudine and lamivudine. The results of the first 24 weeks of treatment
are presented in Chapter 2. 
The objective of the study in Chapter 3 was to compare the plasma
exposure of saquinavir-SGC relative to saquinavir hard-gelatin-capsules
(HGC), and to determine whether there is a relation between saquinavir
plasma exposure and the virological response in patients from the CHEESE
study. 
In Chapters 4 and 5, the influence of age on the regeneration of naive T
cells during HAART was investigated in children and adults, respectively.
We hypothesized that if it were mainly dependent on thymic function, the
T-cell regeneration rate should decrease with age, due to natural involution
of the thymus. To understand the mechanism of naive T-cell reconstitution
during HAART is important because thymus dependent regeneration of T
cells is required for recovery of the HIV induced deletions in the T-cell
repertoire. 
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In Chapter 6, we investigated whether thymic output is decreased in HIV
infected individuals. It has been proposed that thymic output can be
measured by quantifying the number of recent thymic emigrants, which
can be identified by T-Cell Receptor Excision Circles (TRECs). Infection
with HIV results in a decline of the number of TREC positive T cells.
Using a mathematical model, we investigated whether the low number of
TREC positive T cells in HIV infection is best explained by increased
division rates of naïve T cells or by thymic impairment. 
In Chapters 7 and 8, the expression of proliferation and activation
markers on T cells was investigated in untreated HIV-infected patients and
during HAART. Two models have been proposed to explain the
hyperactivation and increased proliferation of T cells in HIV-1 infection.
One model contends that T-lymphocyte activation in HIV infection is due
to a generalized immune activation driven by antigens from HIV and/or
from other pathogens (19, 36, 38). Alternatively, increased activation and
proliferation of CD4+ T cells may be a homeostatic response to compensate
for the loss of CD4+ T cells that are killed by HIV (12,13). The aim of the
studies in Chapter 7 and 8 was to distinguish between these two models.
The objective of the study in Chapter 9 was to determine whether in
patients who achieved plasma HIV RNA levels below 50 copies/ml during
HAART, transient relapses (“blips”) of the plasma HIV RNA are
associated with resistance development and virologic treatment failure.
INTRODUCTION14
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Abstract
Objective: To compare efficacy and tolerability of saquinavir soft gelatin
capsule formulation (SQV-SGC) and indinavir, both given as part of a
triple drug regimen containing zidovudine and lamivudine, in HIV-1-
infected individuals.
Design: Randomized, open label, multicenter study.
Patients: In total 70 patients were included who were antiretroviral-naive
and who had a CD4 cells count <500/µL and/or >10.000 HIV RNA
copies/ml plasma and/or HIV-related symptoms. Subjects were assigned
randomly to zidovudine 200 mg t.i.d. plus lamivudine 150 mg b.i.d. plus
either SQV-SGC 1200 mg t.i.d. (SQV-SGC group) or indinavir 800 mg
t.i.d. (indinavir group). Data are presented for all patients up to week 24.
Results: Mean baseline CD4 counts (± SE) were 301±29 cells/µL and
310±43 cells/µL in the SQV-SGC and indinavir groups, respectively. The
log10 median baseline HIV RNA load was 5.00 copies/ml in the SQV-
SGC group and 4.98 copies/ml in the indinavir group. No difference in
antiretroviral effect between the treatment arms could be demonstrated.
Intention-to-treat analysis (LOCF) at week 24 revealed that RNA levels
decreased to < 50 copies/ml in 74.3% of patients in the SQV-SGC group
and in 71.4% of the patients in the indinavir group (p=0.78). In the on-
treatment analysis the proportion of patients < 50 copies/ml at week 24
was 88.0% in the SQV-SGC group and 84.6% in the indinavir group
(p=0.725). Intriguingly, the mean increase of CD4 cells (ITT) in the first
24 weeks was 162±20 cells/µL in the SQV-SGC group and 89±21 cells/µL
in the indinavir group (p=0.01), but preliminary data indicate that this
difference in CD4 gain may disappear after 24 weeks of treatment. Both
regimens were generally well tolerated.
Conclusion: During the first 24 weeks of the study, we found no difference
in antiviral potency between the indinavir group and the SQV-SGC group.
A significantly higher CD4 response in the SQV-SGC group was observed.
Keywords: clinical trials, combination therapy, indinavir, saquinavir-SGC
THE CHEESE STUDY32
hoofdstuk 02  9/21/00  12:48 PM  Pagina 32
Introduction
Saquinavir is a potent and specific inhibitor of the protease of human
immunodeficiency virus (HIV) types 1 and 2 in vitro. Saquinavir was
initially formulated as a hard-gelatin-capsule (SQV-HGC) which, as part
of a combined antiretroviral treatment has been shown to be clinically
effective (1). However, SQV-HGC has limited oral bioavailability,
resulting in relatively low plasma levels. The recently developed soft-
gelatin-capsule formulation of saquinavir (SQV-SGC) has improved oral
bioavailability over SQV-HGC. At a dosage of 1200mg t.i.d., SQV-SGC
achieves an approximately eight-fold higher plasma exposure to saquinavir
compared with SQV-HGC (600mg t.i.d.) (2). It has been shown that SQV-
SGC provides significantly more reduction of plasma HIV RNA levels in
antiretroviral naive patients than SQV-HGC (3), consistent with the
observation that the antiviral activity of saquinavir is positively correlated
to plasma drug levels (4). Preliminary data from several clinical trials have
demonstrated the antiviral potency of SQV-SGC in combination with two
reverse transcriptase (RT) inhibitors (5,6). 
No previous randomized clinical trial has compared two protease
inhibitors in triple therapy background with the same RT inhibitors. The
objective of this study was to compare the antiviral efficacy and tolerability
of SQV-SGC with indinavir, as part of a triple therapy containing
zidovudine and lamivudine in antiretroviral-naive HIV-1-infected
individuals.
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Methods
Study design
This was a randomized, parallel arm, open label, multi center study
comparing antiviral efficacy and safety of zidovudine plus lamivudine plus
SQV-SGC or zidovudine plus lamivudine plus indinavir, in HIV-1 infected
patients. A stratified randomization procedure was used. Patients were
stratified according to plasma HIV RNA level (either > 100,000 or <
100,000 copies/ml). Data up to week 24 of all patients are presented. The
study was approved by the internal review boards at each site and all
participating patients gave written informed consent.
Study patients
Patients of 18 years and older who were seropositive for HIV type 1 and
who were antiretroviral naive (with exception of zidovudine use for less
than 12 months), were screened for enrollment at eight locations in The
Netherlands. Patients were eligible for study treatment if, at the moment
of screening plasma HIV RNA levels were at least 10,000 copies/ml
(Amplicor HIV monitor test, Roche Diagnostics) and/or if CD4 counts
were less than 500 cells / µL and/or if they had a history of HIV related
symptoms (CDC stage B or C). 
Exclusion Criteria 
Criteria for exclusion were a hemoglobin level less than 7.0 mmol/l (in
males) or 6.5 mmol/l (in females), a platelet count of less than 25 x 109 / l,
a neutrophil count of less than 0.75 x 109 / l, serum creatinine level
exceeding 1.5 fold the upper normal limit or levels of hepatic
aminotransferases (ASAT, ALAT) exceeding 5 fold the upper normal limit.
In addition, patients were excluded if they required acute therapy for an
active opportunistic infection or if they required systemic antineoplastic
chemotherapy and/or radiotherapy. Also excluded were patients with
malabsorbtion or inadequate oral intake or patients with unexplained,
chronic diarrhea persisting for 14 days or more. Pregnant or breastfeeding
women were also excluded as were patients who participated in other
investigational studies within 30 days prior to screening. 
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Treatment Regimens
Eligible patients were assigned randomly to either: (i) indinavir (Crixivan,
Merck, West Point, Pa) 800mg t.i.d. plus zidovudine (Retrovir, Glaxo-
Wellcome, Research Triangle Park, N.C.) 200mg t.i.d. plus lamivudine
(Epivir, Glaxo-Wellcome, Research Triangle Park, N.C.) 150 mg b.i.d. or :
(ii) Saquinavir Soft-Gelatin-Capsules (Fortovase, Hoffmann-La Roche, Inc.,
Nutley, New Jersey) 1200mg t.i.d. plus zidovudine 200mg t.i.d. plus
lamivudine 150 mg b.i.d..
Assessments
The patients were assessed every 4 weeks through week 24. At screening,
baseline and every visit, medical history was reviewed and standard
biochemical and hematological tests were conducted. Plasma
concentrations of the protease inhibitors were determined each study visit.
Virologic and Immunologic Studies
At each site, plasma (EDTA) was processed, stored at -70°C and assayed
later for HIV RNA by a quantitative reverse transcriptase polymerase
chain reaction assay (Roche Amplicor Monitor Standard Assay). The lower
limit of detection was 400 HIV RNA copies/ml in this assay. An
investigational version of an ultrasensitive RT-PCR assay with a lower
limit of detection of 50 copies/ml (Roche Amplicor Monitor) was
performed at a central laboratory.
Absolute numbers of CD4+ and CD8+ T-lymphocytes were determined
performed at a central laboratory by flowcytometry.
Statistical Analysis
The primary parameter of antiretroviral efficacy was HIV RNA (log
transformed to the base 10). Secondary parameters were CD4 counts,
improvement in or progression to AIDS defining illnesses, the incidence of
adverse events and biochemical and haematological safety parameters.
Baseline values of HIV RNA levels and CD4 counts were calculated as the
geometric mean of two consecutive pretreatment determinations, the first
between day -14 and day -7 and the second on day 0. 
Analyses of the variables pertaining to efficacy (plasma HIV RNA and
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CD4 response) were performed on an intention-to-treat basis that included
data of all randomized patients who have received at least one dose of study
medication. The last observation was carried forward as the imputation
method. On treatment analyses, representing all those patients for whom
data were available at that time point, are also presented. 
A repeated measures analysis-of-variance-model was used to detect
differences between the two treatment arms in area under the curve of
plasma HIV RNA levels and CD4 counts with repeated equally spaced
observations within the patients. In the analyses of the proportions of
patients below limit of detection and incidence of adverse events, the
treatments were compared by Fisher’s exact tests. All reported P values are
two-sided. 
Results
Study Patients
Seventy patients were enrolled in the study from January 1997 to February
1998, 35 in each treatment group. The baseline characteristics of the
patients were not different between treatment groups, as is shown in
Table 1. Ten patients discontinued the study after 4-24 weeks for the
following reasons: an adverse event (5) (table 2), lost to follow up (1),
consent withdrawn (1), receiving of erroneous study medication (1),
protocol violation (2). The number of discontinuations was the same
between the two treatment groups.
HIV RNA
Over the initial 24 weeks, plasma HIV RNA levels declined (median) 2.40
log10 in the SQV-SGC group and 2.38 log10 in the indinavir group
(Figure 1). No significant differences were observed between the treatment
groups in the decrease of plasma HIV RNA levels. 
Figure 2A shows the proportion of patients who achieved plasma HIV
RNA levels below 400 copies/ml, according to treatment group. At week
24, using an intention-to-treat analysis (ITT), 82.9% (29/35) in the SQV-
SGC-arm and 85.7% (30/35) in the indinavir arm had plasma HIV RNA
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SQV-SGC Group indinavir Group P value
Characteristic (n=35) (n=35)
Gender - no. of patients (%)
male   32 (91.4) 31 (88.6) p=0.99 §
female 3 (8.6) 4 (11.4)
Mean age (±SD) - yr 38 (± 8.46) 37 (± 9.02) p=0.45¶
Race (ethnic group) - no
of patients (%)
Caucasian 30 (85.7) 33 (94.3) p=0.42 §
Afro-european 4 (11.4) 1(2.9) p=0.35 §
Oriental    1 (2.9) 1(2.9) n.a
Prior zidovudine therapy
- no patients (%)        2 (5.7) 1 (2.9) p=0.99 §
Prior AIDS defining illness -
no of patients (%) 7 (20) 10 (28.6) p=0.58 §
CD4 count - cells / µL
Mean 301 310 p=0.775¶
Range 10-750 30-1075
Plasma HIV RNA 
(log10 copies/ml)
Median 5.00 4.98 p=0.668¶
Range 3.41- 6.87 3.10 - 6.23
¶: Independent-samples t-test
§: Fisher’s exact test
n.a.: not applicable
Table 1. Base-line Characteristics of the study patients 
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levels below 400 copies/ml (p=0.74). In the on-treatment (OT) analysis,
the proportion of patients < 400 copies/ml at week 24 was 90.3% (28/30)
in the SQV-SGC arm and 96.5% (28/29) in the indinavir arm (p=0.57). 
Figure 2B shows the proportion of patients with plasma HIV RNA levels
below 50 copies/ml. At week 24, ITT analysis showed that 74.3% (26/35)
in the SQV-SGC-arm and 71.4% (25/35) in the indinavir arm had plasma
HIV RNA levels below 50 copies/ml (p=0.78). In the OT analysis, the
proportion of patients < 50 copies/ml at week 24 was 88.0% (22/25) in
the SQV-SGC arm and 84.6% (22/26) in the indinavir arm (p=0.73). 
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SQV-SGC Group indinavir Group Fishers’s 
no. of patients no. of patients Exact test
Moderate or severe Adverse Events:
Clinical nephrolithiasis 0 2 N.S.
Diarrhoea 5 1¶ N.S.
Nausea 5 5 N.S.
Serious Adverse Events:
Gastritis 0 1 N.S.
Hematemesis 1 0 N.S.
Urine bladder polyp 0 1 N.S.
Grade 4 Anemia 0 1¶ N.S.
CDC Events:
Non Hodgkin lymphoma 1¶,§ 1¶,§ N.S.
PCP 0 1¶,§ N.S.
Herpes Zoster 2 3 N.S.
Total CDC Events 3 5 N.S.
¶ Resulted in study discontinuation
§ Resulted in death
Table 2. Adverse events According To treatment Group
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CD4 Cell Counts
During the initial 24 weeks of the study, mean numbers of CD4+ T cells in
the peripheral blood (±SEM) increased 162±20 cells / µL and 89±21 cells /
µL (Figure 3) in the SQV-SGC group and the indinavir group, respectively
(ITT). The increase of CD4+ T lymphocytes was significantly greater in
the group assigned to the SQV-SGC containing regimen (repeated
measures analysis, p=0.01). In each group, CD4 count response pattern
was biphasic with a higher rate of increase in the first four weeks of
treatment as compared to the later four-week intervals. 
Adverse Events and AIDS defining events
Both study treatments were generally well tolerated (Table 2). Five
patients withdrew from the study because of an adverse event: In two
patients a non-Hodgkin lymphoma was diagnosed, requiring systemic
antineoplastic chemotherapy. One patient developed severe anemia, one
patient was intolerant to AZT (nausea) and one patient had Pneumocystis
carinii pneumonia. There were three deaths among the study patients
(Table 2).
The incidence of adverse events with moderate or severe intensity shown in
table 2. The most common adverse event experienced by the patients was
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Figure 1. Median plasma HIV RNA levels during the initial 24 weeks of the study.
Median values are shown. Bars are 25th and 75th percentiles.
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Figure 2A. Proportion of patients with plasma HIV RNA levels of less than 400 copies /
milliliter.
Figure 2B. Proportion of patients with plasma HIV RNA levels of less than 50 copies /
milliliter.
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mild-moderate gastro-intestinal discomfort (dyspepsia, nausea, flatulence,
abdominal pain or diarrhoea) with no difference in the reporting of
symptoms between the two treatment groups. 
There were 8 new AIDS defining events during the first 24 weeks of the
study, with no difference in the incidence between treatment groups
(p=0.45)(table 2).
Virologic Failures
In four patients treatment failure was observed (one patient receiving
indinavir, three receiving SQV-SGC). Treatment failure was defined as
absence of virologic response or having rebound of HIV RNA levels above
400 copies/ml on two or more consecutive study visits following a
virological response. Virological response was defined as achieving HIV
RNA levels < 400 copies/ml. 
One patient from the indinavir-arm with rebound of plasma HIV RNA
levels reported intermittent adherence to the study regimen. Later on, this
patient adhered to the study regimen as recommended and again achieved
plasma HIV RNA levels < 400 copies/ml. 
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Figure 3. Changes from baseline in the CD4 cell count during the initial 24 weeks of the
study. Mean values are shown intend to treat analysis. Bars are standard error of the mean.
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Two patients from the SQV-SGC arm with rebound of plasma HIV RNA
levels had low saquinavir plasma levels on several study visits although
patient report and pill count did not show low adherence to study
medications. On several occasions, estimated saquinavir trough levels in
these two patients were less than 50 ng / ml, the calculated EC90 of
saquinavir in vivo (28). In one of these patients, malabsorption of SQV-
SGC was confirmed by recording a full eight-hour pharmacokinetic curve
after observed intake of SQV-SGC with meal. 
One patient in the SQV-SGC arm did not achieve plasma HIV RNA levels
below 400 copies/ml at any time during the initial 24 weeks of treatment.
Adequate saquinavir plasma levels could be detected in this patient. To
determine to what extent drug resistance contributed to the treatment
failure, genotypic resistance measurements were performed on plasma
samples from baseline and week 18. At baseline, no drug resistance
mutations were observed in the reverse transcriptase (RT) gene or the
protease gene of the HIV RNA population derived from this patient’s
plasma. At week 18, the HIV RT gene harbored the M184V mutation,
conferring high level resistance to 3TC. The absence of a virological
response in this patient may be best explained by the high HIV RNA
plasma levels before initiation of therapy (day -14: 3,200,000 copies/ml
and day 0: 11,500,000 copies/ml).
Discussion
This trial has a unique design: it is the first randomized prospective trial in
HIV infected patients comparing two different protease inhibitors given as
part of a triple therapy with the same RT-inhibitor background. Both
regimens displayed a powerful antiretroviral effect. We observed no
significant difference in antiretroviral activity between the SQV-SGC
group and the indinavir group during the initial 24 weeks of the study. At
week 24, 74.3% of the intention-to-treat population in the SQV-SGC
group and 71.4% in the indinavir group had plasma HIV RNA levels
below 50 copies/ml. Eight AIDS defining illnesses were diagnosed with no
difference in incidence between the two treatment groups. 
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Surprisingly, a significantly higher CD4 cell response during the first 24
weeks was observed in the SQV-SGC group as compared with the
indinavir group, but preliminary data from the post 24 week period show
that this difference may disappear at week 32 of treatment. At week 32,
mean CD4 change from baseline (±SEM) was 168±24 cells / µL in the
SQV-SGC group (n=23) and 169±25 cells / µL in the indinavir group
(n=26). 
The explanation for this difference in immunologic response during the
first 24 weeks remains unclear. Low baseline CD4 count and large
magnitude of viral load reduction during treatment are two determinants
of good initial CD4 response during HAART (7,8,9). However, neither
baseline CD4 count nor virus load reduction differed between the two
treatment groups and therefore these parameters do not explain the
difference in CD4 cell response. The rise of CD4+ T cells in blood during
HAART has been explained by two mechanisms: proliferation of CD4+ T
lymphocytes (7) and/or the recirculation of CD4 T lymphocytes which
resided in lymphoid tissue prior to therapy (9). Alternatively, the CD4
count increase during HAART may be explained by a direct influence of
antiretroviral agents on recirculation or proliferation of lymphocytes. In
needlestick-injured personnel given AZT prophylaxis for one month
increases of CD4 counts have been reported (10,11). However,
administration of indinavir in two healthy volunteers did not result in a
rise of CD4 counts (12). We hypothesize that each antiretroviral drug may
have a direct pharmacologic effect on either lymphocyte proliferation
and/or trafficking and that saquinavir-SGC may be different from
indinavir in this aspect, which may explain the initial difference of the
CD4+ T lymphocyte response. 
Although the majority of patients achieved plasma HIV RNA levels below
400 copies/ml in both treatment groups, three patients (one receiving
indinavir, two receiving SQV-SGC) had rebound of HIV RNA levels above
400 copies/ml on two or more consecutive study visits. Non compliance
explains the viral rebound in the patient from the indinavir-arm. In two
patients from the SQV-SGC arm, the viral rebound may be explained by
low saquinavir plasma levels. In one of these two patients, malabsorption
of SQV-SGC was observed. 
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One patient (receiving SQV-SGC) did not achieve plasma HIV RNA levels
below 400 copies/ml, probably due to the extremely high baseline HIV
RNA plasma levels. The potency of AZT/3TC/SQV-SGC was not
sufficient to prevent residual HIV replication and emergence of resistant
virus variants in this patient with a high HIV replication level. In several
studies it was demonstrated that high baseline viral loads are associated
with less efficient viral suppression (13,14) and a slower rate of HIV
clearance from plasma (15). As it has been shown that a five drug regimen
provides improved suppression of HIV replication over triple therapy (16),
five (or four) drug regimens may be required to attain a durable antiviral
response in patients with high pretreatment plasma HIV RNA levels.
In summary, we showed by head-to-head comparison that during the
initial 24 weeks of treatment saquinavir soft gelatin capsule formulation
shows equivalent antiretroviral efficacy to indinavir, when given as part of
a triple therapy containing zidovudine and lamivudine, in antiretroviral-
naive HIV-1-infected patients. SQV-SGC therefore is an appropriate choice
of protease inhibitor for first line therapy. SQV-SGC is generally well
tolerated, which is crucial for long term adherence to antiretroviral
regimens. Prolongation of follow up is required to determine whether over
the long term SQV-SGC and indinavir may differ with respect to toxicity,
antiviral potency or immunologic effect. Studies on a large population may
be performed to confirm our findings.
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Abstract
Objective: To evaluate the exposure to saquinavir when used as soft-gelatin-
capsules (SGC) relative to hard-gelatin-capsules (HGC) and to explore the
relation between SQV exposure and the virological response in 29
antiretroviral naive HIV-1-infected patients. 
Methods: Patients were treated with SQV-SGC 1,200mg tid plus
zidovudine plus lamivudine. Blood samples were obtained at regular
intervals during 48 weeks of treatment. As a measure of SQV plasma
exposure, the concentration ratio (CR) was used of the observed SQV
concentration and the time adjusted average concentration from a reference
population of 20 patients using SQV-HGC 1,200mg tid. 
Results: The median CR of all samples was 0.59 (n=208). No relation could
be observed between SQV plasma exposure and the plasma HIV-1 RNA
decrease during week 0-4 of therapy, nor to plasma HIV RNA clearance
rate during week 4-12 (p≥0.62), nor to the time to achieve plasma HIV-1
RNA <50 copies/ml (p=0.39). The CR was higher in patients with plasma
HIV-1 RNA <50 copies/ml at week 48 than in patients with detectable
plasma HIV-1 RNA at week 48, although not significantly (p≥0.06).
Despite the low SQV plasma exposure, 19/22 patients (84%) had plasma
HIV-1 RNA levels <50 copies/ml at week 48 (OT analysis). Interestingly,
the median CR of SQV decreased from 0.7 at week 4 to 0.55 at week 48
(p=0.04). 
Conclusion: Higher bioavailability of SQV-SGC as compared to SQV-HCG
could not be confirmed. Furthermore, our data suggest that the plasma
SQV exposure may not be related to the virological response during 48
weeks in antiretroviral naive HIV-1-infected patients. 
Introduction
Saquinavir is a potent and specific inhibitor of the protease of the human
immunodeficiency virus type 1 (HIV-1) and was initially formulated as
hard gelatin capsules (SQV-HGC) (1). Due to the limited oral
PK OF SAQUINAVIR IN THE CHEESE STUDY48
hoofdstuk 03  9/21/00  12:50 PM  Pagina 48
bioavailability of SQV-HGC, saquinavir plasma concentrations are
generally low which may predispose for the development of resistant viral
strains and subsequent treatment failure (2). It is therefore recommended
not to use SQV-HGC as a single protease inhibitor in highly active
antiretroviral therapy (HAART) (3). To overcome these pharmacokinetic
limitations, saquinavir has been formulated as soft gelatin capsules (SQV-
SGC), with a bioavailability of 331% as compared to SQV-HGC (1).
Therefore, SQV-SGC may be considered as a single protease inhibitor in
HAART in a dose of 1,200 mg tid (3). The antiviral potency of SQV-SGC
in combination with two nucleoside analogue reverse transcriptase
inhibitors (NRTIs) has been established in several clinical trials (1). In the
CHEESE Study, there was no difference in antiretroviral efficacy between
SQV-SGC 1,200 mg tid (n=35) and indinavir 800 mg tid (n=35), both in
combination with two NRTIs, in antiretroviral naive HIV-1-infected
patients after 48 weeks of treatment (4). However, a slight difference in
the response of CD4+ cells was observed in favour of the SQV-SGC group,
but this difference was not statistically significant (4).
Several studies previously reported relationships between the exposure to
saquinavir and both the decrease in plasma HIV-1 RNA concentration and
the increase in CD4+ cell counts (5-7). Furthermore, patients with an
estimated plasma saquinavir trough concentration above 50 ng/mL had a
significantly higher likelihood to have a sustained decline in HIV-1 RNA
of more than 2 log10 units below baseline after 48 week of therapy, in a
retrospective study in 130 mainly NRTI-pre-treated HIV-1-infected
patients (8). In the current study, we explored if the reported relationships
between the exposure to saquinavir and the virological and immunological
response also apply to antiretroviral naive HIV-1-infected patients treated
with SQV-SGC in combination with two NRTIs. Furthermore, by
comparison of the saquinavir plasma concentrations as observed in the
CHEESE study with the concentrations of saquinavir in a reference
population of 20 HIV-1-infected patients using SQV-HGC 1,200 mg tid,
we explored differences in the exposure to saquinavir between the two
dosage forms.
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Methods
Study design
In this study, the relationship between saquinavir plasma exposure and the
virological and immunological response to therapy was investigated in 29
patients from the previously described CHEESE Study. Briefly, the
CHEESE study was a randomised, parallel arm, open label, multicenter
study comparing the antiviral efficacy and safety of zidovudine (Retrovir;
Glaxo-Wellcome, Research Triangle Park, North Carolina, USA) plus
lamivudine (Epivir; Glaxo-Wellcome) plus SQV-SGC (Fortovase;
Hoffmann-La Roche, Inc., Nutley, New Jersey, USA) or zidovudine plus
lamivudine plus indinavir (Crixivan; Merck, West Point, Pasadena, USA),
in HIV-1 infected patients. Study visits were scheduled every four weeks
until week 24 and every eight weeks up to week 48. At screening, baseline
and every visit, samples for the quantification of the plasma HIV-1 RNA
concentration, the number of CD4+ cells and the plasma saquinavir
concentration were collected. The study was approved by the Institutional
Review Boards at each site and all participating patients gave written
informed consent.
Study patients
Patients of 18 years and older who were seropositive for HIV type 1 and
who were antiretroviral naive (with exception of zidovudine use for less
than 12 months), were screened for enrolment at eight locations in the
Netherlands. Patients were eligible for the CHEESE Study if at the
moment of screening plasma HIV RNA levels were at least 10,000
copies/mL (Amplicor HIV monitor test, Roche Diagnostics), and/or if
CD4 counts were less than 500 cells/µL, and/or if they had a history of
HIV related symptoms (CDC stage B or C). The exclusion criteria have
been described before (9). 
Patients eligible for the present substudy were those assigned to treatment
with SQV-SGC 1,200 mg tid plus zidovudine 200 mg tid plus lamivudine
150 mg bid. Patients were included if they had 3 or more evaluable plasma
saquinavir concentrations. Plasma saquinavir concentrations were
considered evaluable if the time of ingestion of the last saquinavir dose and
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the time of blood sampling were known. One or more evaluable samples
had to be from week 4-12.
Pharmacokinetic analysis
Plasma concentrations of saquinavir were determined at each study visit.
The time of ingestion of the last dose of saquinavir and when a blood
sample was drawn was recorded. Plasma concentrations of saquinavir were
determined with a sensitive and validated reversed-phase high-
performance liquid chromatographic assay with a lower limit of
quantification of 25 ng/mL at a central laboratory (10). The saquinavir
concentrations were compared to the time-adjusted (rounded to half hours)
average saquinavir concentration as measured (in the same laboratory) in a
reference population of 20 HIV-1-infected patients using SQV-HGC
1,200 mg tid plus 2 NRTI’s. The ratio of the observed concentration and
the reference concentration (concentration ratio; CR) was used as a measure
of the exposure to saquinavir for analysis of pharmacokinetic-
pharmacodynamic (PK-PD) relationships.
Virologic and immunologic analysis.
At each site, plasma (EDTA) was processed, stored at -70 °C and assayed
for HIV-1 RNA by an ultrasensitive reverse transcription-PCR assay with
a lower limit of detection of 50 copies/mL (Roche Amplicor Monitor) at a
central laboratory. Absolute numbers of CD4+ and CD8+ T lymphocytes
were determined at a central laboratory by flow cytometry. 
For the analysis of PK-PD relationships the following parameters of
virologic response were defined: (a) the decrease of the plasma HIV-1 RNA
concentration after 4 weeks of therapy, (b) the slope of the ln-transformed
(natural logarithm) HIV-1 RNA decline from week 4 to week 12 as
estimated by least squares linear regression analysis (i.e. the elimination
rate constant, assuming mono-exponential decay between week 4-12), (c)
the time to achieve a plasma HIV-1 RNA concentration < 50 copies/mL,
and (d) the plasma HIV-1 RNA concentration at 48 weeks follow-up. 
The CD4+ increase after 48 weeks was used as a measure of immunological
response.
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Statistical Analysis
Baseline values of plasma log10 HIV-1 RNA concentrations and CD4
+ cell
counts were calculated as the mean of two consecutive pre-treatment
determinations, the first between day -14 and day -7 and the second on
day 0. Analysis of the plasma HIV-1 RNA concentration was performed on
an intention-to-treat (ITT) basis counting missing values either as failures
(ITT-MF) and carrying the last observation forward (ITT-LOCF). On
treatment (OT) analyses, representing all those patients for whom data
were available at 48 weeks, are also presented. 
For the analysis of PK-PD relationships, the median, minimum and
maximum CRs of saquinavir from week 4 to 12, and during 48 weeks were
calculated for each patient. Linear regression analysis was used to test the
association between PK and PD parameters. For statistical calculations,
the Statistical Product and Service Solutions (SPSS) for Windows was used
(version 6.1, SPSS Inc., Chicago, IL, USA). A p-value of 0.05 or less was
considered statistically significant. 
Results
Patients
In total, 35 patients were enrolled in the SQV-SGC treatment arm of the
CHEESE Study from January 1997 to February 1998. Twenty-nine
patients (Table 1) were included in the present study. The mean duration
of follow-up was 45 weeks (range 16 to 48 weeks). Twenty-two patients
completed 48 weeks of follow-up.
Saquinavir pharmacokinetics
A total of 208 evaluable plasma saquinavir concentrations were obtained
from 29 patients. The saquinavir concentrations ranged from undetectable
(< 25 ng/mL) to 4,306 ng/mL (median 152 ng/mL) and the time post
ingestion of the last dose of saquinavir ranged from 0 to 9 hours (median
4.5 h). A scatter plot of all evaluable saquinavir concentrations is shown in
Figure 1. The median CR of all samples was 0.59 (interquartile range 0.26
- 1.49, range 0.00 - 21.35). The intra- and interpatient variability of the
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saquinavir CR was 133% and 104%, respectively (analysis of variance;
ANOVA). 
Three patients had relatively high plasma saquinavir concentrations which
were occasionally above 2,000 ng/mL (Fig.1 ). Except for one CR, these
three patients had CRs which were above 1.0 during the whole study
period. The reason for the relatively high exposure to saquinavir these
patients is unclear (the patients did not use co-medication known to
interfere with saquinavir metabolism and had no signs of abnormal liver
function). 
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Characteristic Values
Gender - no. of patients (%)
male 27 (93.1)
female 2 (6.9)
Mean age (±SD) - yr 39 (± 7.58)
Race (ethnic group) - no of patients (%)
Caucasian 25 (86.2)
Afro-european 3 (10.3)
Oriental 1 (3.5)
Prior AIDS defining illness - no of patients (%) 4 (13.8)
CD4 count - cells / µL
Mean 300
Range 10-750
Plasma HIV RNA (log10 copies/mL)
Median 5.00
Range 3.41- 6.87
Table 1. Baseline characteristics of the study patients (n=29)
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Interestingly, the median CR of saquinavir decreased from 0.70 at week 4
(n=28) to 0.55 at week 48 (n=12) (Figure 2, p=0.04, Pearson´s
correlation). If only the data from the 12 patients of whom CRs were
available at week 48 of therapy were included in this analysis, a similar
relationships was observed (p=0.06, r2 = -0.64, Pearson´s correlation). 
Virological and immunological results
The median log10 decline of the plasma HIV-1 RNA concentration after 4
weeks of therapy was 2.15 (range 0.89 - 3.26). The median elimination
rate constant of plasma HIV-1 RNA from week 4 to 12 was 0.21 week-1
(range -0.60 - 0.51). The median time to achieve a plasma HIV-1 RNA
concentration < 50 copies/mL was 16 weeks, ranging from 4 weeks to >
48 weeks. In an OT analysis 19/22 patients (86.4%) had a plasma HIV-1
RNA concentration < 50 copies/mL after 48 weeks follow-up. In an ITT-
MF and ITT-LOCF analysis 19/29 (65.5%) and 22/29 (75.9%) patients
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Figure 1. Scatter plot of the saquinavir plasma concentrations (n=208) obtained from 29
HIV-1-infected patients at regular intervals during a 48-week period. The patients used
saquinavir soft gelatin capsules 1,200 mg tid plus zidovudine and lamivudine. The solid line
represents the average steady-state saquinavir plasma concentration versus time curve during a
dosing interval as measured in 20 HIV-1-infected patients using saquinavir hard gelatin
capsules 1,200 mg tid.
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had a plasma HIV-1 RNA concentration < 50 copies/mL after 48 weeks
follow-up, respectively. During 48 weeks of treatment, the median
number of CD4+ cells in peripheral blood increased by 150 cells/µL (range
-180 to 730 cells/µL).
Relationships with saquinavir pharmacokinetics
Since it is currently unknown which pharmacokinetic parameter of the
protease inhibitors is best related to the response to therapy, we used the
median, minimum and maximum CR of saquinavir as observed for each
individual patient to explore exposure-response relationships. The median,
minimum and maximum CR of saquinavir during week 4 to 12 were not
related to the decrease in plasma HIV-1 RNA concentration after 4 weeks
of therapy nor to the plasma HIV-1 RNA decay rate during 4 to 12
(p≥0.62).
The median, minimum and maximum CRs of saquinavir during 48 weeks
were not related to the time to achieve a plasma HIV-1 RNA
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Figure 2. Relationship between the median concentration ratio of saquinavir (see text for
explanation) and the duration of treatment as measured in 208 plasma samples obtained from
29 HIV-1-infected patients using saquinavir soft gelatin capsules 1200 mg tid plus zidovudine
and lamivudine (p=0.04, Pearson´s correlation).
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concentration < 50 copies/mL (p≥0.39). The maximum and minimum
CRs (median) for patients with less than 50 HIV-1 RNA copies/mL at
week 48 were 2.42 and 0.21, respectively, as compared to 0.99 and 0.11,
respectively, for those with a higher plasma viral load > 50 copies/mL at
week 48 (p=0.09 and p=0.06, respectively, Mann-Whitney U test, OT
analysis). Patients with a median CR higher than the median CR of all
samples did not have a higher chance to achieve an undetectable plasma
viral load at 48 weeks (p≥0.14, Fisher’s exact test). 
To explore if plasma saquinavir concentrations during the initial three
months of antiretroviral therapy (when plasma HIV-1 RNA concentrations
are high) have more influence on virologic outcome at week 48, than the
overall exposure to saquinavir during 48 weeks, we evaluated the
relationships between CR’s from week 4-12 and the plasma HIV RNA
load at week 48. In an OT analysis, the maximal CR during week 4-12
was higher for patients with a plasma HIV-1-RNA concentration below 50
copies/mL at week 48 as compared to those with a viral load > 50
copies/ml at week 48, although not significantly. (maximal CR values
(medians) were 1.41 and 0.49, respectively, for those with a plasma viral
load below and above 50 copies/mL at 48 weeks of therapy, p=0.053,
Mann-Whitney U test). This difference was less clear in an ITT-MS or
ITT-LOCF analysis (p≥0.22). 
Of note, the baseline plasma log10 HIV-1 RNA concentration was
positively and significantly correlated with the log10 decrease of the
plasma HIV-1 RNA concentration after 4 weeks (p=0.02, r2=0.44,
Pearson´s correlation) and with the time to achieve a plasma HIV-1 RNA
concentration below 50 copies/mL (p<0.01, r2=0.67, Pearson´s correlation,
after exclusion of patients not achieving an undetectable plasma viral load
before week 48). Furthermore, patients with an HIV-1 RNA concentration
of less than 50 copies/mL at 48 week of therapy had a lower baseline log10
HIV-1 RNA concentration as compared to those with a detectable plasma
viral load at 48 weeks, in all analyses (p≥0.08, Mann-Whitney U test). 
PK OF SAQUINAVIR IN THE CHEESE STUDY56
hoofdstuk 03  9/21/00  12:50 PM  Pagina 56
The regimen was generally well tolerated, with diarrhoea (n=11) and
nausea (n=9) as the most frequently reported side-effects. The exposure to
saquinavir was not different between patients with and without side-
effects (data not shown). No relationship was observed between the plasma
exposure to saquinavir and the immunological response to therapy (data
not shown).
Discussion
The soft gelatine capsule of saquinavir, which was used in this study, was
developed to improve the limited oral bioavailability of saquinavir (i.e
approximately 4%) when used as the initially developed hard gelatin
capsules (1). The oral bioavailability of SQV-SGC has been shown to be
331% relative to SQV-HGC (1). However, a higher bioavailability of SQV-
SGC as compared to SQV-HGC could not be confirmed in our study. In
contrast, the overall median concentration is 41% lower as compared to
the concentrations observed in a reference population of 20 HIV-1-infected
patients using SQV-HGC 1,200 mg tid. 
Several causes may have contributed to the observed low saquinavir
concentrations in the CHEESE Study. The plasma saquinavir concentration
versus time curves as measured in the reference population were obtained
after an observed ingestion of 1200 mg SQV-HGC together with a meal,
since it is well known that saquinavir should be ingested with food to
ensure adequate absorption (1). In the CHEESE Study, however, the
medication was ingested at home (unobserved) and incorrect ingestion
(e.g. without an adequate meal) may therefore be an important factor
explaining the relative low plasma saquinavir concentrations, despite the
use of SQV-SGC. 
To exclude the possibility of inaccuracy of our bioanalytical assay as the
cause for the low saquinavir concentrations, 40 samples from the CHEESE
study were re-analysed by a commercial contract laboratory (using a
radioimmunoassay). Cross-analysis of these samples with saquinavir
concentrations ranging from 29 to 1,737 ng/mL (median 237 ng/mL)
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resulted in a median difference in the saquinavir concentrations of 2.2%
(interquartile range -7.4 - 10.8%), which confirmed our results.
During the course of the study the exposure to saquinavir decreased from a
CR of 0.70 at week 4 to a CR of 0.55 at week 48. A similar observation
was recently reported for HIV-1-infected patients using saquinavir 400 mg
bid in combination with ritonavir 400 mg bid (11). In this study, the
plasma pharmacokinetics of saquinavir and ritonavir were assessed in 6
HIV-1-infected patients on 2 occasions, 9-15 months apart. On the second
study day, the area under the plasma concentration versus time curve
(AUC) of saquinavir was decreased by 33% (median value) while the AUC
of ritonavir was unaffected (11). Induction of the expression or activity of
P-glycoprotein (Pgp), a multidrug transporting protein which is present
in, amongst others, the gastrointestinal tract may contribute to this
observation (12). Induction of the expression of Pgp has recently been
reported to occur in response to the exposure to Pi’s in cell culture (13).
Furthermore, changes of the intestinal function due to the exposure to
saquinavir may play a role in this respect (14,15). It was recently shown
that saquinavir, ritonavir and nelfinavir but not indinavir impair the
epithelial barrier in a human intestinal cell line (15). This might explain
our observations in the CHEESE Study since the exposure to saquinavir
decreased over time while the exposure to indinavir did not appear to
change (16). Long-term effects of the exposure to saquinavir on its
metabolism or altered patient adherence to the therapeutic regimen over
time should also be considered.
Several studies have shown relationships between the exposure to protease
inhibitors and their activity and toxicity (5-8, 17,18). These findings, in
combination with the wide inter-individual variability in the
pharmacokinetics of these drugs, have resulted in a growing interest in
therapeutic drug monitoring (TDM) of antiretroviral drugs as an
additional tool in the management of HIV-1-infected patients. In the
current study, however, no such relationships were observed between the
exposure to saquinavir and the virological and immunological response to
triple therapy with SQV-SGC 1,200 mg tid, zidovudine and lamivudine in
antiretroviral naive HIV-1-infected patients during a 48 week follow-up.
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Our findings are in contrast with previously reported positive relationships
between the exposure to saquinavir and the virological and immunological
response. However, the patients in these studies were treated with
saquinavir monotherapy (5,6) or were NRTI-experienced (7,8).
Consequently, the triple drug regimen which was used by antiretroviral
naive patients in the current study is expected to result in a more potent
suppression of viral replication, which may reduce the influence of
variation in saquinavir exposure on the virologic response. Furthermore,
the relative small sample size and the marked intrapatient variability in
the exposure to saquinavir may have hampered the detection of PK-PD
relationships in our study. 
Despite the relatively low plasma saquinavir concentrations in the
CHEESE Study, 65.5% of the patients had a plasma HIV-1 RNA
concentration < 50 copies/mL at 48 weeks of therapy (ITT-MF) with a
median increase in the CD4+ cell count of 150 cells/µL, which was not
different from the control arm consisting of indinavir 800 mg tid plus
zidovudine and lamivudine (16). Of note, the median CR of indinavir in
the CHEESE Study was 1.08 suggesting that the exposure to indinavir was
similar as in a reference population (16). Seventeen patients in our study
continued the combination of SQV-SGC 1200 mg tid plus zidovudine and
lamivudine after 48 weeks. After a median follow-up of 94 weeks (range
62 to 106 weeks), 14/17 (82%) and 17/17 patients (OT) had a plasma
HIV-1-RNA concentration below 50 and 400 copies/mL, respectively. The
overall median CR of saquinavir in these 17 patients during the whole
treatment period was 0.52. The median overall CR in these 17 patients
between week 48 and week 106 was 0.29, suggesting that the observed
decrease in the exposure to saquinavir from week 4 to week 48 continues
thereafter.
The strong antiviral response despite low saquinavir plasma concentration
may be explained by intracellular pharmacokinetics of saquinavir. It was
recently shown that the protease inhibitors have distinct intracellular
pharmacokinetic properties in vitro (19,20). Interestingly, saquinavir
showed more intracellular accumulation as compared to indinavir or
ritonavir (19,20). Furthermore, the intracellular half-life of saquinavir was
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estimated to be approximately 8 h, as compared to a plasma elimination
half-life of 1-2 h (20). As a result, production of infectious HIV-1 was
suppressed for up to 24 h after removal of extracellular saquinavir,
depending on the concentration with which cells were treated initially
(20). Accumulation of saquinavir at the site of HIV-1 replication (i.e.
intracellular) may have contributed to the sustained virological response,
despite relatively low plasma saquinavir concentrations. It was recently
shown that patients with subtherapeutic plasma indinavir concentrations
may have intracellular concentrations within acceptable limits (21). The
relationship between the plasma- and intracellular pharmacokinetics of the
protease inhibitors in vivo is currently unknown and should be investigated
to understand the PK-PD relationships of the protease inhibitors.
In conclusion, a higher bioavailability of saquinavir when used as SQV-
SGC versus hard gelatine capsules was not confirmed in this study.
Furthermore, there is a trend of decreasing exposure to saquinavir over
time. In contrast with previous findings, our data suggest that the plasma
exposure to saquinavir may not be related to the suppression of viral
replication in antiretroviral naive HIV-1-infected patients over a period of
48 weeks when used with a backbone of two NRTIs. Despite the relatively
low plasma saquinavir concentrations in our study, a good virological and
immunological response was observed which was maintained up to 106
weeks of follow-up. These findings warrant further evaluation of
monitoring plasma drug concentrations during the management of HIV-
1-infected patients.
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Abstract
Introduction: Regeneration of CD4+ T lymphocytes has been shown to be
thymus-dependent in bone marrow transplant recipients and after
intensive chemotherapy. The rate of CD4+ T-cell regeneration positively
correlates with enlargement of the thymus on radiographs and higher rates
of CD4+ T-lymphocyte regeneration were observed in children as
compared to adults, consistent with diminishing thymic function with
age.
We hypothesized that in HIV infected patients CD4+ T-cell recovery
during highly active antiretroviral therapy (HAART) may also be thymus
dependent. Therefore, repopulation of naive (CD45RA+), memory
(CD45RO+) and total CD4+ T lymphocytes and total CD8+ T
lymphocytes in peripheral blood was assessed in 13 HIV infected children
during the initial 3 months of HAART. 
Results: Significantly higher recovery rates of naive, memory and total
CD4+ T cells in children below the age of three years were observed as
compared to older children. Kinetics of total CD8+ T cells showed no
relation to age. Moreover, recovery rates of naive CD4+ T cells in patients
below 3 years of age were 10-40 fold higher as compared to previously
reported naive CD4+ T-cell recovery rates in adults on HAART. 
Conclusions: High recovery rates of naive, memory and total CD4+ T cells
can be achieved in children below 3 years of age. Changes of CD8 counts
did not correlate with age. These results indicate that regeneration of
CD4+ T cells during HAART may be a thymus dependent process.
Keywords: CD4, CD8, Pediatrics, Antiretroviral therapy, Immune
Reconstitution.
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Introduction
Treatment of HIV infected adults with highly active antiretroviral
treatment (HAART) results in a decline of plasma HIV RNA levels and an
increase of circulating CD4+ T cells. However, because of slow CD4+ T-
cell regeneration in adults, complete restoration of CD4+ T-cell numbers
and function, if possible at all, will take considerable time. The
reconstitution pattern of CD4+ T cells in peripheral blood during HAART
is biphasic: an initial rapid rise of CD4+ T cells in the first month of
treatment is followed by a much lower rate of CD4+ T-cell increase. The
initial rapid CD4 cell rise is predominantly due to an increase of
circulating memory CD4+ T cells. Recovery rates of naive CD4+ T cells are
low throughout the course of treatment (1,2).
In humans, the capacity to regenerate CD4+ T cells declines with age. In
children who received antineoplastic chemotherapy or bone marrow
transplantation, the rate of CD4+ T-cell regeneration was higher as
compared to adults due to production of CD45RA+ (naive) CD4 cells
(3,4,5). In these children, increased production of CD45RA+/CD4+ T cells
is associated with thymic enlargement on radiographs. On the other hand,
in adults, sustained depletion of CD4+ T cells has been witnessed after
intensive antineoplastic chemotherapies, BMT or CD4 depletion therapy
for multiple sclerosis or rheumatoid arthritis using anti CD4 antibodies
(3-9). The difference in CD4+ T-cell recovery rates between children and
adults suggest that the pathway of CD4+ T-cell regeneration is thymus
dependent (10) and that the capacity for CD4+ T-cell regeneration
diminishes with age as a result of thymic involution. 
In contrast, thymus independent pathways exist for regeneration of CD8+
T cells, via peripheral expansion of mature CD8+ T cells in the lymphoid
organs (11,12).
The thymus-dependence of CD4+ T-cell regeneration leads one to expect a
more pronounced increase of CD4+ T cells following onset of potent
antiretroviral therapy in children as compared to HIV infected adults. In
this study we assessed repopulation in blood of CD4+ and CD8+ T cells
and naive and memory CD4+ T cells in HIV infected children on HAART.
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Methods
Plasma HIV RNA levels and kinetics of CD4+ and CD8+ T-cell subsets
were analyzed as part of a study investigating the efficacy and safety of
combination therapy with zidovudine, lamivudine and indinavir in HIV
infected pediatric patients. Dosages of each drug were as follows;
Zidovudine: 360 mg/mm2/day (t.i.d.); Lamivudine: > 30kg: 150mg
(b.i.d.), < 30 kg: 8mg/kg/day (b.i.d.); Indinavir 100-200 mg/day/kg
metabolic weight (t.i.d.). Blood samples were obtained at baseline and
after two weeks, 4 weeks, 3 months and 6 months from the onset of
therapy. Compliance regarding medication intake was assessed during each
visit.
Plasma HIV RNA levels were measured using a quantitative reverse
transcriptase polymerase chain reaction (RT-PCR) assay (Amplicor HIV-1
Monitor, Roche Diagnostic Systems). The lower limit of detection was 400
copies / ml.
Lymphocyte immuno-phenotyping for CD4+ and CD8+ T cells was
determined in whole blood by two color flow cytometry, using anti CD3,
anti CD4, anti CD8, anti CD45RA and anti CD45RO monoclonal
antibodies. CD4+ T lymphocytes expressing the CD45RA surface antigen
were considered thymic emigrants and naive cells, CD4+ T lymphocytes
expressing the CD45RO surface antigen were considered memory type
cells.
In the analysis, data were included from patients who were at least 90 days
on therapy and of whom immuno-phenotyping data was available from at
least three time points: At baseline, one at 90 days and at least one in
between (at week 2 and / or week 4 after initiation of therapy). Data from
patients with reported non compliance regarding intake of medication,
were excluded from analysis. 
At the moment of this analysis, 26 patients had entered the cohort. Data
from thirteen children could not be used for analysis due to the following
reasons: Of 8 children (0.95-14.9 years old) no blood samples from week
12 were available for immuno-phenotyping and for 2 children (3.1 and 7.3
years old) no blood samples were available from baseline. Two patients (1.1
and 2.5 years old) were non compliant regarding intake of medication. For
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one patient (7.3 years old), no blood samples at all were collected for
immuno-phenotyping. The median age of the group excluded from
analysis was 3.7 years (range 0.95-14.9 years), whereas the median age of
the included group was 7.7 years (range 0.8-16.3 years)). Median CD4
count at baseline of the excluded group was: 502 cells / µl (range 293-
1864 cells / µl). In the included group the median CD4 baseline count was
202 cells / µl (range 4-1720 cells / µl) (table 1). 
Results
Thirteen children were included in the analysis of whom the baseline
characteristics are shown in table 1. Median plasma HIV RNA level at
baseline was 69625 copies / ml. 
CHAPTER 4 67
age (years) plasma HIV RNA CD4
patient (copies / ml) (cells / µl)
a 0.80 682000 1720
b 0.88 761500 1154
c 2.88 51220 153
d 5.39 145273 195
e 5.40 194300 192
f 6.99 32580 4
g 7.70 65700 65
h 9.62 16800 284
i 10.55 18400 202
j 11.17 201700 4
k 13.16 393420 48
l 13.23 1345 233
m 16.33 1910 11
Table 1. Baseline characteristics
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Figure 1A. (Patient b) Responses of circulating numbers of naive and memory and total CD4+
T-lymphocytes during highly active antiretroviral therapy.
Figure 1B. (Patient e) Responses of circulating numbers of naive and memory and total CD4+
T-lymphocytes during highly active antiretroviral therapy.
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Figure 2A. Recovery rates of CD4+/CD45RA+ T lymphocytes (cells/µl/day) versus age
(years).
Figure 2B. Recovery rates of CD4+/CD45RO+ T lymphocytes (cells/µl/day) versus age
(years).
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Figure 2C. Recovery rates of total CD4+T-lymphocytes (cells/µl/day) versus age (years).
Figure 2D. Recovery rates of total CD8+ T-lymphocytes (cells/µl/day) versus age (years).
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During the initial three months of therapy median HIV RNA levels
decreased significantly to 500 copies / ml. Median total CD4+ T cells rose
from 202 (range 4-1864) cells / µl to 327 (range 11-2150) cells / µl.
Median total CD8+ T cells decreased from 936 to 880 cells / µl. 
Responses of naive and memory and total CD4+ T cells of two
representative patients (b and e) are shown in Figure (1A and 1B). Linear
regression analysis was used to calculate recovery rates in blood of total
CD4 and CD8 cells and memory and naive CD4 cells during the first 90
days of treatment. Recovery rates were expressed as the change in the
absolute number of cells per µl blood per day, as is shown in table 2. 
Recovery rates of total CD4+ and total CD8+ T cells and memory and
naive CD4 cells were plotted as a function of age at the start of therapy
(Figure 2A-2D). A significant difference in recovery rates of naive,
memory and total CD4+ cells was observed between children younger then
3 years of age and older children (p<0.02, Wald-Wolfowitz test)(Figure
2A,2B,2C). None of the patients above the age of 3 years had CD4+ T-cell
recovery rates (total, naive or memory) higher than any of the patients
below 3 years of age. In contrast, recovery rates of CD8+ T cells did not
show any relation to the age of the children (figure 2D).
Discussion
We observed that recovery rates of naive (CD45RA+), memory
(CD45RO+) and total CD4+ T cells were higher in patients < 3 years in
comparison to older children. In three children < 3 years we observed
recovery rates of naive CD4+ T cells of 3.20, 8.58 and 9.30 cells/µl/day,
which is 10-40 fold higher as compared to recovery rates of naive CD4+ T
cells in adults (0.2-0.4 cells/µl/day)(1)(Cohen Stuart et al., unpublished
data). Thus, although the number of patients in this analysis is limited,
our data clearly demonstrates the possibility of rapid recovery of naive
CD4+ T cells in young infants below three years of age.
These observations may be explained in several ways. Because the patients
in this study were horizontally infected, except for patient h, k and m (9.6,
13,2 and 16.3 years, respectively) the age of the patient generally equals
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the duration of HIV infection. Therefore, the shorter duration of HIV
infection in the youngest children may explain the high CD4+ T-cell
recovery rates. An age dependent capacity to redistribute T lymphocytes
from lymphoid tissues into the circulation after start of HAART could also
account for differences of CD4 cell recovery rates. However, such
explanation is inconsistent with the absence of any relation between age
and CD8 cell kinetics during HAART in this set of children. 
When comparing the three youngest patients (a-c) with the others (d-m),
it should be noted that patients a and b had higher baseline CD4 counts in
comparison to the others. This is probably related to their age. Babies
often have high numbers of circulating lymphocytes. It may be argued
that high CD4+ T-cell recovery rates in these young children (< 3 years)
may result from high CD4+ T-cell baseline values (table 1). Secondly,
patient a and b had higher plasma viral loads at baseline in comparison to
the other patients. However, in adults, it has been demonstrated that CD4
recovery does not depend on either baseline plasma HIV RNA or baseline
CD4 count values (13). Furthermore, no significant difference in the
magnitude of viral load reduction was found between the group of
youngest (a-c) and the group of older patients (d-m)(Wald-Wolfowitz test:
p=0.71).
Theoretically, CD45 isotype switching from CD45RO to CD45RA
phenotype may also account for increase of CD45RA+/CD4+ T
lymphocytes (15-17). However, direct evidence for reversion from memory
to naive phenotype in CD4 T lymphocytes has exclusively been found in
experimental murine models. Data on reversion of memory to naive
phenotype are conflicting (12) and it is unclear to what extend this
phenomenon plays a role in humans in vivo. Moreover, a rapid increase of
CD45RA+ CD4+ T cells occurred in patients who also had a rapid increase
of total CD4+ T cells. Therefore, if thymus input of CD45RA+ cells would
play a minor role and peripheral CD4 T-cell expansion would account for
CD4 T-cell increase, the reversion from CD45R0 to CD45RA would have
to occur at a substantial level in dividing CD4 cells. This is inconsistent
with data demonstrating CD45R0 expression in dividing T-cell
populations (18). 
We conclude that high recovery rates of naive CD45RA+/CD4+ T cells in
patients <3 years of age during HAART may be best explained by the
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presence of a functional thymus. Recently, it was reported that
regeneration of CD45RA+/CD4+ T cells and expansion of thymus volume
are positively correlated in HIV infected children during HAART (14). 
After antineoplastic chemotherapy, the rate of CD4 cell recovery gradually
diminishes with age (3,4). In children on HAART, we did not find a
gradual decrease of the rate of CD4 recovery but in subjects older than 3
years we observed CD4 recovery rates comparable to the rates of adult HIV
infected patients on HAART. This may be explained by precocious
involution of the thymus, as a result of HIV mediated destruction of
thymic parenchyma.
In summary, we demonstrated that high recovery rates of naive, memory
and total CD4+ T cells can be achieved in children below the age of 3 years
on HAART, whereas CD8+ T-cell kinetics showed no relation to age. This
indicates that regeneration of CD4+ T cells during HAART uses a
thymus-dependent pathway. 
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Abstract
Introduction: The mechanism of regeneration of naive CD4+ and CD8+ T
cells during highly active antiretroviral therapy (HAART) is unclear. If it
were mainly dependent on thymic function, the regeneration rate should
decrease with age, due to thymic involution. 
Objective: To determine the influence of age on the regeneration rate of
naive and memory T cells in 45 adults on HAART. 
Methods: The number of naive and memory T cells was determined in
whole blood. Naive cells were defined as CD45RA+CD27+. Cells negative
for CD45RA and/or CD27 were considered memory type cells.
Results: The age of the patients ranged from 25 to 57 years. On average
(±SEM), the regeneration rates of naive CD4+ and CD8+ T cells were
0.34±0.04 and 0.36±0.04 cells/mm3/day, respectively, which is not
significantly different (p=0.5). The recovery rates of naive CD4+ and CD8+
T cells were negatively correlated to age (r= -0.41 and r= -0.47,
respectively). The recovery rate of memory T cells showed no relation to
age. The regeneration rate of naive CD4+ T cells during HAART is similar
to previously reported regeneration rates in adults following cytotoxic
chemotherapy or CD4 mAb therapy. This suggests a little, or at least
reversible, impact of HIV on naive T-cell production. 
Conculusion: The equal regeneration rate of naive CD4+ and CD8+ T-cells
during HAART, and the inverse correlation between age and the recovery
rate of naive T cells, both suggest that the thymus contributes
considerably to the regeneration of naive T cells in adults on HAART.
Keywords: Antiretroviral therapy, CD4, CD8, Naive/memory, Immune
Reconstitution 
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Introduction
Infection with HIV causes progressive depletion of both naive and memory
CD4+ T cells. The CD8 count of HIV infected patients is usually increased
until shortly before the onset of AIDS. This increase is due to expansion of
the memory CD8+ T-cell population. Naive CD8+ T-cell counts decrease
gradually from early after seroconversion (1,2).
In most patients, highly active antiretroviral therapy (HAART) leads to a
substantial rise of the CD4 count, primarily due to an increase of memory
CD4+ T cells (3-5). The effect of HAART on the CD8 count varies per
study from a slight increase (4,6,7) to a decrease (3,8,9). Naive CD4+ and
naive CD8+ T cells increase slowly during HAART (3,4,10). 
The mechanism of regeneration of the naive T cells during HAART is
unclear. It has been attributed to thymus dependent production (10-13),
proliferation of naive T cells (11,12,14,15) and reversion from the memory
to the naive phenotype (15). To understand the mechanism of naive T-cell
regeneration is important because HIV induced deletions in the T-cell
receptor repertoire (16,17) can exclusively be restored via thymus
dependent production of naive T cells.
The generation and production of T cells is primarily located in the
thymus. Because of thymic involution with increasing age (18,19), the
capacity to regenerate T cells after depletion diminishes with age. It has
been demonstrated that the recovery rate of peripheral CD4+ T cells after
antineoplastic chemotherapy decreased with the age of the patients. In
adults over 20 years of age, CD4+ T-cell recovery after depletion is slower
than in children and appears to be predominantly due to thymus-
independent peripheral proliferation (20-24). 
Here, we tested whether in HIV infected adults the speed of regeneration
of naive T cells during HAART decreases with age. Therefore, we
determined the influence of age on the rate of reconstitution of naive and
memory CD4+ and CD8+ T cells in 45 adults with successful suppression
of plasma HIV RNA levels during HAART. 
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Material and methods
Study population 
The recovery of naive and memory T cells was analyzed in all patients from
the previously described CHEESE study cohort (25) with a sustained
plasma HIV RNA response to less than 50 copies/ml (n=45). Briefly, this
is a randomized study comparing antiviral efficacy of zidovudine (Retrovir,
Glaxo-Wellcome, Research Triangle Park, N.C.) plus lamivudine (Epivir,
Glaxo-Wellcome, Research Triangle Park, N.C.) plus saquinavir-soft-
gelatin-capsules (SQV-SGC, Fortovase, Hoffmann-La Roche, Inc., Nutley,
New Jersey) versus zidovudine plus lamivudine plus indinavir (Crixivan,
Merck, West Point, Pa), in HIV-1 infected patients. Antiretroviral naive
patients were eligible for study treatment if at the moment of screening
plasma HIV RNA levels were at least 10,000 copies/ml and/or if CD4
counts were less than 500 cells/mm3 and/or if they had a history of HIV
related symptoms (CDC stage B or C). During 48 weeks of treatment, the
virologic and the CD4 count response was not different between the two
treatment arms (26). Of the selected patients, 23 were from the indinavir
arm and 22 from the SQV-SGC arm. 
Blood sampling
Blood samples were obtained at week -2, at week 0 and every 4 weeks
through week 24 and every 8 weeks from week 24 through week 48 of
treatment.
Plasma Viral Load
Plasma HIV RNA levels were measured using an investigational version of
the ultra sensitive quantitative reverse transcriptase polymerase chain
reaction (RT-PCR) assay (Amplicor HIV-1 Monitor, Roche Diagnostic
Systems). The lower limit of detection was 50 copies / ml.
Monoclonal antibodies
Peridinin chlorophyll protein (PerCP)-labeled CD4, PerCP-labeled CD8
and phycoerythrin (PE)-labeled CD45RA Mab’s were obtained from
Becton Dickinson (San Jose, CA). FITC labeled CD27 Mab’s were obtained
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from CLB (Amsterdam, the Netherlands).Flow Cytometry. The fraction of
naive and memory (CD45RA- and CD45RA+/CD27-) T cells was
determined by three color FACS analysis using monoclonal antibodies
against CD4 (or CD8), CD45RA, and CD27 on EDTA anticoagulated
venous blood (FACScan; Becton Dickinson Immunocytometry Systems,
San Jose, CA). 
Statistical Analysis
Parametric Pearson’s correlation coefficients were computed to measure
bivariate correlations. All variables used to compute Pearson’s correlation
coefficients were normally distributed, as tested by the Kolmogorov-
Smirnov one-sample test. The paired-samples t test for two related samples
was used to detect a difference between the recovery rates of naive CD4+
and CD8+ T cells. All reported p-values are two-sided. All statistical
analyses were performed using SPSS for Windows (8.0.0).
Results
Because immune recovery during HAART is dependent on virus
suppression to levels below the limit of detection (27), we investigated the
reconstitution of T cells during 48 weeks of therapy in a group of patients
who all achieved plasma HIV RNA levels below 50 copies/ml. The
baseline characteristics of the patients were as shown in Table 1. The mean
age of the patients at baseline was 37.2 years (range 25-57 years). The
median plasma HIV RNA level at baseline was 72,000 copies/ml. The
patients achieved plasma HIV RNA levels below 50 copies/ml within a
median period of 16 weeks (range 4-44). 
In the analysis of T-cell reconstitution, T cells co-expressing CD45RA and
CD27 were considered truly naive cells (28,29). Memory T cells were
defined as CD45RA+/CD27- and as CD45RA- (both CD45RA-/CD27+
and CD45RA-/CD27-). During the initial 48 weeks of therapy, the mean
(±SEM) total, naive and memory CD4+ T-cell count in peripheral blood
increased with 206±34, 112±17 and 53±23 cells/mm3, respectively
(Figure 1). The total and memory CD8+ T-cell count decreased with
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140±60 and 240±55 cells/mm3 in 48 weeks. The number of circulating
naive CD8+ T cells increased with 126±16 cells/mm3 during 48 weeks of
therapy.
To estimate the average recovery rate of naive and memory T cells in the
blood during the initial 48 weeks of HAART, linear regression analysis
was used. The mean (± S.E.M.) recovery rates of naive CD4+ and CD8+ T
cells were 0.34±0.04 and 0.36±0.04 cells/mm3/day, respectively. These
rates are similar to previously reported recovery rates of naive T cells
during HAART in adults (3,4,13). The recovery rates of naive CD4+ and
naive CD8+ T cells were not significantly different (paired samples t test,
p=0.5) and correlated positively (r = 0.7, p<0.001; Figure 2). The recovery
of memory CD4+ T cells was biphasic, with a rapid recovery rate in the
first 4 weeks of therapy (1.46±0.4 cells/mm3/day) and a slow recovery rate
between week 4 and week 48 (0.17±0.06 cells/mm3/day), consistent with
findings of others (4). The mean recovery rate of memory CD4+ T cells
over the whole study period (week 0-week 48) was 0.22±0.05
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BASELINE WEEK 48
Age (years ± SD) 37.2 ± 8.3 N.A.
Plasma HIV RNA levels (copies /ml)
Median 72000 <50
Range 1630-2,310,000 N.A.
Mean T-cell counts (cells/mm3 ± S.E.M):
Total CD4+ 301 ± 28 507 ± 40
Naive CD4+ 98 ± 13 210 ± 21
Memory CD4+ 193 ± 18 286 ± 27
Total CD8+ 1010 ± 80 872 ± 43
Naive CD8+ 131 ± 14 257 ± 17
Memory CD8+ 826 ± 67 586 ± 43
Table 1, Patient Characteristics At Baseline And Week 48 (N=45)
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Figure 1a. Reconstitution of absolute number of circulating (a) CD4+ and (b) CD8+ T cells
during 48 weeks of HAART: total count (), memory cells () and naive cells ().
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cells/mm3/day. The daily decrease of memory CD8+ T cells was 0.72±0.13
cells/mm3/day. No differences of recovery rates were observed between the
two treatment groups (data not shown).
To eliminate the contribution of lymphocyte redistribution on the recovery
of naive T cells in the blood, the recovery rates were also estimated for the
period when plasma HIV RNA levels were below 50 copies/ml.
Redistribution of lymphocytes from lymphoid tissue to the blood
predominantly occurs during the first weeks of HAART, due to decreased
inflammation in the lymphoid tissue (4). The recovery rates of naive CD4+
and CD8+ T cells in the period after the patients achieved plasma HIV
RNA levels <50 copies/ml were 0.34±0.06 and 0.35±0.05 cells/mm3/day,
respectively. These recovery rates were not significantly different from the
recovery rates based on the entire 48 weeks of treatment (p=0.99 and
p=0.7, respectively), suggesting that redistribution had no significant
influence on our estimates of the recovery rate of naive T cells.
Because thymic function diminishes with increasing age, we determined
the influence of age on the speed of naive T-cell regeneration. The recovery
rates of the naive CD4+ and CD8+ T cells correlated negatively with the
age of the patients (r = -0.41, p=0.005 and r = -0.47, p=0.001,
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Figure 2. Correlation between the regeneration rate of naive CD4+ T cells and naive CD8+ T
cells (r = 0.7, p<0.001).
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Figure 3. Correlations between age and recovery rates of T-cell subsets. (a) Correlation between
age and the recovery rate of naive CD4+ T cells (r = -0.41, p=0.005). The decrease of the
recovery rate of naive T cells with increasing age fitted to an exponential function: R(a) =
p1ep2(a), where R(a) is the recovery rate and a is the age. The parameters p1 and p2 (± S.D.),
found by non-linear regression analysis (excluding 2 negative recovery rates) were as follows:
p1=1.7 (±1.8), p2= -0.050 (±0.016), corresponding to a decay rate of 5.0% per year.
(b) Correlation between the age and the recovery rate of naive CD8+ T cells (r = -0.47,
p=0.001). The parameters of the R(a) function (excluding 4 negative recovery rates) were:
p1=1.2 (±1.7), p2= -0.036 (±0.016), corresponding to a decay rate of 3.6% per year.
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Figure 3. Correlations between age and recovery rates of T-cell subsets. 
(c) Correlation between the age and the recovery rate of memory CD4+ T cells (r = -0.07,
p=0.6). 
(d) Correlation between the age and the decrease rate of memory CD8+ T cells (r=0.1, p=0.2).
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Figure 4. Correlation between baseline naive T-cell counts and the recovery rate of naive T cells
during HAART. Figure 4a. Naive CD4+ T cells. Figure 4b. Naive CD8+ T cells.
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respectively; Figure 3). The decrease of the recovery rates with increasing
age fitted best to an exponential function (Figure 3a, 3b). The recovery
rates of naive CD4+ and CD8+ T cells decreased 5.0 % per year (p=0.003)
and 3.6% per year (p=0.02), respectively. The recovery rate of memory
CD4+ T cells was not correlated to the age (r=-0.07, p=0.6), nor was the
daily decrease of memory CD8+ T cells (r=0.1, p=0.2). Thus, our results
indicate that the age of the patients is an important factor in naive T-cell
regeneration.
To investigate whether the regeneration rate of naive T cells depends on
the number of pre-existent naive T cells, we determined the relation
between pretreatment counts of naive CD4+ and CD8+ T cells and the
recovery rate of the respective T-cell subsets. No significant correlations
were observed between naive T cell baseline counts and recovery rates (r =
0.2 p=0.2 and r = -0.1, p=0.4, respectively, Figure 4). This suggests that
peripheral expansion plays a limited role in the regeneration of naive T
cells. 
Next, we determined the contribution of other factors on the speed of
regeneration of naive T cells. First, the reduction of plasma HIV RNA
levels during 48 weeks of HAART did not correlate to the recovery rate of
the naive CD4+ and CD8+ T cells (r = 0.1, p=0.3 and r = 0.07, p=0.6,
respectively). Secondly, no correlation was found between the rate of naive
T-cell recovery and surrogate markers for the stage of HIV disease at
baseline, total CD4 count and HIV RNA plasma levels (each p value >
0.3). Thus, baseline naive T-cell counts, viral load reduction during
therapy and disease stage prior to therapy, do not contribute in a major
way to the regeneration rate of naive T cells during HAART.
Discussion
In this study, we investigated the changes in the blood of the numbers of
phenotypically naive and memory T cells during HAART. For the first
time, we demonstrate that the recovery rate of naive CD4+ and CD8+ T
cells during HAART is inversely correlated to the age of the patients
(figure 3). The rate of increase in memory CD4+ T cells and the decrease
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rate of memory CD8+ T cells showed no relation to the age of the patients.
Regeneration of naive T cells during HAART may involve a thymus
dependent and a thymus independent pathway. Although an influence of
age on the thymic independent pathway cannot be excluded, the most
plausible explanation for the inverse correlation between age and the
regeneration rate of naive T cells is that the thymus dependent pathway
plays an important role in naive T-cell regeneration, because thymic
function diminishes with age (18,19). Moreover, the exponential decrease
of the regeneration rates during aging (5.0% and 3.6% per year for naive
CD4+ and CD8+ T cells, respectively, Figure 3) is in close agreement with
the reported exponential decay of the volume of the thymic epithelial space
at a rate of 4.1% per year in adults above 20 years of age (18). Apparently,
the amount of thymic parenchyma plays a rate limiting role in the
regeneration of naive T cells (13). 
The inverse correlation between age and the recovery rate of naive T cells
should be considered with one caveat, because the older patients may also
have the longest duration of HIV infection. The duration of HIV infection
was unknown in this study. However, laboratory markers of duration of
infection, baseline CD4 count and plasma HIV RNA levels, did not
correlate with either age nor with the recovery rates of naive T cells. The
duration of infection is therefore not likely to be a confounding factor.
The finding that the recovery rates of naive CD4+ and CD8+ T cells during
HAART are not significantly different (p=0.5) appears in contrast with
previous observations that naive CD8+ T-cell regeneration is faster than
naive CD4+ T-cell regeneration after antineoplastic chemotherapy (21,24).
The higher regeneration rate of naive CD8+ T cells was attributed to
extrathymic production of naive CD8+ T cells. However, these studies
used CD45RA expression as the marker of naive CD8+ T cells, which
seems inaccurate because the CD45RA+/CD8+ T-cell population contains
besides naive cells also fully differentiated effector cells (28,29). The very
similar regeneration rate of truly naive CD4+ and CD8+ T-cells
(CD45RA+/CD27+) in our patients suggests that generation of both cell
types is under control of a common mechanism, consistent with thymic
production of naive T cells. 
Interestingly, the rate of increase of naive CD4+ T cells in our patients is
similar to the regeneration rates observed in HIV seronegative adults with
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iatrogenic CD4+ T-cell depletion due to either antineoplastic
chemotherapy or treatment for rheumatoid arthritis with CD4 monoclonal
antibodies (20,22,23,24,30). In our patients, the mean rate of increase of
naive CD4+ was 0.34 cells/mm3/day, corresponding to an 38 year old
subject in Figure 3. After iatrogenic T-cell depletion, the regeneration
rates of naive CD4+ T cells vary from 0.005 to 1.1 cells/mm3/day. For the
total body, the mean regeneration rate of naive CD4+ T cells in our
patients is 0.85 x 108 cells/day, assuming that the total blood volume is 5
liters and that 2% of the lymphocytes are in the blood compartment. This
number is in close agreement with estimates of a total body production
rate of naive CD4+ T cells of ~108 cells/day (31), which was based on the
decay of lymphocytes with stable chromosome damage after radiation.
Thus, in HIV infected patients, the capacity to regenerate naive T cells
during HAART is comparable to the situation after iatrogenic T-cell
depletion.
There is considerable evidence that the thymus dependent pathway to
develop new naive T cells from bone marrow progenitors is downregulated
during HIV infection. First, it was shown that CD34+ hematopoietic
progenitor cells are susceptible to HIV infection (32), and have impaired
survival and clonogenic capacity during HIV infection (33). Second, it was
demonstrated that the thymic tissue is affected in individuals with AIDS
(34). In studies with SCID-hu mice it was shown that HIV infection
results in depletion of CD4+/CD8+ thymocytes and reduction of the
number of CD4+ T-lymphocytes from the thymic implants (35-37).
Finally, measuring T-cell receptor excised circles (TREC’s) to identify
recent thymic emigrants showed that the number of TREC positive T cells
is decreased as compared to HIV negative individuals, which was taken as
evidence for a reduced export of new T cells from the thymus in HIV
infection (11,12). However, the decreased number of TREC positive T
cells in HIV infected individuals may also be explained by the high
division rate of T cells due to HIV infection (38,39). Our finding that the
regeneration rate of naive T cells during HAART is comparable to that
after iatrogenic T-cell depletion suggests that the HIV-induced
dysfunctions of progenitor cells or thymus are either of minor importance
or they are rapidly reversed after introduction of HAART. 
The relatively low correlation coefficients between age and naive T-cell
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recovery rates (Figure 3) may be explained in several ways. First, it may be
due to a large variation of thymic output between individuals, in
agreement with large differences in the numbers of TREC positive T cells
found in healthy individuals (11,12). Secondly, several studies have
suggested that thymus independent pathways of naive T-cell regeneration
also play a role during HAART. 
In one study, it was reported that the number of circulating naive
(CD45RA+/CD62L+) CD4+ T cells increased during HAART in a
thymectomized patient (14). However, the increase of naive CD4+ T cells
was exclusively observed in the first 12 weeks of HAART and the number
remained constant thereafter. The increase of naive CD4+ T cells during 95
weeks of HAART was approximately 25 cells/mm3 (0.038 cells/mm3/day).
In our study, and in studies by others with thymus-bearing patients, naive
T-cell counts increased continuously throughout the complete course of
HAART with a ~10 fold higher rate. The initial rise of naive CD4+ T cells
in the thymectomized patient (14) could therefore be explained by a
redistribution of naive T cells from (lymphoid) tissue to blood, which
typically occurs in the first weeks of HAART (4). 
In two other studies, TRECs were measured to identify recent thymic
emigrants during HAART (11,12). It was shown that the increases in
TREC-positive T cells during HAART were numerically insufficient to
account for the increases in phenotypically naive (CD45RA+/CD62L+) T
cells. This suggests that naive T cells may proliferate without converting
to the memory phenotype. Increased expression of the proliferation marker
Ki67 on naive T cells has been observed in untreated HIV-1 infected
patients with less than 100 naive T cells/mm3 (40). However, Ki67
expression on naive T cells was shown to decrease rapidly during the first
weeks of HAART (40), whereas in our study the increase of naive T cells is
relatively constant, suggesting that proliferation plays a limited role in the
regeneration of naive T cells. The absence of a positive correlation between
baseline naive T-cell counts and the regeneration rates (Figure 4) also
argues against peripheral expansion as a mechanism of naive T-cell
regeneration. 
Theoretically, reversion of memory cells may also contribute to the
recovery of naive T cells during HAART (12,15). It has been suggested
that CD45R0+ (memory) T cells may revert to the CD45RA (naive)
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isoform (41,42). However, using a combination of CD27 and CD45RA
Mab’s we were able to distinguish between truly naive T cells
(CD45RA+/CD27+) and memory/effector T cells of the CD45RA+/CD27-
phenotype, that may have developed via the CD45R0+ stage (28,29). It is
therefore unlikely that reversion of memory cells contributes to the
recovery of truly naive (CD45RA+/CD27+) T cells in our study. 
In conclusion, the similar regeneration rate of naive CD4+ and CD8+ T
cells during HAART, and the inverse correlation between age and recovery
rate of naive T cells, suggest that the thymus plays a considerable role in
the regeneration of naive T cells in adults during HAART. In addition, our
observation that the regeneration rate of naive CD4+ T cells is similar to
the rates observed after iatrogenic T-cell depletion, suggests that HIV-
induced dysfunctions of progenitor cells and the thymus are either of
minor importance or they are rapidly reversed after initiation of HAART.
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Abstract
Recent thymic emigrants can be identified by T Cell Receptor Excision
Circles (TRECs) formed during T-cell receptor rearrangement. Decreasing
numbers of TRECs have been observed with aging and in HIV-1 infected
individuals, suggestive for thymic impairment. Here, we show that in
healthy individuals, declining thymic output will affect the TREC content
only when accompanied by naive T-cell division. The rapid decline in
TRECs observed during HIV-1 infection and the increase following
HAART are best explained not by thymic impairment, but by changes in
peripheral T-cell division rates. Our data indicate that TREC content in
healthy individuals is only indirectly related to thymic output, and in
HIV-1 infection is mainly affected by immune activation.
Introduction
It was postulated that HIV-1 induced CD4+ T-cell depletion could at least
partially be due to interference of HIV with de novo production of T cells at
the level of T-cell progenitor function or thymic output. Several studies
have focused on the influence of HIV-1 infection on thymic function,
however, results were inconclusive (1,2). Recently, a new method has been
reported by Douek and colleagues (3), that may allow a more direct
estimation of thymic T-cell production. Formation of a productive T-cell
Receptor (TCR)α- gene requires deletion of the TCRδ-gene, which is
positioned within the TCRα-locus (4). The TCRδ-gene is flanked by two
TCRδ- deleting elements, δRec and (J-α, which preferentially rearrange to
each other, thereby deleting the TCRδ locus (5-7). The deleted TCRδ-gene
remains present as an extrachromosomal circular excision product, the so-
called Signal joint T-Cell Receptor Excision Circle (Sj TREC or TREC)
(8,9). These circles are episomal, do not replicate during mitosis and are
thus diluted during cell division (4,8). With quantitative PCR, TRECs
can be detected and quantified, thereby offering a tool to identify recent
thymic emigrants and to estimate thymic output. Using TREC
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measurements, it was suggested that, although thymic function declines
with age, limited thymic output was still measurable at old age (3,10-12).
In HIV-1 infected individuals, low TREC contents in T cells and PBMC
were reported in a large percentage of patients studied (3,10,13). TREC
content increased during highly active anti-retroviral therapy (HAART),
suggestive for improvement of pre-treatment impairment of thymic
function (3,10). However, the effect of dilution of these episomal circles,
resulting from repeated episodes of pathogen induced cell division during
life, or from a chronically activated state of the immune system such as
observed in HIV-1 infection (14-16), has not been taken into account in
analyses and interpretation of these data. Here we combined measurements
of TRECs and cell division rates in naive T cells of healthy and HIV-1
infected individuals with mathematical modeling, to come to a better
interpretation of TREC measurements with respect to thymic output.
Sj TRECs in healthy individuals
First, to validate the assay, we measured the TREC content of CD4+ and
CD8+ T cells of 49 HIV-1 negative individuals, from 0 (cord blood) to 84
years of age. The number of TREC copies declined with increasing age (Ps
< 0.001, Rs = -0.800, data not shown). To study whether TRECs were
diluted by cell proliferation, we cultured cord blood peripheral
mononuclear cells (PBMC) from HIV-1 negative donors with IL-7 (10
ng/ml) and phytohemagglutinin (PHA, 1 µg/ml) for seven days.
Sequentially, the number of PBMC, the proportion of cell death, and
TRECs were measured. As expected, in vitro cell division led to dilution of
TRECs (data not shown). We recently demonstrated that during HIV-1
infection peripheral T-cell division rates are differentially increased in all
lymphocyte subsets, including the naive CD4+ and naive CD8+ T-cell
pools (14). This may confound the interpretation of TREC analysis when
measured in total PBMC or unseparated CD4+ and CD8+ T cells. We have
found that the number of TRECs in the naive CD4+ T-cell pool (FACS-
sorted purified CD27+ CD45RA+ cells) is relatively high, although
significant numbers of TRECs were also detected in the memory
population (12) (data not shown). Because of practical limitations, TREC
analysis could only be performed on purified CD45RA+ T cells and not on
‘truly naive’ fractions defined by co-expression of CD27. Therefore,
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subsequent TREC analysis was performed exclusively in purified
CD45RA+ CD4+ and CD45RA+ CD8+ T-lymphocyte subsets, in parallel
with assessment of peripheral cell division rates in the CD27+ CD45RA+
subsets using Ki-67 expression (17) (see Methods). Throughout the text,
the term ‘naive’ denotes truly naive T cells, as being CD45RA+ and
CD27+, otherwise the term CD45RA+ is used.
Sj TRECs during HIV-1 infection
Table 1 shows characteristics of HIV-1 infected patients and age matched
healthy individuals that were included in our study. HIV-1 infected
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CD4+ T cells CD8+ T cells
HIV- HIV+ P- HIV- HIV+ P-
(n = 17) (n = 33) value (n = 14) (n = 7) value
Age 37 41 ns 40 42 ns
(years) (24-62) (24-57) (24-62) (27-54)
T cells 880 400 < 0.001 405 1570 < 0.001
(per µl) (620-1430) (160-1350) (210-640) (770-2720)
Naive T cells 494 150 < 0.001 248 218 ns
(per µl) (276-1027) (22-756) (149-354) (126-440)
Ki-67+ naive T cells 0.4 3.1 < 0.001 0.3 3.4 < 0.001
(%) (0.1-0.8) (0.7-5.7) (0.1-0.9) (1.7-30.7)
Sj TRECs 25.1 12.1 < 0.05 31.4 2.5 < 0.001
(x10-3 copies/ (5.5-221.4) (0.08-57.1) (4.2-219.1) (0.13-7.8)
CD45RA+ cell)
Table 1. Characteristics of healthy individuals and HIV-1 infected patients. Depicted are
median and range. Statistical significance was calculated with the Mann-Whitney U test; p <
0.05 was considered statistically significant. 
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patients had lower numbers of CD4+, and higher numbers of CD8+ T
cells, compared to healthy individuals. The number of naive CD4+, but
not naive CD8+ T cells, was significantly reduced. Percentages of Ki-67+
naive T cells were increased in these subsets. The percentage of Ki-67+
naive CD4+ T cells was negatively correlated with the number of naive
CD4+ T lymphocytes, as reported previously (14) (Rs = - 0.843, Ps <
0.001; data not shown). HIV-1 infected patients had a significantly lower
TREC content of CD45RA+ CD4+ and CD45RA+ CD8+ T lymphocytes
compared to healthy subjects. The number of TRECs per CD45RA+ T cell
correlated with the size of the naive CD4+ T-cell pool, such that patients
with high naive T-cell numbers had a high CD45RA+ CD4+ T-cell TREC
content (Rp = 0.427, Pp = 0.003; Fig. 1). 
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Figure 1. Correlation between TRECs and naive T cell numbers. In HIV-1 infected Dutch
patients (gray dots) and non-infected individuals (black dots), the number of TRECs per
CD45RA+ CD4+ T cell and the size of this subset are correlated (Rp = 0.427, Pp = 0.003).
White dots represent HIV-negative Ethiopian individuals (see text).
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Effects of thymic output and cell division
The TREC content of a naive T-cell population may depend to various
extents on thymic production, cell death and cell division, priming of
naive T cells to become memory lymphocytes, and intracellular
degradation of TRECs (18). We therefore developed a mathematical model
to interpret our data. 
In this model, N is the total number of naive (CD4+ or CD8+) T cells and
T the total amount of TRECs in the naive T-cell population, σ(a) is the age
(a)-dependent source of naive T cells from the thymus, α the rate of naive
T-cell division, δ the rate of cell death and priming of naive cells, and c is
the amount of TRECs in recent thymic emigrants (RTEs). Changes in the
number of naive T cells can be described as 
dN/dt = σ(a) + αN - δN.    (Equation 1)
The total amount of TRECs in this population increases proportionally to
thymic production, and decreases when naive T cells die, become primed,
or possibly because of intracellular degradation of the TRECs (δI), and can
be expressed as
dT/dt = cσ(a) - δT - δiT.    (Eq. 2)
Note that the total amount of TRECs in the naive T-cell population does
not decrease by division (α). Division only affects the average TREC
content per naive T cell. By the “quotient-rule” of differentiation, this
average, defined as A = T/N, should change according to
dA/dt = σ(a) (c - A) / N - δi A - αA (Eq. 3)
The quasi steady state is at 
Â = c / [1 + N (δI + α) / σ(a)].    (Eq. 4)
In the absence of division and degradation, when δi + α = 0, the steady
state is Â = c. In other words, lower thymic output is only reflected by a
reduction in TREC content of a naive cell when there is division of naive T
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cells (α > 0), and/or intracellular degradation (δi > 0). Moreover, if the
number of naive T cells N in our model remains proportional to thymic
production σ(a), the σ(a) term cancels from Equation 4. Thus, in that case
the TREC content per naive T cell is essentially a measure of division
and/or degradation, not of thymic output.
To validate our model, we studied quantitatively how the different
parameters are expected to influence the average TREC content of a naive
T cell. In the following equation thymus production is assumed to decay
exponentially and division to be density dependent:
σ(a) = σ0 exp [- va]    (5a) and α = α0 / (1 + N
2 / h2),    (Eq. 5b)
where σ0 is the newborn thymus production of naive T cells, v the
involution rate of the thymus, α0 is the maximum division rate of naive T
cells (which is approached at the lowest naive T-cell counts), and h the
naive T-cell count at which the division is half maximal. This model is in
good agreement with the data obtained from healthy individuals (12)
(Fig.2). In all three panels, the thymic output decreases exponentially, but
the naive T-cell population is maintained by only modest homeostatic
changes in either the division (α) or the death (δ) rate (see equation 5c). In
the case of a density dependent increase in division rate (α), the average
number of TRECs per naive T cell remains high until puberty, and then
decreases several orders of a magnitude (Fig. 2a). Alternatively, the life
span of naive T lymphocytes could prolong with the decrease in T-cell
density that is associated with age-related decline in thymic output.
Therefore, we included density dependent death of naive T cells, described
as
δ = δ0 + εN (Eq. 5c)
in our model. In this equation, εN allows for a density dependent increase
in death rate. The average TREC content also declines orders of magnitude
when there is a density dependent decrease in the death rate (ε > 0) and a
constant naive T-cell division rate (α = α0, Fig. 2b). However, when α = 0
and δ is density dependent, the average TREC content remains constant
during life (Fig. 2c). 
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When TRECs are measured in separated CD45RA+ T-cell population,
rather then in ‘truly naive’ T cells, reversion of CD45RA- memory cells
into this population could also affect the TREC content. Reversion can be
included in our model by allowing for a “source” of revertants, R, in Eq.1.
Because revertant memory cells should contain little or no TRECs, Eq.2
should remain the same. The R term reflects the number of memory cells
reverting to a naive phenotype on a daily basis. We have studied the
extended model numerically and found that reversion can only have an
observable effect on the TREC content when more than half of the total
production of naive T cells is due to reversion (i.e., when R > σ(a) + αN).
Although there might be reversion of some memory cells (19-21), it seems
unlikely that this occurs at such high rate in healthy people (20). Thus, in
our model it is the increase in division rate around puberty that sets the
decrease in TREC content after puberty. Furthermore, CD45RA-
CD45RO+ memory cells are thought to revert to a CD45RA+ CD45RO-
phenotype only when in a resting state, i.e. in the absence of their specific
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Figure  2. The model behavior as a function of age. Thymic output declines exponentially, and
the naive T cell population is maintained by (a) a modest increase in cell division (α), (b) a
density dependent decrease in death rate (δ) and a constant cell division rate (α = 10-3), or (c) a
density dependent decrease in death rate (δ) in the absence of cell division (α0=0). Solid lines
represent TREC content per naive T cell, dashed lines the total number of naive T cells. a, α0 =
0.1/day, δ = 10-3/day and ε = 0. b, α = 10-3, δ0 = 0/day, and ε = 9.1x10
-16. c, α0 = δ =
0/day, and ε = 8.9x10-16. Parameters: c = 1, δi = 0, h = 2.5x10
10 cells, σ0 = 10
9 cells/day,
and v = 0.1/year.
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antigen. In HIV-1 infection, given the hyperactivation, this is probably a
rare event. If a substantial reversion rate does exist, it just enhances the
decreasing effect of naive T-cell division on TREC content. In any case,
peripheral cell division is required (assuming no intracellular decay), and is
an important factor, for decreasing TREC content.
Effects of HIV-1 infection on TREC content
HIV-1 infection could influence TRECs the naive T-cell compartment in
various ways: 1) direct infection of the thymus could lead to abolishment
of thymic production (σ), 2) HIV-mediated killing of naive cells or an
increase in the rate of priming into memory cells could lead to an
increasing loss of naive T cells (δ), or 3) direct activation of naive T cells, or
virus-induced depletion of the naive T-cell compartment, inducing a
homeostatic response, could lead to a rise in naive T-cell division rates (α).
We investigated these effects separately, by choosing a 30-year old
individual from Fig. 2 and studying the impact of the above mentioned
possibilities during one year of HIV-1 infection (Fig. 3). Blocking thymus
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Figure 3. The model behavior of an HIV-1 infected, 30-year old individual over a time period
of one year. a, Blocking thymic output, i.e. setting σ = 0, hardly influences the average TREC
content (solid line) or naive T cell numbers (dashed line). b, Increasing the death and priming
rate (δ) 10-fold leads to an increase in TREC content and a decrease in the number of naive T
cells. c, Elevating the division rate (α) 10-fold leads to a decrease in TREC content and an
increase in naive T cell numbers. Parameters: α = 7.9x10-4/day or 7.9x10-3/day, c = 1, δ =
10-3/day, δi = 0/day, and σ = 5x10
7cells/day.
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production (σ = 0) hardly influenced the average TREC content or naive
T-cell numbers (Fig. 3a). This is explained by the longevity of these cells.
Increasing the death and priming rate δ 10-fold led to a decrease in the
number of naive T cells and an increase in the TREC content of naive T
cells (Fig. 3b). The latter is due to the fact that by increasing the death
rate, the average naive T cell will become younger. Thus, a larger fraction
of all naive T cells will be a recent thymic emigrant, and will hence have a
higher average TREC content. Finally, increasing the division rate α 10-
fold had a strong and rapid effect on the TRECs (Fig. 3c). Various values of
α were tested, and even when naive T-cell division was increased only
three-fold compared to normal rates, the TREC content of the naive T-cell
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Ethiopians Comparison to
(n = 18) HIV- HIV+
Age 42 ns ns
(years) (35-45)
CD4 T cells 748 ns P < 0.001
(per µl) (427-1354)
Naive CD4 112 P < 0.001 ns
(per µl) (36-316)
Ki67+ naive CD4 (%) 0.9 P < 0.05 P < 0.005
(0.2-6.2)
Sj TRECs (x10-3 copies/ 4.9 P < 0.001 P < 0.01
CD45RA+ cell) (0.56-31.9)
Table 2. Characteristics of HIV-1 negative Ethiopian individuals. Depicted are median and
range. Values were compared to the Dutch HIV-negative (HIV-; n = 17) and HIV-1 infected
(HIV+; n = 33) subjects described in Table 1. Statistical significance was calculated with the
Mann-Whitney U test; P < 0.05 was considered statistically significant.
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population did reduce (data not shown). Theoretically, increasing the
intracellular degradation rate δI 10-fold could lead to a similar decrease in
TRECs, however, the normal lifespan of a TREC is not known, and it
seems unlikely that HIV-1 infection could affect TRECs in this manner.
Thus, our model shows that the decrease in TRECs during the relatively
short period of HIV-1 infection (3 to 7 years) is most simply explained by
increased division rates in the naive T-cell compartment. We have recently
shown that this is mostly driven by immune activation rather than by
homeostatic mechanisms (14). This explanation is supported by our
observation that the proportion of Ki-67+ naive T cells was negatively
correlated with the number of TRECs per CD45RA+ T cell (Rs = -0.556,
Ps = 0.001 and Rp = -0.74, Pp = 0.001 for CD4
+ and CD8+ T-cell subsets
respectively, Fig. 4a and Fig. 4b). Furthermore, compared with the group
of healthy individuals, HIV-infected patients had a significantly decreased
TREC content of the CD45RA+ CD8+ T-cell pool, but did not have lower
numbers of naive CD8+ T cells (Table 1). This is in agreement with our
previous results, demonstrating that cell division rates in the naive CD8+
T-cell compartment were increased in patients with normal numbers of
naive CD8+ T cells (14). Finally, although naive T-cell division is the
simplest explanation, it does not exclude the possibility that reversion of
memory cells from the CD45RA- to the CD45RA+ phenotype contributes
to the observed decrease in TREC content, especially for the CD8+ T cells.
Dilution of TRECs by non-HIV mediated immune activation 
To determine whether a decline in TRECs could be observed
independently of HIV-1 infection, we studied HIV-negative Ethiopians
who have a chronically activated immune system, probably due to the
increased pathogen exposure in the domestic Ethiopian environment (22).
Compared to HIV-negative Dutch individuals, Ethiopians have lower
numbers of naive CD4+ and naive CD8+ T cells, concomitant with an
expansion of the primed CD45RO+ CD27- T-cell compartment (22). If the
decline in TREC content of the CD45RA+ T-cell population in HIV-1
infection were indeed related to peripheral dilution caused by cell division,
one would expect low TREC contents in T cells from this group of
Ethiopian individuals. Eighteen HIV-negative Ethiopians, participating in
a cohort study performed in Akaki, Ethiopia, as part of the Ethiopian-
CHAPTER 6 107
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Figure 4. In vivo dilution of TRECs. In HIV-1 infected Dutch patients (gray dots), and in
non-infected Dutch individuals (black dots) the number of TRECs declines with increasing
percentages of a, dividing naive CD4+ T cells (Rs = -0.556, Ps = 0.001) and b, dividing
naive CD8+ T cells (Rp = -0.740, Pp = 0.001). White dots represent HIV-negative Ethiopian
individuals (see text). c, HIV-negative Ethiopian individuals have an even lower TREC content
per CD45RA+ CD4+ T cell compared with HIV-negative and HIV-infected Dutch subjects (*
P < 0.05). 
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Netherlands AIDS Research Project (ENARP), were selected based on
their seronegative status. Compared with HIV-negative Dutch subjects,
Ethiopian individuals had reduced numbers of naive CD4+ T cells,
increased Ki-67+ naive CD4+ T cells and decreased CD45RA+ T cell
TREC contents (Table 2). The number of TRECs per CD45RA+ CD4+ T
cell in these subjects was even lower than in the HIV-1 infected Dutch
patients included in our study (Fig. 4c). Even though Ki-67 expression is a
measure for ongoing cell division and not for the replicative history of the
naive cells, it does correlate with low TREC content in these individuals
(Fig. 4a).
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Figure 5. Effect of HAART on TREC content. The number of naive CD4+ T cells (white
dots), the percentage of Ki-67+ naive CD4+ T cells (gray dots) and the TREC content per
CD45RA+ CD4+ T cell (black dots) were measured in 33 HIV-1 infected individuals during
untreated HIV-1 infection, after 6 months of HAART and after 1 to 2 years of HAART. At
all timepoints, the number of naive cells, Ki-67 expression in these cells and the number of
TRECs were significantly different from control values (Mann Whitney U test, P < 0.01). 
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Effect of Highly Active Anti-Retroviral Therapy on TRECs
In the above described group of HIV-1 infected Dutch individuals, one to
two years of HAART led to a rise in peripheral naive T-cell numbers, a
steep reduction in the proportion of dividing cells in all subsets, and a
small increase in the TREC content (Fig. 5; data not shown for CD8+ T
cells). None of these parameters reached normal levels (P < 0.01 for all
time points, all parameters, compared with healthy subjects). In eight
patients, we analyzed recovery of TRECs shortly after introduction of
HAART in more detail. Immediate increase of TREC content in the
CD45RA+ T-cell pool was only observed during the first three months of
HAART and coincided with a decline in naive CD4+ T-cell division rates,
but not with improvement of naive CD4+ T-cell numbers. Analysis of the
naive CD8+ T-cell pool revealed similar dynamics (data not shown). 
Discussion
Elevated cell division rates could obscure the interpretation of TREC data.
Because many CD45RA- ‘memory’ T cells, particularly, may have a history
of very rapid cell division in individuals with chronically activated
immune systems (16), lowering the average TREC content (12), we
measured Sj TRECs in purified CD45RA+CD4+ and CD45RA+CD8+ T-
cell subsets in parallel with peripheral cell division rates in the naive
populations. We compared data obtained from healthy individuals with
those from subjects that were shown to have a persistently activated
immune system, including HIV-1 infected patients (14,16) and a group of
HIV-negative Ethiopian factory workers.  Mathematical modeling was
used to describe the relation between the various parameters that affect
TREC content. This showed that when in healthy individuals the net
thymic output decreases, for example because of age-related involution of
thymic tissue, the number of TRECs per produced naive T cell does not
significantly decrease (see equation 3), as has been experimentally shown
(11). The mere fact that the TREC content of naive T cells declines with
age (12), according to our model suggests increased naive peripheral T-cell
division that accompanies lower thymic T-cell production. 
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It is now well established that HIV-1 infection leads to chronic immune
activation reflected in elevated division rates in all T-cell subsets,
including even the naive CD4+ and CD8+ T-cell compartment (14,16,23).
This immune activation is observed immediately following HIV-1
infection, and is most pronounced in CD8+ T cells (24,25). We measured
cell division in truly naive T cells that were characterized by expression of
CD45RA and CD27 antigens. Contamination of this population by
memory cells that reverted to a naive phenotype is thereby excluded, since
expression of the CD27 antigen is lost upon prolonged antigen-specific
stimulation and this loss is irreversible (26). Naive T cells can be activated
by stimulatory cytokines, independent of antigen, without losing their
naive phenotype (27-29). 
According to the model, naive T-cell division would have a rapid and
strong effect on the average TREC content. Even a two- to three-fold
increase in cell division rates, which is not reflected by changes in telomere
lengths (30,31), can induce an observable dilution of TRECs. Indeed,
TREC content is low in HIV-1 infection and acute HIV-1 infection leads
to a significant reduction in the number of TRECs already after ninety
days (10), an observation that our model cannot explain by an immediate
fall in thymic output (Fig. 3a). It has been estimated that in adults,
thymic output is in the order of 107 to 108 lymphocytes per day (32). Even
if HIV-1 infection would immediately and completely abolish thymic
output, this alone could not lead to such a rapid fall in cellular TREC
content (Fig. 3a). Elevated rates of T-cell division of naive cells are the
most likely cause of the reduced TREC content we observed. Our
hypothesis is further supported by the finding that non-HIV mediated
persistent immune activation in healthy Ethiopians also leads to a
significant loss of TRECs. However, because mixing with low-TREC
revertant memory cells could also contribute to the observed reduction in
TREC content, it will be important to obtain information on TREC
contents of sorted naive T cells. Indeed, preliminary data from our lab
obtained in a small group of HIV-1 infected patients showed lower TREC
content of sorted ‘truly naive’ CD27+CD45RA+CD4+ T cells compared
with healthy age-matched individuals (n=5 and n=3, medians 1.3 x10-3
and 7.2 x10-3 Sj TREC copies per CD27+CD45RA+CD4+ T cell,
respectively).
CHAPTER 6 111
hoofdstuk 06  9/21/00  1:02 PM  Pagina 111
Anti-retroviral treatment resulted in improvement of the TREC content of
CD45RA+ T cells which correlated with declining naive T-cell division
rates, but not with increasing naive T lymphocyte numbers. This is in
agreement with recent findings of Zhang et al. (10), who found significant
HAART- induced recovery of TREC content only in patients with low pre-
treatment numbers of TRECs, which did not correlate with recovery of the
naive T-cell pool. Rather, the increase in TREC content during HAART
most likely is a composite of normalizing naive T-cell peripheral death and
division rates (14), some redistribution of naive T cells to the blood (33),
and a continuous but low, possibly normal, thymic lymphocyte
production.
Taken together, loss of TRECs in HIV-1 infection may primarily be caused
by continuous hyperactivation of the immune system as reflected by
increased cell division even of naive T cells. Although interference by HIV
with thymic output could contribute to CD4+ T-cell depletion
(3,30,32,34), measurements of TREC content in CD45RA+ T cells fail to
provide experimental evidence for such thymic impairment. Alternatively,
it may be that the intrinsically low thymic output in adults cannot
compensate for the continuous loss of naive cells incurred by the increased
priming of naive cells due to persistent immune activation, resulting in
gradual depletion of CD4+ T cells without in fact exhaustion of thymic
output (35).
Methods
Subjects
Cryopreserved peripheral blood samples from thirty-three HIV-1 infected
patients and thirty-five non-infected healthy subjects were analyzed.
Cryopreservation was performed using a computerized freezing device that
results in optimal quality of frozen cells for functional studies (36). Frozen
blood samples were stored in liquid nitrogen. Patient blood samples were
obtained from HIV-1 infected individuals participating in three separate
trials: the Amsterdam Cohort Study on HIV-1 Infection in Homosexual
Men (n = 7), the BMS-50 trial (n = 18) and the CHEESE study (n = 8).
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Samples were obtained before and during treatment with triple therapy
regimens, containing two reverse transcriptase inhibitors (nucleoside
analogues) and one protease inhibitor. As controls, HIV-1 negative Dutch
laboratory personnel (n = 17) and Ethiopian factory workers (n = 18) were
included. HIV-1 negative individuals were age-matched with the HIV-1
infected patients. In 14 out of 17 healthy Dutch individuals, and 7 out of
33 HIV-infected subjects, enough material was available to perform
measurements of TRECs in both the CD45RA+ CD4+ and CD45RA+
CD8+ T-cell compartment. Selection of HIV-negative Ethiopian factory
workers was based on their numbers of peripheral blood CD4+ T
lymphocytes, varying from less than 500 to more than 1000 cells per µl.
No correlation was found between the TREC content of CD45RA+ CD4+
T cells and the total number of CD4+ T cells in that population. It is of
notice that although total CD4+ T-cell numbers varied in this study
population, the number of naive CD4+ T cells was significantly lower
compared with HIV-negative Dutch individuals, even when total CD4+ T-
cell numbers were comparable (Table 2).
Cell proliferation
Peripheral blood T-cell proliferation was studied by flow cytometric
measurements of Ki-67 nuclear antigen expression on naive CD27+
CD45RO- CD4+ and naive CD27+ CD45RO- CD8+ T cells, as described
previously (14,37,38). Measurements of cell division rates with this
method yield similar results as have been obtained previously by in vivo
labeling of dividing cells with deuterated glucose (39). Peripheral blood
mononuclear cells were thawed and incubated with CD4- or CD8-PerCP
mAb, CD45RO-PE (Becton Dickinson, San Jose, California) and
biotinylated CD27 mAb (CLB, Amsterdam, The Netherlands). After
washing, cells were incubated with Streptavidin-APC (Becton Dickinson).
Cells were then fixated and permeabilized with FACS Lysing Solution and
FACS Permeabilization Buffer (Becton Dickinson), respectively.
Lymphocytes were stained intracellular with Ki-67-FITC mAb
(Immunotech, Marseille, France), after which cells were fixed using Cellfix
(Becton Dickinson) and analyzed on a FACSCalibur (Becton Dickinson)
with Cellquest software.
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Cell separation
CD45RA+ CD4+ and CD45RA+ CD8+ T cells were purified from thawed
PBMC by magnetic separation over columns, using the MiniMACS
multisort kit according to manufacturers instructions (Miltenyi Biotec Inc,
Sunnyvale, California). Briefly, after 15 minutes incubation with 20 µl
CD4 or CD8 conjugated magnetic beads per 107 cells, CD4+ and CD8+ T
cells were isolated from PBMC by positive selection over MiniMACS
separation columns. Magnetic beads were then released, cells were
incubated with CD45RA-conjugated magnetic beads and passed over
columns. With this technique, at least 90% purity of the fractions was
achieved, such that less then 10% of CD4+ or CD8+ T-cell fractions were
contaminated with CD8+ or CD4+ T cells, respectively, or with CD45RA-
T cells. As outlined above, truly naive T cells are defined by co-expression
of CD45RA and CD27, however, due to practical reasons, TREC analysis
was performed in purified CD45RA+ T cells. Contamination of purified
CD45RA+ T cells with CD27- CD45RA+ cells such that it will affect
TREC contents cannot be excluded, especially in the CD8+ T-cell subset of
HIV infected individuals (26). It is less likely to occur in CD4+ T cells,
since the population of CD4+ CD27- CD45RA+ T cells is limited in size
(22).
Real-time PCR
DNA was purified from CD45RA+ CD4+ and CD45RA+ CD8+ T-cell
fractions using the QIAamp Blood Kit according to manufacturers
instructions (Qiagen, Hilden, Germany). In order to detect Sj TRECs, a
real-time quantitative PCR method was used (40). In this PCR, annealing
of primers with a site-specific probe, containing a quencher and a reporter
dye, results in AmpliTaq Gold DNA Polymerase mediated cleavage of the
probe and subsequent separation of the quencher from the reporter,
thereby inducing fluorescence of the reporter dye. Each PCR reaction was
performed in a 50 µl solution containing 100-200 ng DNA of cell
suspension of interest, 1.0 x TaqMan Buffer A (Perkin Elmer Biosystems,
Nieuwerkerk a/d IJssel, The Netherlands), 5.0 mM MgCl2, 200 µM
dNTPs, 900 nM forward and reverse primer, 200 nM probe, and 1.25 U
AmpliTaq Gold (PE Biosystems). The sequences of the utilized primers
and probe are the following: forward primer 5’-CCATGCTGACA
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CCTCTGGTT-3’, reverse primer 5’-TCGTGAGAACGGTGAATGAAG-
3’ and the probe 5’-CACGGTGATGCATAGGCACCTGC-3’. As an
internal control measurement, to normalize for input DNA, the Cα
constant region that remains present on TCR genes despite rearrangement
processes was amplified in every sample tested (forward primer 5’-
CCTGATCCTCTTGTCCCACAG-3’; reverse primer 5’-GGATTTAGA
GTCTCTCAGCTGGTACA-3’ and probe 5’-ATCCAGAACCCTGACC
CTGCCG-3’). Using these primer/probe combinations (PE Biosystems),
sequences of 131 basepairs (bp) and 70 bp, respectively, were amplified. A
standard was created, by cloning the Sj fragment in the Hind III site of a
pUC-19 vector, and the number of Sj copies present in a given cell
population was calculated by including a dilution series of this standard in
each PCR experiment. 
PCR was performed under the following conditions: 50 °C for 2 minutes
followed by 95 °C for 10 minutes, after which 50 cycles of amplification
were carried out (95 °C for 15 seconds, 60 °C for 1 minute). For each
sample the Ct-value, defined as the minimal number of cycles necessary to
exceed threshold values, was measured and applied to the standardization
curve created from the dilution series described above. 
Statistical analysis
Group characteristics were compared with the Mann-Whitney U test.
Normality of groups was tested using the Shapiro-Wilk W Test for
normality. Based on the outcome of this test, correlations were calculated
using either Spearman’s rank correlation coefficient (Rs) or Pearson’s
correlation coefficient (Rp). 
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Abstract
In HIV-1 infection, highly increased T-cell turnover was proposed to cause
exhaustion of lymphocyte production and consequently development of
AIDS. Here, we investigated cell proliferation, as measured by expression
of the Ki-67 nuclear antigen, in peripheral blood CD4+ and CD8+
lymphocyte subpopulations before and during HAART. In untreated HIV-
1 infection, both the percentage and number of Ki-67+ CD4+ and CD8+
lymphocytes were significantly increased, as compared to values obtained
from healthy individuals. A more then 10-fold increase in the percentage
of dividing naive CD4+ T cells in the blood was found when the number of
these cells were below 100 per mm3 . HAART induced an immediate
decline in Ki-67 antigen expression despite often very low CD4+ T-cell
numbers, arguing against increased proliferation being a homeostatic
response. After approximately 24 weeks of HAART treatment, a transient
increase in the number of proliferating cells was seen, but only in the
CD4+ CD27+ memory pool. In the CD8+ T-cell compartment, the number
of dividing cells was elevated 20- to 25-fold. This increase was most
notable in the CD27+ and CD27- CD45RO+ memory CD8+ T-cell pool,
corresponding with the degree of expansion of these subsets. Reduction of
plasma HIV-RNA load by HAART was accompanied by a decrease in
numbers and percentages of dividing cells in all CD8+ T-cell subsets.
Taken together, our results indicate that peripheral T-cell proliferation is a
consequence of generalized immune activation.
Introduction
Several hypotheses have been presented to explain the loss of CD4+ T
lymphocytes, the major hallmark of HIV-1 infection that leads to severe
immune depletion and ultimately AIDS and death. The model of high
lymphocyte turnover has received considerable attention over the past few
years (1,2). Based on the observation that during the first few weeks of
highly active anti-retroviral therapy (HAART) the number of CD4+ T
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cells increases, it was postulated that HIV-1 infection leads to a rapid
turnover of lymphocytes, reflecting a new balance between production and
death of lymphocytes. The increased production rate would eventually lead
to exhaustion of the CD4+ T-cell renewal capacity and result in CD4+
lymphocyte depletion. Indeed, in SIV infected macaques increased T-cell
production was observed (3), however, there was a parallel rise in the
turnover of B cells and NK cells (4). Moreover, the highest increase was
observed in CD8+ T cells, the compartment that is initially expanded and
does not get depleted until very late in the course of HIV-1 infection (5-9).
HIV-induced lymphocyte depletion and subsequent recovery after
HAART appeared to be variable when studied at the level of T-cell
subsets. Infection with HIV-1 induces an early decline in the number of
naive CD4+ and CD8+ and memory CD4+ T lymphocytes. Conversely, the
memory and activated CD8+ T-cell compartments expand initially. Only
shortly preceding progression to AIDS, the numbers of these latter cell
types fall as well (10-12). HAART induces an early rise of memory CD4+
and CD8+ T-cell numbers, accompanied by a slow increase in naive CD4+
and CD8+ T-cell numbers (13,14). From this, it was concluded that
different mechanisms are involved in the dynamics of depletion and
recovery of the various T lymphocyte subsets. These mechanisms include
interference of HIV with de novo T-cell production capacity (15)
(D.R.Clark et al, submitted for publication) and enhanced sequestration of
cells in lymphoid tissues (14;16-18). Recently several groups have
reported on cross-sectional studies of T-cell production levels. Most of
these reports studied total CD4+ and CD8+ T-cell populations, and did not
discriminate between naive and memory subsets (3;7;8;19;20).
To answer the question whether increased T-cell proliferation could be
involved in CD4+ lymphocyte depletion we measured expression of the
Ki-67 antigen in naive and memory CD4+ T-cell subsets in the blood.
Furthermore, we investigated the role of T-cell proliferation in the
expansion and depletion of naive, memory and effector CD8+ T-
lymphocyte subsets. Our approach was longitudinal: cell division rates
were studied from the stage of chronic untreated HIV-1 infection up to a
year of treatment with HAART. 
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Materials and Methods
Patients
To study T-cell turnover before and during anti-retroviral treatment,
sequential cryopreserved peripheral blood samples from HIV-1 infected
participants of the CHEESE study were used. Cryopreservation was
performed using a computerized freezing device that results in optimal
quality of viably frozen cells for functional studies (21). Frozen blood
samples were stored in liquid nitrogen. No differences in Ki-67 expression
were found between freshly isolated or frozen cells in a pilot experiment
(data not shown). In the multicenter CHEESE study patients received
either zidovudine (Retrovir; 200 mg, three times/day), lamivudine (Epivir;
150 mg, twice/day) and saquinavir soft gel capsules (Fortovase; 1200 mg,
three times/day) or zidovudine, lamivudine and indinavir (Crixivan; 800
mg, 3 times/day). The inclusion criteria for this trial were no previous
treatment with anti-retroviral therapy except for AZT less than 12
months, CD4+ T-cell count < 500 per µl, and/or HIV RNA > 10000
copies per ml, and/or CDC stage B or C (22). Sixteen out of sixty
participants were selected based on baseline CD4+ T-cell numbers and the
availability of frozen peripheral blood mononuclear cell (PBMC) samples.
Patients were equally distributed among both therapy arms. Expression of
the Ki-67 antigen was analyzed at five timepoints: during untreated HIV
infection (t=0) and after four (t=4), twelve (t=12), twenty-four (t=24) and
forty-eight (t=48) weeks of therapy. As controls, cryopreserved PBMC
from five HIV-negative blood bank donors were used.
Monoclonal antibodies
CD4-PerCP, CD8-PerCP, CD45RO-PE mAb, and Streptavidin-APC were
obtained from Becton Dickinson (San Jose, CA). Biotinylated CD27 mAb
was purchased from the CLB (Amsterdam, The Netherlands), and FITC-
labeled Ki-67 mAb was purchased from Immunotech (Marseille, France).
Flow Cytometry
CD4+ and CD8+ T cells were subdivided into naive (CD45RO-/ CD27+),
CD27+ memory (CD45RO+/CD27+), CD27- memory (CD45RO+/CD27-)
T-CELL DIVISION IN HIV-1 INFECTION122
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and CD27- effector (CD45RO-/CD27-) cells, as previously described
(23;24). In contrast to these earlier studies, CD45RA mAb was replaced
by CD45RO mAb and the definition of the T-cell subsets was adjusted to
the used mAb combination. Cell proliferation was studied by measuring
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Table 1. Number of Ki-67+ CD4+ T cells (per ml)
Naive CD27+ memory CD27- memory Total
HIV+ 1.6* 13.6* 5.9* 22.8*
(0.3-3.5) (3.2-26) (1-17) (4.7-42)
HIV- 0.8 5.5 2.7 9.0
(0.6-1.4) (4.3-7.3) (2.1-3.1) (7.5-12)
x-fold increase 2 2.5 2.2 2.5
Table 2. Number of Ki-67+ CD8+ T cells (per ml)
Naive CD27+ memory CD27- memory CD27- effector Total
HIV+ 6.9* 33.9* 27.8* 11.3* 98.3*
(1.2-101) (8-534) (4.1-515) (1-195) (14-1297)
HIV- 0.4 0.7 0.5 0.5 2.6
(0.3-1.5) (0.5-2.1) (0.1-1.4) (0.2-1.1) (1.5-5.1)
x-fold increase 17.3 48.4 55.6 22.6 37.8
Number of Ki-67 antigen expressing cells within the total CD4+ (1) and CD8+ (2) T cell
population and T cell subsets of untreated HIV-1 infected patients and healthy individuals.
Median values for the groups, ranges and the x-fold increase observed in HIV-1 infection
compared to the healthy situation are shown. Asterix (*) represents significant difference with
control values (p<0.05; Mann-Whitney U Test).
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expression of the Ki-67 antigen, which is expressed by cells in late G1, S,
G2 and M phase of the cell division circle (25-28). 
Cryopreserved peripheral blood mononuclear cells were thawed and
incubated with CD4- or CD8-PerCP mAb, CD45RO-PE and biotinylated
CD27 mAb. After washing with PBS/0,5 % BSA, cells were incubated
with Streptavidin-APC. Red blood cells were lysed and lymphocytes
fixated with Facs Lysing Solution (Becton Dickinson). Subsequent
permeabilisation was performed by incubating cells with FACS
Permeabilisation Buffer (Becton Dickinson), after which cells were stained
intracellularly with Ki-67-FITC mAb. Cells were fixed, using Cellfix
(Becton Dickinson), and analyzed on a FACSCalibur (Becton Dickinson)
with Cellquest software. All incubation steps were performed at 4 °C for
20 minutes; for fixation and permeabilization samples were kept at room
temperature for 10 minutes.
Viral load
Plasma viral load was determined using RT-PCR detecting HIV-1 RNA
(Roche Amplicor Monitor Standard Assay, Roche Diagnostics,
Branchburg, New Jersey, USA).
Statistical analysis
Patient characteristics at baseline and after various timepoints during
treatment with HAART were compared using Wilcoxon Signed Ranks
Test and Mann-Whitney-U Test for comparison with healthy control
values. Correlations were calculated using Spearman’s correlation
coefficients.
Results
Ki-67 antigen expression in chronic HIV-1 infection
During chronic untreated HIV-1 infection, both the percentage and the
absolute number of Ki-67+ CD4+ and CD8+ T cells was significantly
increased (figure 1, table 1 and 2; p=0.001), as compared to healthy
controls. The percentage of Ki-67 expression was significantly elevated in
T-CELL DIVISION IN HIV-1 INFECTION124
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Figure 1. Percentage of Ki-67+ T lymphocytes within the CD4+ (A) and CD8+ (B)
peripheral blood T cell populations of healthy individuals (gray bars) and untreated HIV-
infected patients (black bars). Asterix (*) represents statistical difference compared to control
value (p<0.005; Mann-Whitney U Test).
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all subsets (p<0.005), except for the CD8+ CD27- effector T-cell
population (figure 1). Naive T cells showed a ten- (CD4) to twenty- (CD8)
fold elevation in Ki-67+ T-cell percentage, and in the memory and effector
T-lymphocyte compartment Ki-67 expression was increased up to seven-
fold (figure 1). When absolute numbers instead of percentages of dividing
cells were analyzed, cell proliferation in the CD4+ T-cell subsets was
elevated less than three-fold, whereas in the CD8+ compartment, a twenty-
to more then fifty-fold rise was observed (table 1 and 2). This increase was
T-CELL DIVISION IN HIV-1 INFECTION126
Figure 2. Correlation between the number of CD4+ and CD8+ naive or CD27+ memory T
cells and the percentage of Ki-67+ naive or CD27+ memory cells of untreated HIV-infected and
non-infected individuals (Spearman’s correlation coefficients).
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most notable in the CD27+ memory and CD27- memory lymphocyte
population (see t=0 figure 4B).
The percentage of naive Ki-67+ CD4+ T lymphocytes was inversely
correlated with the number of naive cells (figure 2), but did not correlate
with plasma viral load (data not shown). Strikingly, only when the number
of naive CD4+ T cells dropped below 100 cells per µl, the proportion of
Ki-67 expressing cells in this subset exceeded two percent (naive CD4
count > 100/µl: r = -0.79, p = 0.004; naive CD4 count < 100/µl: r = -
0.73, p = 0.025; stratification arbitrary). The same overall trend, but not a
significant correlation, was observed for the naive CD8 T-cell
compartment (figure 2). The size of the CD27+ memory CD4+ T-cell pool
was negatively correlated with the percentage of proliferating cells in this
compartment (figure 2; r = -0.68, p = 0.001). In the CD8+ T-cell
compartment the opposite was observed. Here, an increase in the
percentage of Ki-67 expressing cells correlated positively with the size of
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Figure 3. Longitudinal analysis of lymphocyte recovery and plasma HIV-RNA load decline.
White dots represent HIV-RNA load, black dots CD4+ T cells and gray dots CD8+ T cells. 
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Figure 4. CD4+ and CD8+ T cell subset recovery. Naive (circles), CD27+ memory
(triangles), CD27- memory (squares) and CD27- effector (diamonds) lymphocytes within the
CD4+ (A) and CD8+ (B) T cell compartments are shown. Sequential patient values were
compared using the Wilcoxon Signed Ranks Test, and the Mann-Whitney U Test was used for
comparison with healthy individuals (*: p<0.05). 
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the CD27+ memory T lymphocyte subset (figure 2; r = 0.50, p = 0.024)
and the size of the CD27- memory T-cell subset (data not shown; r = 0.52,
p = 0.016). No correlation was found between the same parameters in the
CD4+ CD27- memory or the CD8+ CD27- effector T-cell population, or
between Ki-67 antigen expression and viral load (data not shown). 
Longitudinal analysis of immune recovery during HAART
Infection with HIV-1 resulted in CD4+ T-cell depletion and expansion of
the CD8+ T-cell pool as has been described above (t=0 in figure 4A and
4B). Treatment with anti-retroviral therapy resulted in a significant
decrease of plasma HIV-RNA to levels below the limits of detection (lower
limit of detection 400 RNA copies/ml). In parallel, total numbers of CD4+
T cells increased, and a fall in total numbers of CD8+ T lymphocytes was
observed (figure 3). Figure 4A shows that the therapy-induced rise in
CHAPTER 7 129
Figure 5. Early recovery of CD4+ naive and CD27+ memory T lymphocytes. Patients were
stratified according to baseline naive T cell values. Black and white dots represent naive and
CD27+ memory cells, respectively.
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CD4+ T cells observed in the first four weeks of HAART was accounted for
by an increase of both CD27+ memory and naive T lymphocytes.
Stratification of patients into two groups based on their baseline naive
CD4+ T-cell counts revealed that the HAART-induced restoration of the
naive subset was better in patients with higher baseline naive CD4+ T-cell
values (figure 5).  After one year of treatment, numbers of naive and
CD27+ memory CD4+ T cells had risen significantly compared to pre-
treatment levels, but were still lower compared to control levels (figure
4A, p<0.05). In the same period, as depicted in figure 4B, the number of
naive CD8+ T cells increased. The CD27+ and CD27- memory and CD27-
effector CD8+ T lymphocyte subsets remained significantly expanded
compared to control values (p<0.05), despite an initial decrease in cell
number that was significant for CD27+ and CD27- memory T cells after
respectively one and three months (p<0.05). 
Ki-67 antigen expression during HAART-induced immune recovery
Immediately upon reduction of plasma HIV-RNA load by HAART, the
total number (figure 6A and 6B) and the percentage (data not shown) of
CD4+ and CD8+ Ki-67+ T cells and of Ki-67+ T lymphocytes in all
subsets declined. In the CD4+ T-cell compartment, this decline was
relatively slow when compared to the rapid decline observed in the CD8+
T-cell population. Furthermore, after six months of HAART, a temporary
increase in the number of Ki-67+ lymphocytes was observed in the total
CD4+ T-cell population. After one year of treatment numbers of dividing
CD4+ T cells had returned to normal. Interestingly, the percentage of
proliferating CD4+ naive and CD27+ memory T lymphocytes was still
significantly elevated at that time point (p<0.05; data not shown). In the
CD8+ T-cell compartment, the steepest decline in the number of Ki-67+ T
cells was observed in the first four weeks of treatment (figure 6B; p<0.05
for t=0 vs. t=4 in total CD8+ T cells and in naive, CD27+ and CD27-
memory T-cell subsets). After one year, the percentage (data not shown),
but not the absolute number of Ki-67+ CD27+ and CD27- memory and
Ki-67+ CD27- effector T lymphocytes had returned to normal values
(p<0.008). 
Despite the severe depletion of the naive T-cell pool, the number of Ki-67+
naive T lymphocytes fell immediately upon introduction of HAART
T-CELL DIVISION IN HIV-1 INFECTION130
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Figure 6. Longitudinal analysis of Ki-67 antigen expression in CD4+ (A) and CD8+ (B) T
lymphocyte subsets and total populations. Decline of the number of total (gray circles), naive
(black circles), CD27+ memory (black triangles), CD27- memory (black squares) and CD27-
effector (black diamonds) Ki-67+ T cells is shown. Sequential patient values were compared
using the Wilcoxon Signed Ranks Test, and the Mann-Whitney U Test was used for comparison
with healthy individuals (*: p<0.05).
hoofdstuk 07  9/21/00  1:05 PM  Pagina 131
(figure 6A and 6B). Figure 7 depicts data of the individual Ki-67 decline
in naive CD4+ T lymphocytes. Reduction of Ki-67 expression was
relatively slow in two patients who had less then 100 naive CD4+ T cells
per µl and the highest percentage of dividing naive CD4+ T cells at
baseline. However, as is shown in figure 8A, no correlation was found
between early naive, CD27+ memory or CD27- memory (data not shown)
CD4+ T-cell recovery with the baseline size of these subsets or with the
number of dividing lymphocytes. In the CD8+ T-cell compartment (figure
8B), recovery of the naive subset correlated negatively with its baseline size
and with the number of dividing cells within this pool (r = -0.511, p=
0.043 and r = -0.743, p = 0.001 respectively). Finally, patients with the
most pronounced reduction in size of the CD27+ or CD27- memory T-cell
subset had highest numbers of CD27+ or CD27- memory CD8+
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Figure 7. HAART-induced decline in the percentage of proliferating Ki-67+ naive CD4+ T
cells. The courses of individual patients are shown. Black dots represent patients with baseline
naive CD4+ T cell numbers < 300/µl (n=9), gray dots represent individuals with baseline
naive CD4+ T cell counts > 300/µl but < 400/µl (n=5) and white dots represent patients with
baseline naive CD4+ T cell count > 600/µl (n=2).
hoofdstuk 07  9/21/00  1:05 PM  Pagina 132
CHAPTER 7 133
Figure 8. Early recovery of the naive and CD27+ memory CD4+ (A) and naive, CD27+
memory and CD27- memory CD8+ (B) T cell pool. Correlations are shown between T cell
subset recovery in the first four weeks of HAART (delta t=0 versus t=4) and baseline size of
subset or number of Ki-67+ cells within each subset (Spearman’s correlation coefficients).
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T lymphocytes (r = -0.568, p = 0.022 and r = -0.591, p = 0.016), and
highest numbers of dividing cells (r = -0.776, p = 0.000 and r = -0.618, p
= 0.011) at baseline. A similar trend, albeit not significant, was observed
for the CD27- effector T-cell subset (data not shown).
Discussion
In this longitudinal study, we measured expression of the Ki-67 antigen,
which is taken as a measurement for proliferating cells, in peripheral blood
lymphocyte subsets of HIV-1 infected patients. In untreated HIV-1
infection, both the percentage and number of Ki-67+ CD4+ and CD8+
lymphocytes were significantly increased, as compared to values obtained
from healthy individuals. These data confirm previous (mainly cross-
sectional) studies (5;7;8;29), showing that T-cell turnover is increased
maximally two- to three- fold in the CD4+, and six- to seven- fold in the
CD8+ T-cell population. However, when investigating the role of T-cell
proliferation in the pathogenesis of HIV-1 infection, lymphocyte subsets
rather then total CD4+ or CD8+ T-cell pools should be studied, as naive,
memory and effector T lymphocytes follow different courses of depletion
or expansion. We therefore analyzed changes in expression of the Ki-67
antigen within naive, CD27+ and CD27- memory and CD27- effector
CD4+ and CD8+ lymphocyte populations before and during the course of
HAART.
The finding that in untreated HIV-1 infection, the number of proliferating
cells was elevated two to three times in all CD4+ T-cell subsets is in good
agreement with earlier results demonstrating that the number of apoptotic
cells within the CD4 population was equally distributed over all subsets
(10). Together these data show that in general, HIV-1 infection affects
both naive and memory peripheral blood CD4+ T cells to a similar degree.
The early decrease in the number of naive CD4+ T cells could therefore
reflect interference of the virus with T-cell renewal capacity rather than
with peripheral production of these cells.
The median percentage of dividing naive CD4+ T cells was elevated ten-
fold. Higher increases in percentages of Ki-67+ CD4+ naive T cells were
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observed only when the number of naive cells fell below 100 cells per µl.
When depletion of lymphocytes would be the driving force for the increase
in peripheral naive CD4+ T-cell production, one would expect the high
rate of cell division to be maintained during treatment with HAART until
the number of cells would be normalized. We observed, however, an
immediate decline in the number and percentage of Ki-67+ naive CD4+
lymphocytes, despite the fact that CD4+ T cells were still severely
depleted. From this we conclude that increased Ki-67 expression in the
naive CD4+ T-cell subset was caused by generalized immune activation
rather then being a T-cell homeostatic response to compensate for T-cell
depletion.
Furthermore, our data show that the early therapy-induced increase in
CD4+ T cells is accounted for by a rise in the number of both naive and
CD27+ memory T cells. Our finding that in both subsets the percentage
and number of dividing lymphocytes decreased during anti-retroviral
treatment points towards other mechanisms than peripheral expansion
involved in recovery of the CD4+ T-cell pool. It confirms previous reports
indicating that in the first four weeks of HAART, redistribution of
trapped CD27+ cells significantly adds to therapy-induced increase in
peripheral blood CD4+ T-cell numbers (14;16;17).
Whereas early restoration of the CD27+ memory CD4+ T lymphocyte
compartment was fairly constant between patients, recovery of the naive
CD4+ T-cell pool was variable. In patients with less severe depletion of
naive CD4+ T cells, a relatively steep increase in the number of naive
lymphocytes was observed during the first four weeks of HAART,
confirming recently published data by Hengel et al (31). After this first
steep rise, replenishment occurred at a slower rate. Several factors may
contribute to restoration of the naive lymphocyte compartment, such as
reappearance of pre-existing naive T cells in the peripheral blood, as well
as de novo T-cell production from a thymic source. The relative importance
of each mechanism in recovery of the immune system needs to be
established. Recently, it was reported that thymic production of T cells
increased substantially during HAART. Its dependence on disease
progression remains to be studied (15). 
In contrast to the changes occurring in the CD4+ T-cell compartment, in
the naive CD8+ T-cell pool, percentages of dividing cells were elevated
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regardless of the size of this subset. This points towards a distinct
regulation of peripheral T-cell production rates in CD4+ and CD8+ cells.
The high proliferation rate in the latter population most likely reflects
antigen-induced expansion. The degree of expansion of the CD8+ T-cell
subset correlated with the degree of cell proliferation during chronic HIV-
1 infection observed in that particular subset. Ongoing antigenic pressure
during untreated HIV-1 infection could lead to continuous recruitment of
naive CD8+ T cells, thereby maintaining increased percentages of Ki-67
antigen expression in this subset. During HAART both the percentage
and the total numbers of dividing cells declined, suggesting that
activation related cell division was the driving force for expansion of the
primed subset during chronic HIV-1 infection. The early therapy-induced
drop in the number of primed CD8+ T cells reached a plateau after six
months, at which the CD27+ or CD27- CD45RO+ memory and CD27-
CD45RO- effector CD8+ lymphocyte pool remained significantly
expanded. Although the absolute number of dividing primed CD8+ T cells
remained elevated, the percentage of Ki-67+ T cells within this subset
returned to normal values. Using tetrameric HLA-peptide complexes, it
has been shown that HAART reduced the frequency of HIV-1 specific
CTLs several fold (32). The early decline in primed CD8+ T cells that we
observed could therefore reflect apoptosis of HIV specific CTLs. 
The numbers of dividing cells in healthy individuals found in this study
correspond well to the range of earlier results obtained with Ki-67 staining
(7;8) and with deuterated glucose labeling of dividing cells (19). However,
when studying HIV-1 infected patients, in these reports, the average total
peripheral blood production of proliferating CD4+ T cells was 5.2 x 107
(range 2.7-8.3 x 107) and 10.8 x 107 (range 7.1-12.9 x 107) of CD8+ T cells.
These values are lower then those reported in our study (11.4x107 (range 2.4-
21.0 x107) and 49.2x107 (range 7.0-648.5 x107), respectively), most likely
due to the more advanced disease stage of our patients (see Table 3). 
Following the initial HAART-induced decline, we observed a transient rise
in the number of proliferating CD4+ T cells after six months of therapy,
after which these numbers declined further. Since this rise was only due to
increased numbers of proliferating CD27+ memory cells, and coincided
with normalization of the size of this subset, it could reflect improvement
of the functional capacity of these cells. Indeed, T-cell function, as
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measured by the in vitro proliferative response to CD3 and CD28 mAb,
improved and reached a plateau phase after six months of HAART (data
not shown). Whereas in our study the rise in T-cell proliferation did not
exceed pretreatment values, in a study reported by Fleury et al., a clear
increase in cell production was seen over baseline after six months of
HAART (7). In that report, the baseline CD4+ T-cell counts were
relatively high, on average over 600 cells per µl. We found the transient
rise in numbers of dividing cells to be more pronounced in patients with
higher baseline CD4+ T-cell counts (data not shown), pointing towards
variances in the stage of HIV-1 infection as the cause of the observed
differences.
Taken together, our data are compatible with the idea that most of the
elevated cell division and cell death in HIV-1 infection is related to strong
persistent immune activation (30;33), rather than a response to, or the
cause of lymphocyte depletion. Therefore, alternative factors leading to T-
cell decline must be involved in HIV-1 pathogenesis. As has been proposed
previously, CD4+ T-cell depletion may be due to a diminished capacity for
T-cell renewal as a direct or indirect result of HIV-1 infection or could be
related to an intrinsically low capacity for renewal in adults which can not
even compensate for a slightly enhanced T-cell death due to HIV-1
infection and generalized immune activation (34-37). Furthermore, we
observed a clear distinction between CD4+ and CD8+ T cells with respect
to proliferation rates. A similar dichotomy was found before, when much
more cell activation induced death and shortened telomeres were found in
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CD4+ T cells CD8+ T cells
HIV- 1824 1391
(n = 5) (466-1391) (101-598)
HIV+ 1280 1350
(n = 16) (50-1060) (490-3160)
Table 3. Baseline numbers of CD4+ and CD8+ T lymphocytes in HIV-1 infected patients and
healthy individuals. Median values and ranges are shown.
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the CD8+ T-cell fraction (5;38). This may fit well with differential
requirements for clonal expansion to exercise CD4+ helper and CD8+
effector cell functions. Since cell division diminished rapidly with HAART
even when T-cell numbers were still very low, our results suggest that the
increased peripheral lymphocyte proliferation is not a homeostatic response
to T-cell depletion.
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Abstract
To distinguish between antigenic stimulation and CD4+ T-cell
homeostasis as the cause of T-cell hyperactivation in HIV infection, we
studied T-cell activation in 47 patients before and during HAART. We
show that expression of HLA-DR, CD38 and Ki67 on T cells decreased
during HAART but remained elevated over normal values until week 48
of therapy. We confirm previous reports that T-cell activation correlates
positively with plasma HIV RNA levels (suggesting antigenic
stimulation), and negatively with CD4 count (suggesting CD4+ T-cell
homeostasis). However, these correlations may be spurious, i.e. misleading,
due to the well-established negative correlation between CD4 count and
plasma HIV RNA levels. To resolve this, we computed partial correlation
coefficients. Correcting for CD4 counts, we show that plasma HIV RNA
levels contributed to T-cell hyperactivation. Correcting for plasma HIV
RNA levels, we show that CD4+ T-cell depletion contributed to T-cell
activation. Correcting for both, the activation of CD4+ and CD8+ T cells
remained positively correlated. Since this suggests that the the CD4+ and
CD8+ T-cell activation is caused by a common additional factor, we
conclude that antigenic stimulation by HIV or other (opportunistic)
infections is the most parsimonious explanation for T-cell activation in
HIV infection. Persistence of HIV antigens would explain why T-cell
activation fails to revert to levels of healthy individuals after 48 weeks of
therapy.
Keywords: Activation, Proliferation, T lymphocytes, CD4, CD8,
Antiretroviral therapy.
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Introduction
The T lymphocytes of HIV infected individuals have increased expression
of activation markers HLA-DR and CD38 (1-11) and increased
proliferation rates. The latter has been demonstrated using two different
techniques. First, by determining the fraction of dividing cells via the
expression of the nuclear antigen Ki67 (12), it was shown that T-cell
proliferation rate is increased maximally two- to three fold in the CD4+
population, and 6-7 fold in the CD8 population (13-16). This limited
increase in the division rate is consistent with studies measuring the
replicative history of T cells by the average telomere lengths (17,18). The
second technique, using deuterated glucose to label DNA in vivo, showed
that the turnover of CD4+ and CD8+ T cells in HIV infected patients is ~3
times higher than that of healthy individuals (19). Increased turnover of
CD4+ and CD8+ T lymphocytes has also been observed in SIV infected
macaques using BrdU to label DNA in vivo (20).
Two models have been proposed to explain the hyperactivation and
increased proliferation of T cells in HIV-1 infection. One model contends
that T-lymphocyte activation in HIV infection is driven by antigens from
HIV and/or from other pathogens (15, 21,22). Alternatively, increased
production of CD4+ T cells may be a homeostatic response to compensate
for the loss of CD4+ T cells that are killed by HIV (23,24). The goal of this
study was to determine which of these to mechanisms best explains the T-
lymphocyte activation in HIV infection. We therefore performed a cross-
sectional and a longitudinal analysis of the activation status of T
lymphocytes, T-lymphocyte population density, and plasma HIV RNA
levels in a large cohort of HIV infected patients before and during
HAART.
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Materials and methods
Study population 
The activation and proliferation status of T cells was analyzed in 47
patients from the previously described CHEESE study cohort (26)  with a
sustained plasma HIV RNA response to levels < 50 copies/ml. Briefly, this
is a randomized study comparing antiviral efficacy of zidovudine (Retrovir,
Glaxo-Wellcome, Research Triangle Park, N.C.) plus lamivudine (Epivir,
Glaxo-Wellcome, Research Triangle Park, N.C.) plus saquinavir-soft-
gelatin-capsules  (SQV-SGC, Fortovase, Hoffmann-La Roche, Inc., Nutley,
New Jersey) versus zidovudine plus lamivudine plus indinavir (Crixivan,
Merck, West Point, Pa), in HIV-1 infected patients. Antiretroviral naive
patients were eligible for study treatment if at the moment of screening
plasma HIV RNA levels were at least 10,000 copies/ml and/or if CD4
counts were less than 500 cells / µL and/or if they had a history of HIV
related symptoms (CDC stage B or C). During 48 weeks of treatment, the
virologic and the CD4 count response was not different between the two
treatment arms (data not shown). Of the selected patients, 25 were from
the indinavir arm and 22 from the SQV-SGC arm. 
Healthy Controls
As controls for the expression of Ki67+ on T lymphocytes, cryopreserved
PBMC’s from five HIV-seronegative blood bank donors were used. As
controls for expression of CD38 and HLA-DR on T cells, freshly isolated
PBMC’s from 12 healthy HIV-seronegative donors were used.
Blood sampling
Blood samples were obtained at baseline, and every 4 weeks through week
24, and every 8 weeks from week 24 through week 48 of treatment.
Plasma Viral Load
Plasma HIV RNA levels were measured using an investigational version of
the ultra sensitive quantitative reverse transcriptase polymerase chain
reaction (RT-PCR) assay (Amplicor HIV-1 Monitor, Roche Diagnostic
Systems). The lower limit of detection was 50 copies / ml.
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Activation Marker r Controlled for CD4
%Ki67 (CD4) 0.47 § 0.46 §
%HLA-DR (CD4) 0.22 § 0.20 ¶
%Ki67 (CD8) 0.47 § 0.54 §
%HLA-DR (CD8) 0.27 § 0.26 §
%CD38 (CD8) 0.64 § 0.60 §
¶:p<0.05
§:p<0.001
Table 1. Correlation between viral load and T-cell activation/proliferation.
Activation Marker r Controlled for CD4
%Ki67 (CD4) -0.58 § -0.55 §
%HLA-DR (CD4) -0.46 § -0.43 §
%Ki67 (CD8) -0.30 ¶ -0.12, p=0.3
%HLA-DR (CD8) -0.12 ¶ -0.03, p=0.3
%CD38 (CD8) -0.42 § -0.32 §
¶:p<0.05
§:p<0.001
Table 2. Correlation between CD4 count and T-cell activation/proliferation.
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Monoclonal antibodies
Peridinin chlorophyll protein (PerCP)-labeled CD4, PerCP-labeled CD8
and phycoerythrin (PE)-labeled HLA-DR monoclonal antibodies were
obtained from Becton Dickinson (San Jose, CA). Fluorescein
isothiocyanate (FITC) labeled CD38 and FITC labeled Ki67 monoclonal
antibodies were obtained from Immunotech (Marseille, France).
Flow Cytometry
The fraction of activated CD4+ and CD8+ T cells was determined by three
color FACS analysis using monoclonal antibodies against CD4 (or CD8),
CD38 and HLA-DR on heparin-anticoagulated venous blood (FACScan;
Becton Dickinson Immunocytometry Systems, San Jose, CA). In 16
patients, the fraction of proliferating T cells was determined before
therapy and at week 4,12, 24 and week 48 of HAART by measuring the
expression of the nuclear antigen Ki67 on cryopreserved PBMC’s.
Statistical Analysis
The non-parametric Mann-Whitney-U-Test  (Wilcoxon-Rank-Sum-W
Tests) was used to compare patients with controls. Longitudinal changes of
patient characteristics were tested using the non-parametric Wilcoxon
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CD8+ T cells CD4+ T cells r Controlled Controlled Controlled
for for for CD4 and
CD4 Viral Load Viral Load
%HLA-DR %HLA-DR 0.58 § 0.62 § 0.56 § 0.62 §
% CD38 %HLA-DR 0.39 § 0.24 § 0.33 § 0.23 §
%Ki67 % Ki67 0.62 § 0.49 § 0.28 § 0.32 ¶
¶:p<0.05
§:p<0.001
Table 3. Correlation between activation/proliferation in CD4+ and CD8+ T-cell subsets.
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Matched Pairs Signed-Rank Test. Pearson’s correlation coefficients were
computed to measure bivariate correlations. Partial correlations were
calculated to analyze the correlation that remains between two variables
after removing the correlation that is due to their mutual association with
a third variable (51). Correlations were computed for pooled data of all
time points (week 0-48) and for data of baseline only. Similar correlations
were found for baseline and for the pooled data, although the p-values were
generally higher in the baseline correlations probably due to a smaller
sample size (Table 1-3). Reported p-values are two-sided. All statistical
analyses were performed using SPSS for Windows (8.0.0). Non linear
regression analysis was performed using Mathematica, version 2.1.
Results 
Expression of activation markers before HAART 
T cells expressing Ki67 were considered to be proliferating.  Ki67 is a
protein expressed by cells in the late G1 and the S, G2 and M  phase of the
cell cycle (12). T cells expressing HLA-DR were considered to be activated
cells. The CD8+ T cells expressing CD38 were also to be considered
activated (2,4,6-11). We confirm previous reports (1-11) that, prior to the
start of HAART, the expression of HLA-DR and Ki67 on CD4+ T
lymphocytes, and the expression of HLA-DR, CD38 and Ki67 on CD8+ T
lymphocytes, is higher in HIV-1 infected patients as compared with
healthy controls (see Figure 1).
Effect of HAART on plasma viral load, CD4 count and CD8 count
The median plasma viral load decreased from 40.000 copies/ml to <50
copies/ml in 16 weeks (p<0.001). The CD4 count increased from 301±28
at baseline to 507±40 cells/µl at week 48 (p<0.001). The increase of CD4
count during the first 4 weeks of therapy was higher (2.0 cells/mm3/day) as
compared with the mean CD4 count rise during later 4 week intervals
(0.38 cells/mm3/day), in agreement with a biphasic response pattern of the
CD4+ T cells to HAART (27). The CD8 count decreased from 1050±70
cells/mm3 at baseline to 870±60 cells/mm3 at week 48 (p=0.023).
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Figure 1. The effect of HAART on the expression of activation antigens on T lymphocytes.
Mean values are shown. Bars represent standard error of the mean. The dotted lines represent
mean expression levels in healthy HIV-seronegative controls. Figure 2a and 2b show the
expression of HLA-DR and Ki67 on CD4+ T cells, respectively. Figure 2c, 2d and 2e show the
expression of HLA-DR, CD38 and Ki67 on CD8+ T cells, respectively. At week 48, the mean
expression levels of the activation markers on T cells were still significantly higher than in
healthy controls (p<0.05 each comparison of patients vs controls (Mann-U-Whitney test)).
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Effect of HAART on expression of HLA-DR, CD38 and Ki67 on T
lymphocytes
The expression of all activation markers on CD4+ and CD8+ T cells
gradually decreased during HAART (all p values < 0.005). At week 48
however, the mean expression levels were still significantly higher than in
healthy controls, even though all patients had plasma HIV RNA levels
below 50 copies / ml for a median period of 32 (range 0-44) weeks
(Figure 1), consistent with the findings of others (28-32).
Correlation between CD4 count, plasma viral load and percentage of
activated and proliferating T cells
It has been established before that T-cell activation markers are positively
correlated with the plasma viral load, and negatively with CD4 counts
(11,14). For all 3 activation markers, we report similar correlations
(Table 1 and 2). However, these correlations may be spurious, due to the
indirect effect of the negative correlation between CD4 count and plasma
HIV RNA levels (at baseline r = -0.4, p=0.04). We therefore corrected for
the negative correlation between CD4 count and plasma HIV RNA by
computing partial correlations. The positive correlations that were
observed between the plasma viral load and the expression of activation
markers on T lymphocytes (Table 1) are hardly affected by controlling for
the indirect effect of the CD4 count. Apparently, independent of
homeostatic effects via the CD4 count, the plasma HIV RNA level has a
true contribution to the T-cell hyperactivation. This supports the model
that antigenic stimulation plays a role in T-cell hyperactivation during
HIV infection. Similarly, the negative correlation between the CD4 count
and activation of CD4+ T cells, persists after controlling for the plasma
HIV RNA load. This suggests that there is a true additional role for CD4
homeostatic effects on CD4+ T-cell activation. Thus, in the CD4+ T-cell
compartment, both mechanism seem to play a role. The negative
correlation between the CD8 activation markers and the CD4 count
however largely disappears (HLA-DR, Ki67, Table 2) when controlling for
plasma HIV RNA.  Apparently, activation of CD8+ T cells is largely due
to plasma HIV RNA levels, and is not directly related to the CD4 count. 
In contrast to the inverse relation between CD4 count and the percentage
of activated CD4+ T cells, which suggests homeostasis (Table 2), no
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association was observed between the CD8 count and percentage of CD8+
T cells expressing HLA-DR or CD38 (r =0.12 and r = -0.01, respectively,
p>0.05). This seems natural as homeostasis is not expected to play a role in
the expanded CD8 population. A weak positive correlation between CD8
count, and the percentage of Ki67 expressing CD8 cells was observed (r =
0.22, p=0.047). 
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Figure 2. Figure 2a and 2b show the negative correlation between CD4 count and expression
of HLA-DR and Ki67 on CD4+ T cells, respectively, suggesting homeostatic effects in the
CD4+ T-cell population. Black dots represent baseline data, white dots represent data from week
4 through week 48 of therapy. Figure 2c shows the correlation between expression of HLA-DR
on CD4+ T cells and on CD8+ T cells. Figure 2d shows the correlation between expression of
Ki67 on CD4+ T cells and on CD8+ T cells. Figure 2a and 2c: n = 461; Figure 2b and 2d:
n = 79. 
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The rate of decay of T-cell activation markers during HAART
To determine whether a relation exists between decreasing plasma HIV
RNA levels and T-cell activation during HAART, we estimated the second
phase slope (week 4-48) of HIV RNA from plasma for each patient by
linear regression analysis. In addition, the decay rates of the activation
markers on T cells were estimated assuming that the percentage of
activated T cells at baseline is a, and that T-cell activation decreases with
rate per day c to a level of healthy individuals b. We estimated a, b and c by
fitting equation y = b + a[exp(-ct)] to the measurements of T-cell
activation, where y is the percentage of activated T cells and t is  time. No
significant correlations were found between the rate of decline of plasma
HIV RNA and the decay rates c of HLA-DR and Ki67 expression on
CD4+ T cells, or the decay rates of HLA-DR, CD38 and Ki67 expression
on CD8+ T cells (each absolute Pearson’s coefficient < 0.37, each p value
>0.24). These findings indicate that the daily decrease of plasma HIV
RNA plays a limited role in the decay rate of T-cell activation.
To determine the influence of increasing CD4 counts on CD4+ T-cell de-
activation during HAART, we also estimated the daily increase of the CD4
count during HAART for each patient. Because of the biphasic pattern of
CD4 count increase, the speed of increase was estimated for the first phase
(week 0-4), and the second phase (week 4-48), using linear regression
analysis. During both phases, no significant correlations were observed
between the daily increase in CD4 count and the decay rates of expression
of HLA-DR and Ki67 on CD4+ T cells (each absolute Pearson’s coefficient
< 0.24, each p value >0.45). These findings indicate that the daily increase
of the CD4 count plays a limited role in the decay rate of T-cell activation.
Correlation between activation and proliferation status of CD4+ and CD8+
cells
We confirm observations by Sachsenberg et al. (14) that Ki67+ expression
on CD4+ and CD8+ T cells is positively correlated (Table 3, Figure 2d).
Similarly, the percentage of HLA-DR+ CD4+ T cells was positively
correlated with the percentage of HLA-DR+ or CD38+ CD8+ T cells
(Figure 2c). This suggests that CD4+ and CD8+ T-cell activation is driven
by a common mechanism. 
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The fact that the positive correlation between CD4+ and CD8+ T-cell
activation persists after controlling for the indirect effect of CD4 count
(Table 3), suggests that other factors than CD4 homeostasis drive CD4+
and CD8+ T-cell activation. This positive correlation however also persists
when we control for plasma HIV RNA level, and when we control for both
CD4 count and plasma HIV RNA levels. These findings indicate that
additional factors may play a role in T-cell activation, such as immune
activation by other infections or HIV antigens that are not correlated with
the plasma HIV RNA load.
Discussion
The aim of this study was to determine the mechanisms involved in
increased activation and division of T lymphocytes in HIV infected
patients. We found a negative correlation between the CD4 count and the
percentage of activated CD4+ T cells, which remains after controlling for
plasma HIV RNA load. Observations like this suggest a homeostatic
response of the CD4+ T-cell population to compensate for the CD4+ T-cell
depletion in HIV infection (23,24). Several other observations however
argue against a general role for homeostasis in the increased activation of
CD4+ and CD8+ T cells in HIV infection. First, the activation and
proliferation is also in the expanded CD8+ T-cell population. Second,
because the expression of activation markers on CD4+ and CD8+ T cells
remains positively correlated after controlling for the CD4 count (Table 3),
factors other than CD4+ T-cell depletion appear to play a role in driving
the activation of both CD4+ and CD8+ T cells. Third, the percentage of
CD4+ T cells expressing HLA-DR and Ki67 decreased rapidly after the
start of HAART eventhough CD4+ T cells were still depleted (15). Fourth,
at no time point during therapy, the decrease in the expression of HLA-DR
and Ki67+ on CD4+ T cells was correlated to the increase in CD4 count
(data not shown). 
The plasma viral load correlated positively with the expression of HLA-
DR, CD38 and Ki67 on T cells. This positive correlation suggests that
plasma HIV RNA load and HIV replication drive T-cell activation.
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However, two of our observations suggest that additional factors play a
role. First, even though at week 48 of HAART all patients had plasma
HIV RNA loads below 50 copies/ml for a mean interval of 32 weeks, the
level of T-cell activation and proliferation remained significantly higher
than in healthy controls. Second, the decay rate of the percentage of
activated and proliferating T cells was not correlated with the elimination
rate of HIV RNA from plasma. Third, the expression of activation markers
on CD4+ and CD8+ T cells remains positively correlated after controlling
for plasma HIV RNA, suggesting that other factors than plasma HIV
RNA contributes to T-cell activation.
What additional factors, apart from CD4 homeostasis and plasma HIV
RNA levels, could contribute to the T-cell activation? The positive
correlation between fractions of activated cells in the CD4+ and CD8+ T-
cell population, which persist after controlling for the CD4 count and the
plasma HIV viral load, suggests that CD4+ and CD8+ T-cell activation are
governed by similar factors. Thus, we believe that the most parsimonious
explanation for the hyperactivation of both CD4+ and CD8+ T-cell
populations is antigenic stimulation. This may involve (long-lived)
antigens from HIV and/or other (opportunistic) pathogens. 
The negative correlation between the CD4 count and T-cell activation,
which could be taken as evidence for a homeostatic response of the CD4+
T-cell population, may also be explained by antigenic stimulation. A low
CD4 count increases the risk of developing opportunistic infections with
Pneumocystis Carinii, Cytomegalovirus (CMV) or Mycobacterium Avium
Complex (33,34). Moreover, in the blood of patients with low CD4 counts
signs of active CMV and Epstein-Barr virus replication have been observed
(35-38). These (Opportunistic) infections are associated with increased T-
cell activation (11,39-41). Antigenic stimulation also explains the positive
correlation between the plasma viral load and T-cell activation. A high
plasma viral load is associated with an increases the risk of developing
opportunistic infections, and replication of HIV itself will also increase the
antigenic load.
The slow decay of T-cell activation during HAART may be explained in
two ways. First, the clearance of antigens from other anatomic
compartments than the blood, e.g. lymphoid tissue, is expected to be slow
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(42-44). In line with this, we observed persistence of HIV p24 antigen in
lymphoid tissue, after 18 months of HAART with plasma viral loads
below 50 copies / ml (data not shown). Secondly, low level ongoing HIV
replication during HAART may play a role. Based on theoretical
considerations (45) and the detection of HIV mRNA in lymphoid tissue of
patients on HAART with plasma viral load < 50 copies / ml (46-47), it has
been hypothesized that a low level of HIV replication may occur during
HAART. In addition, it has been demonstrated that the presence of
episomal HIV-1 infection intermediates perisist in patients with
undectable plasma HIV RNA levels during HAART (48).
There is a strong interaction between HIV replication and T-cell activation
because productive HIV infection is largely restricted to CD4+ T cells that
are activated (22,25). Several predator-prey type mathematical models of
HIV infection describe this interaction, assuming that activated CD4+ T
cells are the primary target cells of HIV (49). In contrast to our
observations (Figure 1) however, the number of activated CD4+ T cells
increases during HAART in these models.  Thus, the number of  target
cells increases if HIV is suppressed. Our results therefore suggest that
current mathematical models should be extended with mechanisms for
CD4+ T-cell activation by HIV and/or other antigens. One such
mechanism, obviously, would be to allow for the immune response to HIV
(and/or other antigens).
In conclusion, our results suggest that antigenic stimulation is the
dominant mechanism of T-cell activation in HIV infection, rather than
CD4+ T-cell homeostasis. Persistence of HIV antigens, or low level
ongoing HIV replication during HAART may explain why T-cell
activation fails to revert to levels of healthy individuals after 48 weeks of
therapy. 
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Abstract
Introduction: In a large number of patients on HAART who achieved
plasma HIV RNA levels below the limit of detection (50 copies/ml),
transient relapses of HIV RNA levels (“blips”) are observed. 
Objective: To determine whether relapses of plasma HIV RNA during
HAART are associated with development of drug resistance.
Methods: Plasma samples from 15 patients with a transient viral load
relapse during HAART were studied. All regimens contained lamivudine
(3TC). We used an ultrasensitive sequence approach to analyze the
presence of protease and reverse transcriptase drug resistance mutations
during the relapse.
Results: The median plasma HIV RNA load of the relapse was 72 copies/ml
(range 50-1253).  In 11 of 15 cases, a genotype of HIV could be obtained.
Mutations in the RT and protease gene conferring resistance to one or
more drugs were observed in 8 of 11 patients, 6 of whom had the M184V
substitution. During a median follow up of 12 months after the relapse,
plasma HIV RNA levels remained undetectable in 14 of 15 patients.
Conclusion: Plasma HIV RNA blips during HAART are associated with
selection of drug resistant HIV in the majority of cases. This indicates that
viral replication occurs during HAART, probably due to a temporary
decrease in active drug concentrations. In some instances, blips are due to
the production of wild type viruses, which can be due to activation of the
latent virus reservoir. Independent of the cause, blips did not preclude
successful inhibition of viral replication below 50 copies/ml during a year
follow-up.
Keywords: antiretroviral therapy, transient viral load relapse, resistance,
genotype. 
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Introduction
In a majority of patients, highly active antiretroviral therapy (HAART)
results in a sustained suppression of plasma HIV RNA levels to below 50
copies/ml. However, during prolonged follow up of patients on HAART,
transient relapses of the plasma viral load to levels above 50 copies/ml
(“blips”) can be observed in up to 40% percent of the patients (1-3). The
clinical implications of these blips are unclear.
Two mechanisms may account for blips of the plasma viral load during
HAART. First, activation of latently infected memory pool could result in
the production of HIV particles, analogous to increased plasma HIV RNA
levels during opportunistic infections (4,5), after interleukin-2
administration (6) and after influenza  pneumococcal vaccination (7-9).
Under such circumstances, second rounds of replication of HIV will be
prevented by HAART and consequently, no drug resistant virus will be
generated. Second, blips of the plasma viral load during HAART could be
caused by diminished inhibition of HIV replication as a result of
temporary reductions of the concentrations of antiretroviral drugs. This
could be due to of interactions with other drugs, intermittent adherence to
the regimen or temporary alterations in absorption. As consequence of
continuous replication during suboptimal suppression the replicating
viruses will acquire drug resistance mutations.
The goal of this study was to distinguish between the two mechanisms
underlying transient relapses of the plasma viral load during HAART. We
therefore determined the genotype of the plasma HIV population using a
ultrasensitive approach during a transient viral load relapse in a well
defined cohort of 15 intensively monitored patients on HAART. The
regimens of all patients contained lamivudine (3TC). Because continuing
HIV replication in the presence of 3TC results in rapid selection of HIV
variants harbouring the M184V mutation in the reverse transcriptase (RT)
gene of HIV (11-14), emergence of M184V variants could be used as a
marker for HIV replication during the relapse. 
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Materials & Methods 
Patients
A cohort of 15 patients with transient plasma HIV RNA relapses during
HAART was selected from the outpatient clinic of the division of internal
medicine of the university of Toronto, Canada. Patients were selected if
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patient HAART Pre-HAART Pre-HAART Duration Duration of
number regimen viral load treatment of HAART follow up
(copies/ml) at relapse after relapse
(months) (months)
1 azt/3tc/idv 50294 azt 22 10
2 d4t/3tc/nfv 2808 azt 22 14
2 d4t/3tc/nfv 2808 azt 23 13
2 d4t/3tc/nfv 2808 azt 26 10
3 azt/3tc/sqv unk¶ naïve 22 19
4 d4t/3tc/nvp 60000 naïve 18 10
5 3tc/ddi/rtv/sqv 6313 azt/ddi 28 14
5 3tc/ddi/rtv/sqv 6313 azt/ddi 29 13
6 d4t/3tc/nfv/sqv 202900 naïve 17 12
7 d4t/3tc/idv 2559 azt 18 13
8 d4t/3tc/rtv/sqv 689600 azt/3tc 21 15
9 azt/3tc/idv 2137 naïve 20 15
10 d4t/3tc/idv 50550 naïve 17 12
11 d4t/3tc/idv 9756 azt/3tc 19 12
12§ d4t/3tc/idv 9039 naive 29 15
13§ d4t/3tc/idv 38560 naive 26 13
14§ d4t/3tc/idv 205042 azt/ddc 11 12
15§ d4t/3tc/nfv/sqv unk* naive 36 15
¶ No baseline plasma HIV RNA level available.
§ No HIV RNA amplification at blip
Table 1. Characteristics of patients.
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they were on antiretroviral therapy containing at least three antiretroviral
drugs, one of which was lamivudine. A transient relapse was defined as
having a detectable viral load in an ultrasensitive assay (cut-off 50
copies/ml) during HAART, whereas a plasma viral load < 50 copies/ml
was achieved during HAART prior to the blip, and at least one sample
obtained subsequent to the blip had a plasma viral load < 50 copies/ml.
Antiretroviral Regimens
In 10 of the 15 patients, the antiretroviral regimen at the time of the
plasma viral load relapse consisted of lamivudine plus one other nucleoside
analogue RT inhibitor (NRTI) and one or two protease inhibitors (Table
1). Four patients were treated with lamivudine, stavudine, plus two
protease inhibitors (patients 5, 6, 8 and 15) and one patient was treated
with lamivudine, stavudine plus nevirapine (Patient 4).  Seven patients
were pretreated with  mono or dual therapy prior to initiation of HAART
(Table 1).  
Plasma HIV RNA load
The ultrasensitive HIV RNA plasma levels were measured using a bDNA
assay with a lower limit of detection of 20 copies/ml (Quantiplex HIV
RNA assay version 3.0; Chiron Corp., Emeryville, Calif.). In some cases (as
indicated in Figure 1)  HIV RNA plasma levels were measured using a
bDNA assay with a lower limit of detection of 500 copies/ml (Quantiplex
HIV RNA assay version 2.0; Chiron Corp., Emeryville, Calif.).
Ultrasensitive HIV RNA isolation and amplification
To be able to isolate and amplify low copy numbers of HIV RNA from the
plasma at the moment of relapse, RNA was extracted from large volumes
(1.7 to 3.7 ml) of EDTA plasma using the method by Boom et al. (15). An
equivalent of 340µl-740µl serum was used for reverse transcription and
amplification of the RT gene. The RNA input in the RT-PCR assay varied
between 26 and 446 copies of HIV RNA. 
A previously described one-tube RT-PCR procedure (16) was performed
using oligonucleotides RT18 (sense) 5’-GGAAACCAAAAATGATAGG
GGGAATTGGAGG-3’ (nucleotides 2376-2406) and RT21 (antisense) 5’-
CTGTATTTCTGCTATTAAGTCTTTTGA
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TGG-3’ ( nucleotides 3511-3538) for the RT gene and oligonucleotides
5’prot1 (sense) 5’-AGGCTAATTTTTTAGGGAAGATCTGGCCTTCC-3’
(nucleotides 2076-2108) and 3’prot1 (antisense) 5’-GCAAATACTGGAG
TATTGTATGGATTTTCAGG-3’ (nucleotides 2733-2702) for the
protease gene. A nested PCR was used to amplify the amount of DNA
from the first PCR, using oligonucleotides RT19 (sense) 5’-
GGACATAAAGCTATAGGTACAG-3’ (nucleotides 2453-2474) and
RT20 (antisense) 5’-CTGCCAGTTCTAGCTCTGCTTC-3’ (nucleotides
3461-3440) for direct sequencing of the RT gene, and oligonucleotides
5’prot2 (sense) 5’-TCAGAGCAGACCAGAGCCAACAGCCCCA-3’
(nucleotides 2135-2166) and  3’prot2 (antisense) 5’-AATGCTTTTATTT
TTTCTTCTGTCAATGGC-3’ (nucleotides 2620-2649) for the protease
gene. A nested PCR using oligonucleotides SPP2A (sense) 5’-TGTTGAC
TCAGATTGGTTGCACTTTA-3’ (nucleotides 2518-2543) and SPP6A
(antisense) 5’-TTCTGTATGTCTTAGACAGTCCAGCT-3’ (nucleotides
3325-3300) was used for the point mutation assay.  
Population Sequencing
After nested PCR amplification, fragments were ethanol precipitated and
used for direct sequencing according to the Big-dye-terminator protocol
(Perkin-Elmer, Foster City, CA, USA). Sequence analysis was performed
using the ABI automated sequencer 377 (ABI, Foster City, CA, USA). The
relative amount of wildtype and mutant variants was estimated from the
sequence electropherograms (cut-off approximately 10%). 
Point Mutation Assay
To be able to detect minority HIV populations with higher sensitivity
than with population sequencing, the wildtype / mutant ratio of amino
acid position 184 of the HIV-RT gene was determined using a primer
guided nucleotide incorporation assay or point mutation assay (detection
level 3%), as previously described (17).
Drug resistance mutations
For the protease gene, we distinguished primary mutations that confer
drug resistance by themselves from secondary or compensatory mutations,
that improve the fitness of HIV containing one or more primary mutations
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without increasing resistance (18). Primary resistance mutations are
M46I/L and/or V82A/F/T for indinavir, V82A for ritonavir, G48V and/or
L90M for saquinavir and D30N and N88D for nelfinavir (18,19). 
In the RT gene, mutations considered to confer drug resistance were are
M41L, T69N, K70R, T215Y and K219Q for zidovudine, L74V for
didanosine, M184V for lamivudine, Y181C/I and/or G190A for
nevirapine and V75T for stavudine. In addition, the presence of AZT
mutations were also considered to confer resistance to d4T (20,21).   
Results
Plasma HIV RNA levels during HAART
The median plasma HIV RNA load at the start of HAART was 44427
copies/ml (range 2137-689600 copies/ml)(Table 1). All patients achieved
plasma HIV RNA levels below <50 copies / ml after initiation of HAART.
The median viral load at the time of relapse was 72 copies/ml (range 50-
1239 copies/ml)(Figure 1). Figure 1 shows the plasma HIV RNA levels
patterns during therapy of each patient.  
Two patients had two transient relapses throughout the course of HAART
(Patients 2 and 7). One patient (Patient 1) had failure of antiretroviral
therapy after the transient relapse, i.e. had a viral load more than 400
copies/ml at two or more consecutive time points without achieving a
plasma viral load < 50 copies/ml at a later time point while continuing at
the same HAART regimen (Figure 1).
CD4 counts
The median CD4 count at the moment of the plasma viral load blip was
547 cells/mm3 (range 300-1084 cells/mm3). The CD4 counts at the time
of the relapse were not significantly different from the CD4 count
measurements directly preceding or following the relapse (Wilcoxon
Signed Rank Test for two related samples: p=0.3 and p=0.2, respectively,
data not shown). 
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Time characteristics of the relapses
The median duration that patients were on HAART at the time of relapse
was 21.5 months (range 5-36 months) (Table 1). The median duration of
follow up after the relapse was 12 months (5-15 months) (Table 1). The
median duration that plasma HIV RNA levels were < 50 copies/ml prior
to the blip was 11 months (range 2-13 months). The median duration that
HIV RNA BLIPS AND DRUG RESISTANCE168
Figure 1. Plasma HIV RNA levels during HAART. Triangles refer to plasma HIV RNA
levels that were undetectable in an assay with a lower limit of detection of 500 copies/ml.
Arrows refer to the moment and plasma HIV RNA level at the time of relapse.
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plasma HIV RNA levels were < 50 copies/ml after the blip was 12 months
(range 1-16 months). The median duration of a blip (from the last moment
that the plasma viral load was < 50 copies/ml preceding the blip to the
first moment after the blip) was 27 weeks (range 13-87 weeks).
Genotype of HIV plasma variants at the time of the relapse
From 11 of the 15 patients, HIV RNA could be successfully extracted and
amplified for sequencing and the point mutation assay. The drug resistance
mutations at the time of relapse are shown in Table 2. Eight patients had
mutations conferring resistance to one or more of the antiretroviral agents
given at the time of relapse (Table 2: patients 1-8). In 3 patients, wild type
viruses were observed at the time of relapse (Table 2: patients 9, 10 and
11). 
From patients 2 and 5,  the genotype of the HIV plasma population was
determined at two and three moments respectively (Figure 1, Table 1). In
patient 5, the same drug resistance mutations were observed at the two
time points, which were part of the same relapse (Figure 1). In patient 2,
the same mutations were observed at the two time points during the first
relapse. During the second relapse, an additional mutation at amino acid
position 71 in protease was observed (A71V).
The M184V mutation in RT
Sequencing of the RT gene revealed that HIV variants with the M184V
mutation in were present in 6 of 11 patients at the time of the plasma viral
load relapse (Table 2). Using the point mutation assay, M184V variants
were detected in the same 6 patients (Table 2). In general, the observed
wild type/mutant ratio was similar in both assays. 
The M184V mutation was the most common resistance mutation. Patients
with the M184V mutation had more drug resistance mutations in protease
than patients who had HIV that was wild type at codon 184. No primary
drug resistance mutations in protease were observed in the absence of the
M184V mutation. 
HIV RNA BLIPS AND DRUG RESISTANCE170
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Discussion
In this study we investigated in 15 patients on HAART whether resistant
HIV variants emerge during a transient relapse of the plasma viral load
from below 50 copies/ml to a median load of 72 copies/ml. Using an
ultrasensitive genotyping procedure, the genotype from the HIV plasma
population could be determined in 11 of 15 patients. Mutations in the RT
and protease gene conferring resistance to one or more of the given drugs
were observed in 8 of 11 evaluable patients. Thus, blips of the plasma HIV
RNA during HAART are associated with drug resistance in the majority
of cases.  
The emergence of drug resistant HIV variants during a blip of the viral
load indicates that HIV replication occurred during HAART, probably
due to a transient reduction in bioavailability of antiretroviral drugs.
Suboptimal drug levels that allow HIV replication while still exerting a
selective pressure will cause a rapid selection of drug resistant HIV
variants. 
We propose that a significant amount of replication must have occurred in
the patients in which the M184V mutation emerged, because the M184I
was not observed in these patients. Emergence of M184I variants usually
precedes the emergence of M184V variants when HIV is allowed to
replicate in  the presence of 3TC (11). 
In three patients (9, 10 and 11), no drug resistant HIV variants were
observed. Assuming that the plasma virus population during a blip may
contain a mixture of wildtype and resistant virus variants, it could be
argued that the observed absence of drug resistant HIV variants in these
three patients is due to selective amplification of wildtype virus during the
RT-PCR reaction. Selective amplification effects have been observed with
ultra low genotyping, when plasma HIV RNA levels were below 60
copies/ml. (24). Because patients 9, 10 and 11 had low plasma HIV RNA
levels during the blip (≤ 54 copies/ml), it can not be excluded that besides
wild type HIV variants, drug resistant variants were present in these
patients.
The transient outgrowth of drug sensitive, wild type viruses during
HAART in patients 9, 10 and 11 could be explained by several
CHAPTER 9 171
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mechanisms. It could result from production of wildtype HIV virions by
activated memory T cells that were infected prior to the start of HAART.
RT inhibitors and protease inhibitors cannot inhibit the production of HIV
virions in latently infected cells, although the produced virions will not be
infectious for new cells due to the activity of protease inhibitors (22,23). 
Immunologic stimulation of latently infected cells could be due to
concomitant infections, although this may not always be clinically evident.
A clinically evident concomitant infection (influenza) was observed in one
of the patients at the moment of the relapse (patient 11). The HIV plasma
population of this patient was indeed sensitive to all agents in the regimen
(Table 2). 
Alternatively, transient outgrowth of drug sensitive viruses during
HAART could be due to temporary discontinuation of the antiretroviral
therapy. It seems an unlikely explanation since the patients in this study
indicated that they were fully compliant as assessed by patient interviews.
In the absence of plasma drug levels however it can not be excluded that
therapy non-compliance may have played a role. 
Our observations may have clinical implications. We show that,
independent of the presence of drug resistant HIV variants, transient
relapses of the plasma viral load are not predictive of treatment failure
during a 12 months follow up. Only one of 15 patients experienced a
treatment failure after the relapse, as defined by a plasma viral load >400
copies/ml at two consecutive time points (patient 1). More research is
required to determine the long term consequences of transient relapses of
plasma HIV RNA levels.
It is surprising that in three patients (2,4,and 5) with two or more
resistance mutations conferring resistance to two or more of the agents, the
plasma HIV RNA levels could be re-suppressed to <50 copies/ml after the
relapse. It is unlikely that this is due to the natural course of HIV infection
since the plasma HIV RNA loads in these patients prior to start with
HAART were 2808, 60.000 and 6313 copies/ml, respectively. Suppression
by HAART of genotypically multidrug resistant HIV can be explained in
several ways. First, the viruses may still be phenotypically sensitive to the
combination administered drugs, despite the presence of multiple
mutations that are known to confer resistance to each individual drug.
Second, multidrug resistant variants could have a compromised capacity to
HIV RNA BLIPS AND DRUG RESISTANCE172
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replicate, i.e. have a reduced fitness (25-29). Third, because the three
patients with multidrug resistant HIV during the relapse were on
HAART for a relatively long period time (~100 weeks), reconstitution of
the immune system may play a role in re-suppression of HIV after the
relapse. HAART has been shown to diminish the activation of CD4+ T
cells (30,31), thus reducing the number of primary target cells for HIV,
which are the activated (HLA-DR+) CD4+ T cells (32).  
Because 6 of the 8 patients with drug resistance mutations to the given
drugs had the M184V mutation, this mutation could also play a role in the
re-suppression of HIV after the relapse. It has been suggested that
selection of M184V HIV variants during antiretroviral therapy may be
beneficial for therapy outcome due to several reasons. First, M184V
variants have reduced replication capacity in vitro due to a decreased
processivity of the M184V RT as compared to the wildtype enzyme
(13,25). Second, resistance to AZT is delayed by the presence of M184V
variants in patients who were treated with AZT/3TC dual therapy (12-14).
In vitro it was shown that AZT resistance is suppressed by the M184V
mutation. Third, it has been demonstrated that the fidelity of the M184V
enzyme is higher as compared to the wildtype enzyme (33,34). It was
hypothesized that this might reduce the mutation rate of the mutant HIV
and delay the generation of mutations conferring resistance to the other
compounds of the regimen. However, it was shown that the increased
fidelity of the M184V enzyme does not reduce the overall error rate of the
M184V virus (35). Fourth, cytotoxic T lymphocytes that specifically target
M184V HIV variants have been observed. It has been suggested that the
M184V specific CTL´s may play a role in the suppression of HIV after
selection of the M184V mutation (36). 
In conclusion, our data show that HIV RNA blips during HAART are
associated with the development of drug resistance in the majority of the
cases. This indicates that viral replication may occur during HAART,
probably caused by a temporary decrease in the active drug concentrations.
In the remaining cases, blips are due to the production of drug sensitive
wildtype viruses, which may be caused by activation of pre-therapy
infected memory cells. Independent of the cause, transient relapses of the
plasma viral load did not preclude successful inhibition of viral replication
below 50 copies/ml during a year follow-up after the relapse.
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Inleiding
Het humaan immuundeficiëntie virus (HIV) is de veroorzaker van het
verworven immuundeficiëntie syndroom (Acquired Immunodeficiency
Syndrome, AIDS). Een infectie met HIV leidt tot een afname van het
aantal CD4+ T cellen. Deze cellen spelen een centrale rol bij de afweer van
het lichaam tegen ziekmakende micro-organismen, zoals gisten,
schimmels, bacteriën en virussen. De CD4+ T cellen worden wel de helper
cellen van het afweer systeem genoemd. Afname van het aantal helper
cellen door een HIV infectie maakt het afweersysteem minder effectief en
uiteindelijk ontwikkelt zich bij de meeste HIV geïnfecteerde patiënten
AIDS. 
De schadelijke werking die HIV uitoefent op het afweersysteem kan
afgeremd worden door behandeling met een combinatie van HIV
remmers. Deze geneesmiddelen worden ook wel antiretrovirale
geneesmiddelen genoemd. HIV is immers een zogenaamd retrovirus. In de
kliniek worden op het ogenblik twee typen antiretrovirale middelen
gebruikt, die elk een specifiek enzym van HIV remmen: protease remmers
en reverse transcriptase remmers. In dit proefschrift worden onderzoeken
beschreven naar het effect van deze combinaties (“cocktails”) van
antiretrovirale geneesmiddelen op de replicatie (vermenigvuldiging) van
HIV en het naar het herstel van het afweersysteem tijdens zo’n combinatie
therapie.
De hoofdstukken
Als inleiding op dit proefschrift wordt in hoofdstuk 1 een overzicht
gegeven van de huidige kennis over de pathogenese van HIV infectie en de
effecten van antiretrovirale therapie. 
Hoofdstuk 2 beschrijft de CHEESE studie. CHEESE staat voor
Comparative trial in HIV infected patients Evaluating Efficacy and Safety
of saquinavir Enhanced oral formulation and indinavir given as part of a
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triple therapy. In deze studie werd de antiretrovirale effectiviteit en de
bijwerkingen van twee combinatie therapieën met elkaar vergeleken, te
weten een combinatie van saquinavir soft-gelatin-capsules (SGC) +
zidovudine (AZT) + lamivudine (3TC) versus een combinatie van
indinavir + AZT + 3TC (de standaard therapie toen de studie werd
gestart). Het was de eerste studie waarin twee protease remmers
(saquinavir en indinavir) met elkaar vergeleken werden, toegediend in
combinatie met dezelfde reverse transcriptase remmers. Het was een
gerandomiseerde, “open label” studie (dus iedereen wist welke medicatie er
na loting aan de patiënten toegediend werd), uitgevoerd in 8 ziekenhuizen
in Nederland. In totaal namen er 70 HIV geïnfecteerde (volwassen)
patiënten deel aan de studie, 35 in elke arm. De patiënten waren voor het
begin van deze studie nooit behandeld met HIV remmers. 
De antiretrovirale effectiviteit van beide therapie armen was niet
verschillend na 24 weken en na 48 weken therapie. In beide
behandelarmen van de studie was een snelle afname van het aantal virus
deeltjes in het plasma waarneembaar. Na 24 weken therapie was het
percentage patiënten met minder dan 50 kopieën HIV RNA (het
genetisch materiaal van HIV) per milliliter plasma 74.3% in de saquinavir
groep en 71.4% in de indinavir groep. Dit verschil is niet significant. De
toename van het aantal CD4+ T cellen in de eerste 24 weken was hoger in
de saquinavir-SGC groep dan in de indinavir groep (162±20 VS. 89±21
cellen per mm3). Echter, na 32 weken therapie was geen verschil in het
CD4 getal meer aantoonbaar was tussen beide therapie armen.  
De soft-gel-capsules van saquinavir zijn ontwikkeld omdat de
oorspronkelijke toedieningsvorm van saquinavir, de hard-gel-capsules, een
lage biologische beschikbaarheid heeft van slechts 4% (het wordt niet goed
opgenomen in het lichaam). In hoofdstuk 3 is onderzocht of gebruik van
de saquinavir soft-gel-capsules leidt tot hogere saquinavir spiegels in
plasma bij patiënten dan bij gebruik van de hard-gel-capsules. Een hogere
biologische beschikbaarheid van de soft-gel-capsules ten opzichte van de
hard gel capsules kon niet aangetoond worden. Tevens kon geen relatie
aangetoond worden tussen de saquinavir spiegels in het plasma van de
patiënten en de antiretrovirale repons gedurende 48 weken therapie.   
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In hoofdstuk 4 en hoofdstuk 5 is de relatie onderzocht tussen de leeftijd
van HIV geïnfecteerde patiënten en de regeneratie (de heraanmaak) van
nieuwe T cellen gedurende antiretrovirale combinatie therapie. Nieuwe T
cellen worden aangemaakt in de thymus (zwezerik). Dit is een orgaan dat
vlak bij het hart ligt. Nieuwe T cellen worden ook wel naïeve T cellen
genoemd omdat ze nooit in aanraking zijn geweest met lichaamsvreemd
materiaal (antigeen). Een infectie met HIV leidt tot een afname van het
aantal naïeve T cellen waardoor de afweer tegen nieuwe infecties
gecompromitteerd kan worden. Onze hypothese was dat de snelheid
waarmee het aantal naïeve T cellen toeneemt tijdens antiretrovirale
combinatie therapie afneemt met de leeftijd, omdat de thymus kleiner
wordt als iemand ouder wordt. De snelheid van naïeve T-cel aanmaak
bleek inderdaad omgekeerd evenredig te zijn met de leeftijd van de
patiënten. Dit geldt zowel voor kinderen in de leeftijdscategorie van 0-16
jaar (hoofdstuk 4) als voor volwassenen van 25 tot 56 jaar (hoofdstuk 5). 
In hoofdstuk 6 is onderzocht of de productie van naïeve T cellen door de
thymus is verminderd in HIV geïnfecteerde patiënten.  Door sommige
onderzoekers is gesteld dat De T-cel productie van de thymus bepaald kan
worden door het aantal T cellen te meten die recent de thymus verlaten
hebben. Deze nieuwe T cellen kan men herkennen aan de aanwezigheid
van een T-cel receptor excisie cirkel (TREC). Deze TRECs zijn
cirkelvormige stukjes DNA die ontstaan bij het T-cel rijpingsproces in de
thymus, tijdens de vorming van de antigeen receptor van de T cel. Een
infectie met HIV leidt tot een afname van het aantal T cellen dat TRECs
bevat. Gebruik makend van een wiskundig model hebben wij aangetoond
dat de verlaging van het aantal TREC positieve T cellen tijdens HIV
infectie beter verklaard kan worden door de toename van deling van de
naïeve T cellen dan door een vermindering van de thymus functie.
In hoofdstuk 7 en hoofdstuk 8 is de activatie en deling van T cellen
onderzocht in  onbehandelde HIV geïnfecteerde patiënten en in patiënten
tijdens combinatie therapie. Een infectie met HIV leidt tot een toename in
de activatie en deling van T cellen. Deze T-cel hyperactivatie kan verklaard
worden met twee modellen. Volgens het eerste model is de hyperactivatie
het gevolg van een gegeneraliseerde immuunactivatie, veroorzaakt door
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antigenen van HIV zelf, en van andere pathogenen (bijvoorbeeld van
opportunistische pathogenen). Volgens het andere model is de toegenomen
activatie en deling van T cellen tijdens HIV infectie het gevolg van een
regelmechanisme van het afweersysteem, dat probeert de afname van het
aantal CD4+ T cellen door HIV te compenseren (een homeostatische
respons). In hoofdstuk 7 en hoofdstuk 8 is geprobeerd uit te maken welk
van deze twee modellen het beste de T cel hyperactivatie verklaart.
Stimulatie door antigenen lijkt de beste verklaring voor de T-cel
hyperactivatie in HIV infecties.
Bij een meerderheid van de patiënten leidt krachtige antiretrovirale
combinatie therapie tot een zodanige onderdrukking van HIV dat geen
HIV RNA kopieën in het plasma meer aantoonbaar is, althans minder dan
50 kopieeen per milliliter. Echter, nadat het virus eenmaal ondetecteerbaar
is geworden in het plasma tijdens combinatie therapie, vinden bij een
aanzienlijk deel van de patiënten (tot 40%) kortdurende perioden van HIV
viremie plaats. Deze perioden van viremie heten hebben wij “blips”
genoemd. Het doel van de studie in hoofdstuk 9 was om te bepalen of
deze blips geassocieerd zijn met de ontwikkeling van resistentie van HIV
tegen combinatie therapie. Bij een meerderheid van de patiënten met een
blip was HIV resistentie aantoonbaar op genetisch niveau.
Hoofdstuk 10 is de algemene discussie. 
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Dit proefschrift is tot stand gekomen dankzij de inspanning van velen.
Mijn dank gaat uit naar een ieder van hen. In het bijzonder noem ik de
volgende mensen:
De patiënten die deelnamen aan de studies. Jullie inzet en toewijding
vormt de basis van dit werk.
Mijn co-promotor bij de Medische Microbiologie, Charles Boucher.
Charles, om jou kwam ik naar het UMC. Zeer veel heb ik van je geleerd.
Van je scheppingsdrang, je creativiteit en je kracht. Maar Bakunin’s
stelling is omkeerbaar. Veel heb ik daarom ook geleerd van je
destructiezin. Je bent een mooi mens, het ga je goed.
Mijn co-promotor bij de afdeling infectie ziekten en AIDS, Jan Borleffs.
Jan, jouw oprechte aandacht voor mij, gecombineerd met gevoel voor
humor, waren regelmatig onmisbaar. Moet ik overigens nog brieven
schrijven? Volgens mij ben jij de beste “principal investigator” die
denkbaar is. Maar waarom nu toch CHEESE? Succes als directeur
onderwijs van de medische faculteit Utrecht.
Mijn promotor, professor Hoepelman. Andy,  je vermogen om de grote
lijnen te zien en die te integreren met details is uitzonderlijk. Ten prooi
aan veel verbazing enerzijds en bewondering anderzijds heb ik met je
samengewerkt. Je bent uniek en inspirerend. Dank voor je steun tijdens
mijn queeste naar een professionele toekomst.
De CHEESE studie groep. Alle internisten, verpleegkundigen, mensen bij
Roche en U-gene (Pieter, mag ik nog eens met je op reis naar het einde van
de nacht?)
Het CLB: Mette Hazenberg, Dörte Hamann, Marijke Roos en Frank
Miedema. De samenwerking was ideaal. Dank voor alle scholing op het
gebied van T-cel immunologie. Marijke, succes met die waanzinnig enorm
grote super immuun reconstitutie analyse. 
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De farmacologen: Richard Hoetelmans, David Burger en Rolf van
Heeswijk. Kennis over de farmacologie is inderdaad cruciaal voor optimale
antiretrovirale behandeling. 
De theoretisch biologen: Rob de Boer en André Noest. Wiskunde is goed
voor de mens. 
Iedereen betrokken bij het NAP of  de “Dutch study group for children
with HIV infections”.
De collega’s en studenten van de virologie research afdeling, het voormalig
ATL. Corjan, wat jij ziet zie ik niet (in die coupes), maar lachen was het
wel. Rob, bij jou blijf ik me altijd student voelen. Tom, de master-
sequencer, bedankt voor je geduld. Loek, zouden die pleuris cirkeltjes
eigenlijk wel bestaan?
De collega’s van het Laboratorium voor Medische Microbiologie “Eijkman
Winkler Instituut” ofwel het EWI. Dank voor de goede tijd, de feesten, de
taart, de koepels. 
De collega’s van afdeling Infectieziekten en AIDS. Ik zal ze missen, die
rondjes langs de zelfkant van de samenleving op donderdag middag.
Mariska, logistiek wonder en ZIS-wizz-kid. Zonder jou was mijn poli
ondenkbaar.
Marguérite Schipper van de afdeling Pathologische Anatomie. MEIS, voor
mijn ben je het vrouwelijke evenbeeld van Louis Ferdinand Céline. Laten
we snel weer eens een gezamenlijke scheldpartij organiseren.
De secretaresses van de virologie: Leonie, Ireen, Jeanette, Alice, Marije,
Riny. Soms leek het wel of jullie taak principieel en fundamenteel
onuitvoerbaar was. Ireentje, je kunt het.  
Mijn kamergenoten. Annemarie B., Annemarie W., Ben, Camiel, Desirée,
Gunnar, Hessel, Leonie, Leontien, Mireille, Monique, Ruzena, Wilco,
Wouter en toch ook Steven. Ik zal jullie niet vergeten. Stuiterend door het
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gebouw, mijn bloed gistend van de speciale UMC koffie melange, was onze
kamer mijn thuis. Rustpunt zal ik niet schrijven. Die gallons koffie,
geserveerd op dat coupe blaadje van de PA, het delen van lief en leed, de
gang naar de Bush onder leiding van de grote roerganger, de niet-mobiele
telefoon, de discussies ter meerdere glorie van de wetenschappelijke
transdisciplinaire interactie, de drank, onze belangwekkende
ontdekkingen op het gebied van de statistiek zoals de “Orendi
transformatie” en “significantie generatie”, de appelbol.
Lieve Ingrid, weet dat de vogels niet dood zijn, ze zijn gevlogen.
Mijn vrienden, ouders en andere dierbaren vormen het fundament van wat
ik ben.
Jij, die het eind van ieder streven,
begrijpt in het geleidend licht.
Kun jij mij sneeuw en storm vergeven, 
mijn waanzin, duister en gedicht. 
Jean Pierre Rawie
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1981-1987 Gymnasium Haganum te ‘s Gravenhage.
1987-1988 Propedeuse Geneeskunde, Universiteit van Amsterdam.
1988-1992 Doctoraal Geneeskunde, Universiteit van Amsterdam.
1992-1994 Doctoraal Medische Biologie, Universiteit van
Amsterdam, cum laude.
1994-1996 Co-assistentschappen.
1996 Examen tot Arts, cum laude.
1997-2000 Promotie onderzoek bij het Laboratorium voor Medische
Microbiologie, Eijkman-Winkler Instituut, en de afdeling
Interne Geneeskunde, onderafdeling Infectieziekten &
AIDS, Universitair Medisch Centrum Utrecht
2000 Virology Networks, Utrecht
2001- McKinsey & Company, Amsterdam
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